<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
	<META HTTP-EQUIV="CONTENT-TYPE" CONTENT="text/html; charset=utf-8">
	<TITLE></TITLE>
	<META NAME="GENERATOR" CONTENT="LibreOffice 3.5  (Linux)">
	<META NAME="AUTHOR" CONTENT="Jacinto Dávila">
	<META NAME="CREATED" CONTENT="20150817;19141500">
	<META NAME="CHANGEDBY" CONTENT="Jacinto Dávila">
	<META NAME="CHANGED" CONTENT="20150817;19394700">
	<META NAME="CHANGEDBY" CONTENT="Jacinto Dávila">
	<STYLE TYPE="text/css">
	<!--
		@page { margin: 2cm }
		P { margin-bottom: 0.21cm }
	-->
	</STYLE>
</HEAD>
<BODY LANG="es-VE" DIR="LTR">
<P STYLE="margin-bottom: 0cm">1. Cell Rep. 2012 Nov 29;2(5):1197-206.
doi: 10.1016/j.celrep.2012.10.012. Epub 2012</P>
<P STYLE="margin-bottom: 0cm">Nov 8.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">DNA binding by GATA transcription
factor suggests mechanisms of DNA looping and</P>
<P STYLE="margin-bottom: 0cm">long-range gene regulation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Chen Y(1), Bates DL, Dey R, Chen PH,
Machado AC, Laird-Offringa IA, Rohs R, Chen 
</P>
<P STYLE="margin-bottom: 0cm">L.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Molecular and Computational Biology
Program, Departments of Biological</P>
<P STYLE="margin-bottom: 0cm">Sciences and Chemistry, University of
Southern California, Los Angeles, CA 90089,</P>
<P STYLE="margin-bottom: 0cm">USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">GATA transcription factors regulate
transcription during development and</P>
<P STYLE="margin-bottom: 0cm">differentiation by recognizing distinct
GATA sites with a tandem of two conserved</P>
<P STYLE="margin-bottom: 0cm">zinc fingers, and by mediating
long-range DNA looping. However, the molecular</P>
<P STYLE="margin-bottom: 0cm">basis of these processes is not well
understood. Here, we determined three</P>
<P STYLE="margin-bottom: 0cm">crystal structures of the full
DNA-binding domain (DBD) of human GATA3 protein,</P>
<P STYLE="margin-bottom: 0cm">which contains both zinc fingers, in
complex with different DNA sites. In one</P>
<P STYLE="margin-bottom: 0cm">structure, both zinc fingers wrap
around a palindromic GATA site, cooperatively</P>
<P STYLE="margin-bottom: 0cm">enhancing the binding affinity and
kinetic stability. Strikingly, in the other</P>
<P STYLE="margin-bottom: 0cm">two structures, the two fingers of GATA
DBD bind GATA sites on different DNA</P>
<P STYLE="margin-bottom: 0cm">molecules, thereby bridging two
separate DNA fragments. This was confirmed in</P>
<P STYLE="margin-bottom: 0cm">solution by an in-gel fluorescence
resonance energy transfer analysis. These</P>
<P STYLE="margin-bottom: 0cm">findings not only provide insights into
the structure and function of GATA</P>
<P STYLE="margin-bottom: 0cm">proteins but also shed light on the
molecular basis of long-range gene</P>
<P STYLE="margin-bottom: 0cm">regulation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2012 The Authors.
Published by Elsevier Inc. All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3978094</P>
<P STYLE="margin-bottom: 0cm">PMID: 23142663 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Mol Biol. 2008 Sep
19;381(5):1292-306. doi: 10.1016/j.jmb.2008.06.072. Epub</P>
<P STYLE="margin-bottom: 0cm">2008 Jul 2.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Crystal structures of multiple GATA
zinc fingers bound to DNA reveal new insights</P>
<P STYLE="margin-bottom: 0cm">into DNA recognition and
self-association by GATA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Bates DL(1), Chen Y, Kim G, Guo L, Chen
L.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Chemistry and
Biochemistry, University of Colorado at Boulder,</P>
<P STYLE="margin-bottom: 0cm">Boulder, CO 80309-0215, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The GATA family of transcription
factors (GATA1-6) binds selected GATA sites in</P>
<P STYLE="margin-bottom: 0cm">vertebrate genomes to regulate specific
gene expression. Although vertebrate GATA</P>
<P STYLE="margin-bottom: 0cm">factors have two highly conserved zinc
finger motifs, how the two fingers act</P>
<P STYLE="margin-bottom: 0cm">together to recognize functional DNA
elements is not well understood. Here we</P>
<P STYLE="margin-bottom: 0cm">determined the crystal structures of
the C-terminal zinc finger of mouse GATA3</P>
<P STYLE="margin-bottom: 0cm">bound to DNA containing two variously
arranged GATA binding sites. Our structures</P>
<P STYLE="margin-bottom: 0cm">and accompanying biochemical analyses
reveal two distinct modes of DNA binding by</P>
<P STYLE="margin-bottom: 0cm">GATA to closely arranged sites. One
mode involves cooperative binding by two GATA</P>
<P STYLE="margin-bottom: 0cm">factors that interact with each other
through protein-protein interactions. The</P>
<P STYLE="margin-bottom: 0cm">other involves simultaneous binding of
the N-terminal zinc finger (N-finger) and 
</P>
<P STYLE="margin-bottom: 0cm">the C-terminal zinc finger of the same
GATA factor. Our studies represent the</P>
<P STYLE="margin-bottom: 0cm">first crystallographic analysis of GATA
zinc fingers bound to DNA and provide new</P>
<P STYLE="margin-bottom: 0cm">insights into the DNA recognition
mechanism by the GATA zinc finger. Our crystal 
</P>
<P STYLE="margin-bottom: 0cm">structure also reveals a dimerization
interface in GATA that has previously been 
</P>
<P STYLE="margin-bottom: 0cm">shown to be important for GATA
self-association. These findings significantly</P>
<P STYLE="margin-bottom: 0cm">advance our understanding of the
structure and function of GATA and provide an</P>
<P STYLE="margin-bottom: 0cm">important framework for further
investigating the in vivo mechanisms of</P>
<P STYLE="margin-bottom: 0cm">GATA-dependent gene regulation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 18621058 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Bioorg Med Chem Lett. 2008 Nov
15;18(22):5895-9. doi: 10.1016/j.bmcl.2008.08.029.</P>
<P STYLE="margin-bottom: 0cm">Epub 2008 Aug 14.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Discovery of inhibitors of the
channel-activating protease prostasin (CAP1/PRSS8)</P>
<P STYLE="margin-bottom: 0cm">utilizing structure-based design.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Tully DC(1), Vidal A, Chatterjee AK,
Williams JA, Roberts MJ, Petrassi HM,</P>
<P STYLE="margin-bottom: 0cm">Spraggon G, Bursulaya B, Pacoma R,
Shipway A, Schumacher AM, Danahay H, Harris</P>
<P STYLE="margin-bottom: 0cm">JL.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Genomics Institute of the Novartis
Research Foundation, 10675 John J. Hopkins 
</P>
<P STYLE="margin-bottom: 0cm">Dr., San Diego, CA 92121, USA.
dtully@gnf.org</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structure-based design was utilized to
guide the early stage optimization of a</P>
<P STYLE="margin-bottom: 0cm">substrate-like inhibitor to afford
potent peptidomimetic inhibitors of the</P>
<P STYLE="margin-bottom: 0cm">channel-activating protease prostasin.
The first X-ray crystal structures of</P>
<P STYLE="margin-bottom: 0cm">prostasin with small molecule
inhibitors bound to the active site are also</P>
<P STYLE="margin-bottom: 0cm">reported.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 18752942 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Biochemistry. 2004 Aug
24;43(33):10628-41.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Crystal structure of the actin binding
domain of the cyclase-associated protein.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Dodatko T(1), Fedorov AA, Grynberg M,
Patskovsky Y, Rozwarski DA, Jaroszewski L, 
</P>
<P STYLE="margin-bottom: 0cm">Aronoff-Spencer E, Kondraskina E,
Irving T, Godzik A, Almo SC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biochemistry, Albert
Einstein College of Medicine, Bronx, New</P>
<P STYLE="margin-bottom: 0cm">York 10461, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cyclase-associated protein (CAP or
Srv2p) is a modular actin monomer binding</P>
<P STYLE="margin-bottom: 0cm">protein that directly regulates
filament dynamics and has been implicated in a</P>
<P STYLE="margin-bottom: 0cm">number of complex developmental and
morphological processes, including mRNA</P>
<P STYLE="margin-bottom: 0cm">localization and the establishment of
cell polarity. The crystal structure of the</P>
<P STYLE="margin-bottom: 0cm">C-terminal dimerization and actin
monomer binding domain (C-CAP) reveals a highly</P>
<P STYLE="margin-bottom: 0cm">unusual dimer, composed of monomers
possessing six coils of right-handed</P>
<P STYLE="margin-bottom: 0cm">beta-helix flanked by antiparallel
beta-strands. Domain swapping, involving the</P>
<P STYLE="margin-bottom: 0cm">last two strands of each monomer,
results in the formation of an extended dimer</P>
<P STYLE="margin-bottom: 0cm">with an extensive interface. This
structural and biochemical characterization</P>
<P STYLE="margin-bottom: 0cm">provides new insights into the
organization and potential mechanistic properties 
</P>
<P STYLE="margin-bottom: 0cm">of the multiprotein assemblies that
integrate dynamic actin processes into the</P>
<P STYLE="margin-bottom: 0cm">overall physiology of the cell. An
unanticipated finding is that the unique</P>
<P STYLE="margin-bottom: 0cm">tertiary structure of the C-CAP monomer
provides a structural model for a wide</P>
<P STYLE="margin-bottom: 0cm">range of molecules, including RP2 and
cofactor C, proteins involved in X-linked</P>
<P STYLE="margin-bottom: 0cm">retinitis pigmentosa and tubulin
maturation, respectively, as well as several</P>
<P STYLE="margin-bottom: 0cm">uncharacterized proteins that exhibit
very diverse domain organizations. Thus,</P>
<P STYLE="margin-bottom: 0cm">the unusual right-handed beta-helical
fold present in C-CAP appears to support a 
</P>
<P STYLE="margin-bottom: 0cm">wide range of biological functions.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 15311924 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Nat Commun. 2014;5:3004. doi:
10.1038/ncomms4004.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structural analysis of human
2'-O-ribose methyltransferases involved in mRNA cap 
</P>
<P STYLE="margin-bottom: 0cm">structure formation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Smietanski M(1), Werner M(2), Purta
E(2), Kaminska KH(2), Stepinski J(3),</P>
<P STYLE="margin-bottom: 0cm">Darzynkiewicz E(4), Nowotny M(5),
Bujnicki JM(6).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)1] Laboratory of Bioinformatics and
Protein Engineering, International</P>
<P STYLE="margin-bottom: 0cm">Institute of Molecular and Cell Biology
in Warsaw, ul. ks. Trojdena 4, PL-02-109 
</P>
<P STYLE="margin-bottom: 0cm">Warsaw, Poland [2] Laboratory of
Protein Structure, International Institute of</P>
<P STYLE="margin-bottom: 0cm">Molecular and Cell Biology in Warsaw,
ul. ks. Trojdena 4, PL-02-109 Warsaw,</P>
<P STYLE="margin-bottom: 0cm">Poland. (2)Laboratory of Bioinformatics
and Protein Engineering, International</P>
<P STYLE="margin-bottom: 0cm">Institute of Molecular and Cell Biology
in Warsaw, ul. ks. Trojdena 4, PL-02-109 
</P>
<P STYLE="margin-bottom: 0cm">Warsaw, Poland. (3)Division of
Biophysics, Institute of Experimental Physics,</P>
<P STYLE="margin-bottom: 0cm">Faculty of Physics, University of
Warsaw, ul. Zwirki i Wigury 93, PL-02-089</P>
<P STYLE="margin-bottom: 0cm">Warsaw, Poland. (4)1] Division of
Biophysics, Institute of Experimental Physics, 
</P>
<P STYLE="margin-bottom: 0cm">Faculty of Physics, University of
Warsaw, ul. Zwirki i Wigury 93, PL-02-089</P>
<P STYLE="margin-bottom: 0cm">Warsaw, Poland [2] Centre of New
Technologies, University of Warsaw, ul. Zwirki i</P>
<P STYLE="margin-bottom: 0cm">Wigury 93, PL-02-089 Warsaw, Poland.
(5)Laboratory of Protein Structure,</P>
<P STYLE="margin-bottom: 0cm">International Institute of Molecular
and Cell Biology in Warsaw, ul. ks. Trojdena</P>
<P STYLE="margin-bottom: 0cm">4, PL-02-109 Warsaw, Poland. (6)1]
Laboratory of Bioinformatics and Protein</P>
<P STYLE="margin-bottom: 0cm">Engineering, International Institute of
Molecular and Cell Biology in Warsaw, ul.</P>
<P STYLE="margin-bottom: 0cm">ks. Trojdena 4, PL-02-109 Warsaw,
Poland [2] Laboratory of Bioinformatics,</P>
<P STYLE="margin-bottom: 0cm">Institute of Molecular Biology and
Biotechnology, Faculty of Biology, Adam</P>
<P STYLE="margin-bottom: 0cm">Mickiewicz University, ul. Umultowska
89, PL-61-614 Poznan, Poland.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The 5' cap of human messenger RNA
contains 2'-O-methylation of the first and</P>
<P STYLE="margin-bottom: 0cm">often second transcribed nucleotide
that is important for its processing,</P>
<P STYLE="margin-bottom: 0cm">translation and stability. Human
enzymes that methylate these nucleotides, termed</P>
<P STYLE="margin-bottom: 0cm">CMTr1 and CMTr2, respectively, have
recently been identified. However, the</P>
<P STYLE="margin-bottom: 0cm">structures of these enzymes and their
mechanisms of action remain unknown. In the</P>
<P STYLE="margin-bottom: 0cm">present study, we solve the crystal
structures of the active CMTr1 catalytic</P>
<P STYLE="margin-bottom: 0cm">domain in complex with a methyl group
donor and a capped oligoribonucleotide,</P>
<P STYLE="margin-bottom: 0cm">thereby revealing the mechanism of
specific recognition of capped RNA. This</P>
<P STYLE="margin-bottom: 0cm">mechanism differs significantly from
viral enzymes, thus providing a framework</P>
<P STYLE="margin-bottom: 0cm">for their specific targeting. Based on
the crystal structure of CMTr1, a</P>
<P STYLE="margin-bottom: 0cm">comparative model of the CMTr2
catalytic domain is generated. This model,</P>
<P STYLE="margin-bottom: 0cm">together with mutational analysis,
leads to the identification of residues</P>
<P STYLE="margin-bottom: 0cm">involved in RNA and methyl group donor
binding.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3941023</P>
<P STYLE="margin-bottom: 0cm">PMID: 24402442 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Mol Biol. 2014 Oct
23;426(21):3509-19. doi: 10.1016/j.jmb.2014.08.012. Epub</P>
<P STYLE="margin-bottom: 0cm">2014 Aug 23.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A structural portrait of the PDZ domain
family.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ernst A(1), Appleton BA(2), Ivarsson
Y(1), Zhang Y(2), Gfeller D(1), Wiesmann</P>
<P STYLE="margin-bottom: 0cm">C(2), Sidhu SS(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Banting and Best Department of
Medical Research and Department of Molecular</P>
<P STYLE="margin-bottom: 0cm">Genetics, University of Toronto, The
Donnelly Centre, 160 College Street,</P>
<P STYLE="margin-bottom: 0cm">Toronto, ON M5S 3E1, Canada.
(2)Department of Early Discovery Biochemistry,</P>
<P STYLE="margin-bottom: 0cm">Genentech Inc, San Francisco, CA 94080,
USA. (3)Banting and Best Department of</P>
<P STYLE="margin-bottom: 0cm">Medical Research and Department of
Molecular Genetics, University of Toronto, The</P>
<P STYLE="margin-bottom: 0cm">Donnelly Centre, 160 College Street,
Toronto, ON M5S 3E1, Canada. Electronic</P>
<P STYLE="margin-bottom: 0cm">address: sachdev.sidhu@utoronto.ca.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PDZ (PSD-95/Discs-large/ZO1) domains
are interaction modules that typically bind 
</P>
<P STYLE="margin-bottom: 0cm">to specific C-terminal sequences of
partner proteins and assemble signaling</P>
<P STYLE="margin-bottom: 0cm">complexes in multicellular organisms.
We have analyzed the existing database of</P>
<P STYLE="margin-bottom: 0cm">PDZ domain structures in the context of
a specificity tree based on binding</P>
<P STYLE="margin-bottom: 0cm">specificities defined by peptide-phage
binding selections. We have identified 16 
</P>
<P STYLE="margin-bottom: 0cm">structures of PDZ domains in complex
with high-affinity ligands and have</P>
<P STYLE="margin-bottom: 0cm">elucidated four additional structures
to assemble a structural database that</P>
<P STYLE="margin-bottom: 0cm">covers most of the branches of the PDZ
specificity tree. A detailed comparison of</P>
<P STYLE="margin-bottom: 0cm">the structures reveals features that
are responsible for the diverse</P>
<P STYLE="margin-bottom: 0cm">specificities across the PDZ domain
family. Specificity differences can be</P>
<P STYLE="margin-bottom: 0cm">explained by differences in PDZ
residues that are in contact with the peptide</P>
<P STYLE="margin-bottom: 0cm">ligands, but these contacts involve
both side-chain and main-chain interactions. 
</P>
<P STYLE="margin-bottom: 0cm">Most PDZ domains bind peptides in a
canonical conformation in which the ligand</P>
<P STYLE="margin-bottom: 0cm">main chain adopts an extended β-strand
conformation by interacting in an</P>
<P STYLE="margin-bottom: 0cm">antiparallel fashion with a PDZ
β-strand. However, a subset of PDZ domains bind</P>
<P STYLE="margin-bottom: 0cm">peptides with a bent main-chain
conformation and the specificities of these</P>
<P STYLE="margin-bottom: 0cm">non-canonical domains could not be
explained based on canonical structures. Our</P>
<P STYLE="margin-bottom: 0cm">analysis provides a structural portrait
of the PDZ domain family, which serves as</P>
<P STYLE="margin-bottom: 0cm">a guide in understanding the structural
basis for the diverse specificities</P>
<P STYLE="margin-bottom: 0cm">across the family.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2014 Elsevier Ltd. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 25158098 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Proc Natl Acad Sci U S A. 2011 Aug
30;108(35):14443-8. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1073/pnas.1105898108. Epub 2011 Aug
15.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structural basis of simultaneous
recruitment of the transcriptional regulators</P>
<P STYLE="margin-bottom: 0cm">LMO2 and FOG1/ZFPM1 by the
transcription factor GATA1.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Wilkinson-White L(1), Gamsjaeger R,
Dastmalchi S, Wienert B, Stokes PH, Crossley 
</P>
<P STYLE="margin-bottom: 0cm">M, Mackay JP, Matthews JM.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)School of Molecular Bioscience,
University of Sydney, New South Wales, 2006</P>
<P STYLE="margin-bottom: 0cm">Sydney, Australia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The control of red blood cell and
megakaryocyte development by the regulatory</P>
<P STYLE="margin-bottom: 0cm">protein GATA1 is a paradigm for
transcriptional regulation of gene expression in 
</P>
<P STYLE="margin-bottom: 0cm">cell lineage differentiation and
maturation. Most GATA1-regulated events require 
</P>
<P STYLE="margin-bottom: 0cm">GATA1 to bind FOG1, and essentially all
GATA1-activated genes are cooccupied by a</P>
<P STYLE="margin-bottom: 0cm">TAL1/E2A/LMO2/LDB1 complex; however, it
is not known whether FOG1 and</P>
<P STYLE="margin-bottom: 0cm">TAL1/E2A/LMO2/LDB1 are simultaneously
recruited by GATA1. Our structural data</P>
<P STYLE="margin-bottom: 0cm">reveal that the FOG1-binding domain of
GATA1, the N finger, can also directly</P>
<P STYLE="margin-bottom: 0cm">contact LMO2 and show that, despite the
small size (&lt; 50 residues) of the GATA1 N</P>
<P STYLE="margin-bottom: 0cm">finger, both FOG1 and LMO2 can
simultaneously bind this domain. LMO2 in turn can 
</P>
<P STYLE="margin-bottom: 0cm">simultaneously contact both GATA1 and
the DNA-binding protein TAL1/E2A at</P>
<P STYLE="margin-bottom: 0cm">bipartite E-box/WGATAR sites. Taken
together, our data provide the first</P>
<P STYLE="margin-bottom: 0cm">structural snapshot of multiprotein
complex formation at GATA1-dependent genes</P>
<P STYLE="margin-bottom: 0cm">and support a model in which FOG1 and
TAL1/E2A/LMO2/LDB1 can cooccupy</P>
<P STYLE="margin-bottom: 0cm">E-box/WGATAR sites to facilitate
GATA1-mediated activation of gene activation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3167507</P>
<P STYLE="margin-bottom: 0cm">PMID: 21844373 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Biomol NMR. 1999 Mar;13(3):249-62.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The solution structure of the
N-terminal zinc finger of GATA-1 reveals a specific</P>
<P STYLE="margin-bottom: 0cm">binding face for the transcriptional
co-factor FOG.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Kowalski K(1), Czolij R, King GF,
Crossley M, Mackay JP.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biochemistry,
University of Sydney, NSW, Australia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zinc fingers (ZnFs) are generally
regarded as DNA-binding motifs. However, a</P>
<P STYLE="margin-bottom: 0cm">number of recent reports have
implicated particular ZnFs in the mediation of</P>
<P STYLE="margin-bottom: 0cm">protein-protein interactions. The
N-terminal ZnF of GATA-1 (NF) is one such</P>
<P STYLE="margin-bottom: 0cm">finger, having been shown to interact
with a number of other proteins, including 
</P>
<P STYLE="margin-bottom: 0cm">the recently discovered transcriptional
co-factor FOG. Here we solve the</P>
<P STYLE="margin-bottom: 0cm">three-dimensional structure of the NF
in solution using multidimensional 1H/15N</P>
<P STYLE="margin-bottom: 0cm">NMR spectroscopy, and we use 1H/15N
spin relaxation measurements to investigate</P>
<P STYLE="margin-bottom: 0cm">its backbone dynamics. The structure
consists of two distorted beta-hairpins and 
</P>
<P STYLE="margin-bottom: 0cm">a single alpha-helix, and is similar to
that of the C-terminal ZnF of chicken</P>
<P STYLE="margin-bottom: 0cm">GATA-1. Comparisons of the NF structure
with those of other C4-type zinc binding 
</P>
<P STYLE="margin-bottom: 0cm">motifs, including hormone receptor and
LIM domains, also reveal substantial</P>
<P STYLE="margin-bottom: 0cm">structural homology. Finally, we use
the structure to map the spatial locations</P>
<P STYLE="margin-bottom: 0cm">of NF residues shown by mutagenesis to
be essential for FOG binding, and</P>
<P STYLE="margin-bottom: 0cm">demonstrate that these residues all lie
on a single face of the NF. Notably, this</P>
<P STYLE="margin-bottom: 0cm">face is well removed from the putative
DNA-binding face of the NF, an observation</P>
<P STYLE="margin-bottom: 0cm">which is suggestive of simultaneous
roles for the NF; that is, stabilisation of</P>
<P STYLE="margin-bottom: 0cm">GATA-1 DNA complexes and recruitment of
FOG to GATA-1-controlled promoter</P>
<P STYLE="margin-bottom: 0cm">regions.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 10212985 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Proc Natl Acad Sci U S A. 2005 Jan
18;102(3):583-8. Epub 2005 Jan 11.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zinc fingers as protein recognition
motifs: structural basis for the</P>
<P STYLE="margin-bottom: 0cm">GATA-1/friend of GATA interaction.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Liew CK(1), Simpson RJ, Kwan AH, Crofts
LA, Loughlin FE, Matthews JM, Crossley M,</P>
<P STYLE="margin-bottom: 0cm">Mackay JP.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)School of Molecular and Microbial
Biosciences, University of Sydney, Sydney,</P>
<P STYLE="margin-bottom: 0cm">New South Wales 2006, Australia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">GATA-1 and friend of GATA (FOG) are
zinc-finger transcription factors that</P>
<P STYLE="margin-bottom: 0cm">physically interact to play essential
roles in erythroid and megakaryocytic</P>
<P STYLE="margin-bottom: 0cm">development. Several naturally
occurring mutations in the GATA-1 gene that alter 
</P>
<P STYLE="margin-bottom: 0cm">the FOG-binding domain have been
reported. The mutations are associated with</P>
<P STYLE="margin-bottom: 0cm">familial anemias and thrombocytopenias
of differing severity. To elucidate the</P>
<P STYLE="margin-bottom: 0cm">molecular basis for the GATA-1/FOG
interaction, we have determined the</P>
<P STYLE="margin-bottom: 0cm">three-dimensional structure of a
complex comprising the interaction domains of</P>
<P STYLE="margin-bottom: 0cm">these proteins. The structure reveals
how zinc fingers can act as protein</P>
<P STYLE="margin-bottom: 0cm">recognition motifs. Details of the
architecture of the contact domains and their 
</P>
<P STYLE="margin-bottom: 0cm">physical properties provide a molecular
explanation for how the GATA-1 mutations 
</P>
<P STYLE="margin-bottom: 0cm">contribute to distinct but related
genetic diseases.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC545545</P>
<P STYLE="margin-bottom: 0cm">PMID: 15644435 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Cell Rep. 2012 Nov 29;2(5):1197-206.
doi: 10.1016/j.celrep.2012.10.012. Epub 2012</P>
<P STYLE="margin-bottom: 0cm">Nov 8.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">DNA binding by GATA transcription
factor suggests mechanisms of DNA looping and</P>
<P STYLE="margin-bottom: 0cm">long-range gene regulation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Chen Y(1), Bates DL, Dey R, Chen PH,
Machado AC, Laird-Offringa IA, Rohs R, Chen 
</P>
<P STYLE="margin-bottom: 0cm">L.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Molecular and Computational Biology
Program, Departments of Biological</P>
<P STYLE="margin-bottom: 0cm">Sciences and Chemistry, University of
Southern California, Los Angeles, CA 90089,</P>
<P STYLE="margin-bottom: 0cm">USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">GATA transcription factors regulate
transcription during development and</P>
<P STYLE="margin-bottom: 0cm">differentiation by recognizing distinct
GATA sites with a tandem of two conserved</P>
<P STYLE="margin-bottom: 0cm">zinc fingers, and by mediating
long-range DNA looping. However, the molecular</P>
<P STYLE="margin-bottom: 0cm">basis of these processes is not well
understood. Here, we determined three</P>
<P STYLE="margin-bottom: 0cm">crystal structures of the full
DNA-binding domain (DBD) of human GATA3 protein,</P>
<P STYLE="margin-bottom: 0cm">which contains both zinc fingers, in
complex with different DNA sites. In one</P>
<P STYLE="margin-bottom: 0cm">structure, both zinc fingers wrap
around a palindromic GATA site, cooperatively</P>
<P STYLE="margin-bottom: 0cm">enhancing the binding affinity and
kinetic stability. Strikingly, in the other</P>
<P STYLE="margin-bottom: 0cm">two structures, the two fingers of GATA
DBD bind GATA sites on different DNA</P>
<P STYLE="margin-bottom: 0cm">molecules, thereby bridging two
separate DNA fragments. This was confirmed in</P>
<P STYLE="margin-bottom: 0cm">solution by an in-gel fluorescence
resonance energy transfer analysis. These</P>
<P STYLE="margin-bottom: 0cm">findings not only provide insights into
the structure and function of GATA</P>
<P STYLE="margin-bottom: 0cm">proteins but also shed light on the
molecular basis of long-range gene</P>
<P STYLE="margin-bottom: 0cm">regulation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2012 The Authors.
Published by Elsevier Inc. All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3978094</P>
<P STYLE="margin-bottom: 0cm">PMID: 23142663 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Mol Biol. 2008 Sep
19;381(5):1292-306. doi: 10.1016/j.jmb.2008.06.072. Epub</P>
<P STYLE="margin-bottom: 0cm">2008 Jul 2.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Crystal structures of multiple GATA
zinc fingers bound to DNA reveal new insights</P>
<P STYLE="margin-bottom: 0cm">into DNA recognition and
self-association by GATA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Bates DL(1), Chen Y, Kim G, Guo L, Chen
L.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Chemistry and
Biochemistry, University of Colorado at Boulder,</P>
<P STYLE="margin-bottom: 0cm">Boulder, CO 80309-0215, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The GATA family of transcription
factors (GATA1-6) binds selected GATA sites in</P>
<P STYLE="margin-bottom: 0cm">vertebrate genomes to regulate specific
gene expression. Although vertebrate GATA</P>
<P STYLE="margin-bottom: 0cm">factors have two highly conserved zinc
finger motifs, how the two fingers act</P>
<P STYLE="margin-bottom: 0cm">together to recognize functional DNA
elements is not well understood. Here we</P>
<P STYLE="margin-bottom: 0cm">determined the crystal structures of
the C-terminal zinc finger of mouse GATA3</P>
<P STYLE="margin-bottom: 0cm">bound to DNA containing two variously
arranged GATA binding sites. Our structures</P>
<P STYLE="margin-bottom: 0cm">and accompanying biochemical analyses
reveal two distinct modes of DNA binding by</P>
<P STYLE="margin-bottom: 0cm">GATA to closely arranged sites. One
mode involves cooperative binding by two GATA</P>
<P STYLE="margin-bottom: 0cm">factors that interact with each other
through protein-protein interactions. The</P>
<P STYLE="margin-bottom: 0cm">other involves simultaneous binding of
the N-terminal zinc finger (N-finger) and 
</P>
<P STYLE="margin-bottom: 0cm">the C-terminal zinc finger of the same
GATA factor. Our studies represent the</P>
<P STYLE="margin-bottom: 0cm">first crystallographic analysis of GATA
zinc fingers bound to DNA and provide new</P>
<P STYLE="margin-bottom: 0cm">insights into the DNA recognition
mechanism by the GATA zinc finger. Our crystal 
</P>
<P STYLE="margin-bottom: 0cm">structure also reveals a dimerization
interface in GATA that has previously been 
</P>
<P STYLE="margin-bottom: 0cm">shown to be important for GATA
self-association. These findings significantly</P>
<P STYLE="margin-bottom: 0cm">advance our understanding of the
structure and function of GATA and provide an</P>
<P STYLE="margin-bottom: 0cm">important framework for further
investigating the in vivo mechanisms of</P>
<P STYLE="margin-bottom: 0cm">GATA-dependent gene regulation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 18621058 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Mol Biol. 2007 Oct
12;373(1):141-52. Epub 2007 Aug 2.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structure and function of the
engineered multicopper oxidase CueO from</P>
<P STYLE="margin-bottom: 0cm">Escherichia coli--deletion of the
methionine-rich helical region covering the</P>
<P STYLE="margin-bottom: 0cm">substrate-binding site.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Kataoka K(1), Komori H, Ueki Y, Konno
Y, Kamitaka Y, Kurose S, Tsujimura S,</P>
<P STYLE="margin-bottom: 0cm">Higuchi Y, Kano K, Seo D, Sakurai T.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Division of Material Sciences,
Graduate School of Natural Science and</P>
<P STYLE="margin-bottom: 0cm">Technology, Kanazawa University,
Kakuma, Kanazawa 920-1192, Japan.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">CueO is a multicopper oxidase (MCO)
that is involved in the homeostasis of Cu in 
</P>
<P STYLE="margin-bottom: 0cm">Escherichia coli and is the sole
cuprous oxidase to have ever been found.</P>
<P STYLE="margin-bottom: 0cm">Differing from other MCOs, the
substrate-binding site of CueO is deeply buried</P>
<P STYLE="margin-bottom: 0cm">under a methionine-rich helical region
including alpha-helices 5, 6, and 7 that</P>
<P STYLE="margin-bottom: 0cm">interfere with the access of organic
substrates. We deleted the region</P>
<P STYLE="margin-bottom: 0cm">Pro357-His406 and replaced it with a
Gly-Gly linker. The crystal structures of a 
</P>
<P STYLE="margin-bottom: 0cm">truncated mutant in the presence and in
the absence of excess Cu(II) indicated</P>
<P STYLE="margin-bottom: 0cm">that the scaffold of the CueO molecule
and metal-binding sites were reserved in</P>
<P STYLE="margin-bottom: 0cm">comparison with those of CueO. In
addition, the high thermostability of the</P>
<P STYLE="margin-bottom: 0cm">protein molecule and its spectroscopic
and magnetic properties due to four Cu</P>
<P STYLE="margin-bottom: 0cm">centers were also conserved after
truncation. As for functions, the cuprous</P>
<P STYLE="margin-bottom: 0cm">oxidase activity of the mutant was
reduced to ca 10% that of recombinant CueO</P>
<P STYLE="margin-bottom: 0cm">owing to the decrease in the affinity
of the labile Cu site for Cu(I) ions,</P>
<P STYLE="margin-bottom: 0cm">although activities for laccase
substrates such as</P>
<P STYLE="margin-bottom: 0cm">2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic
acid), p-phenylenediamine, and</P>
<P STYLE="margin-bottom: 0cm">2,6-dimethoxyphenol increased due to
changes in the access of these organic</P>
<P STYLE="margin-bottom: 0cm">substrates to the type I Cu site. The
present engineering of CueO indicates that 
</P>
<P STYLE="margin-bottom: 0cm">the methionine-rich alpha-helices
function as a barrier to the access of bulky</P>
<P STYLE="margin-bottom: 0cm">organic substrates, which provides CueO
with specificity as a cuprous oxidase.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 17804014 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Cell. 1994 May 6;77(3):451-9.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Crystal structure of MyoD bHLH
domain-DNA complex: perspectives on DNA</P>
<P STYLE="margin-bottom: 0cm">recognition and implications for
transcriptional activation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ma PC(1), Rould MA, Weintraub H, Pabo
CO.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biology, Howard Hughes
Medical Institute, Massachusetts</P>
<P STYLE="margin-bottom: 0cm">Institute of Technology, Cambridge
02139.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The crystal structure of a MyoD
basic-helix-loop-helix (bHLH) domain-DNA complex 
</P>
<P STYLE="margin-bottom: 0cm">has been solved and refined at 2.8 A
resolution. This structure proves that bHLH 
</P>
<P STYLE="margin-bottom: 0cm">and bHLH-leucine zipper (bHLH-ZIP)
proteins are remarkably similar; it helps us</P>
<P STYLE="margin-bottom: 0cm">understand subtle differences in
binding preferences for these proteins; and it</P>
<P STYLE="margin-bottom: 0cm">has surprising implications for our
understanding of transcription. Specifically,</P>
<P STYLE="margin-bottom: 0cm">Ala-114 and Thr-115, which are required
for positive control in the myogenic</P>
<P STYLE="margin-bottom: 0cm">proteins, are buried at the protein-DNA
interface. These residues are not</P>
<P STYLE="margin-bottom: 0cm">available for direct protein-protein
contacts, but they may determine the</P>
<P STYLE="margin-bottom: 0cm">conformation of Arg-111. Comparisons
with Max suggest that the conformation of</P>
<P STYLE="margin-bottom: 0cm">this arginine, which is different in
the two structures, may play an important</P>
<P STYLE="margin-bottom: 0cm">role in myogenic transcription.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 8181063 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Biochim Biophys Acta. 2013
Oct;1834(10):2036-44. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.bbapap.2013.05.020. Epub 2013
Jun 5.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Mechanistic features of Salmonella
typhimurium propionate kinase (TdcD): insights</P>
<P STYLE="margin-bottom: 0cm">from kinetic and crystallographic
studies.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Chittori S(1), Simanshu DK, Banerjee S,
Murthy AM, Mathivanan S, Savithri HS,</P>
<P STYLE="margin-bottom: 0cm">Murthy MR.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Molecular Biophysics Unit, Indian
Institute of Science, Bangalore, Karnataka</P>
<P STYLE="margin-bottom: 0cm">560012, India. Electronic address:
sagar@mbu.iisc.ernet.in.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Short-chain fatty acids (SCFAs) play a
major role in carbon cycle and can be</P>
<P STYLE="margin-bottom: 0cm">utilized as a source of carbon and
energy by bacteria. Salmonella typhimurium</P>
<P STYLE="margin-bottom: 0cm">propionate kinase (StTdcD) catalyzes
reversible transfer of the γ-phosphate of</P>
<P STYLE="margin-bottom: 0cm">ATP to propionate during l-threonine
degradation to propionate. Kinetic analysis 
</P>
<P STYLE="margin-bottom: 0cm">revealed that StTdcD possesses broad
ligand specificity and could be activated by</P>
<P STYLE="margin-bottom: 0cm">various SCFAs
(propionate&gt;acetate≈butyrate), nucleotides (ATP≈GTP&gt;CTP≈TTP;</P>
<P STYLE="margin-bottom: 0cm">dATP&gt;dGTP&gt;dCTP) and metal ions
(Mg(2+)≈Mn(2+)&gt;Co(2+)). Inhibition of StTdcD by</P>
<P STYLE="margin-bottom: 0cm">tricarboxylic acid (TCA) cycle
intermediates such as citrate, succinate,</P>
<P STYLE="margin-bottom: 0cm">α-ketoglutarate and malate suggests
that the enzyme could be under plausible</P>
<P STYLE="margin-bottom: 0cm">feedback regulation. Crystal structures
of StTdcD bound to PO4 (phosphate), AMP, 
</P>
<P STYLE="margin-bottom: 0cm">ATP, Ap4 (adenosine tetraphosphate),
GMP, GDP, GTP, CMP and CTP revealed that</P>
<P STYLE="margin-bottom: 0cm">binding of nucleotide mainly involves
hydrophobic interactions with the base</P>
<P STYLE="margin-bottom: 0cm">moiety and could account for the broad
biochemical specificity observed between</P>
<P STYLE="margin-bottom: 0cm">the enzyme and nucleotides. Modeling
and site-directed mutagenesis studies</P>
<P STYLE="margin-bottom: 0cm">suggest Ala88 to be an important
residue involved in determining the rate of</P>
<P STYLE="margin-bottom: 0cm">catalysis with SCFA substrates.
Molecular dynamics simulations on monomeric and</P>
<P STYLE="margin-bottom: 0cm">dimeric forms of StTdcD revealed
plausible open and closed states, and also</P>
<P STYLE="margin-bottom: 0cm">suggested role for dimerization in
stabilizing segment 235-290 involved in</P>
<P STYLE="margin-bottom: 0cm">interfacial interactions and ligand
binding. Observation of an ethylene glycol</P>
<P STYLE="margin-bottom: 0cm">molecule bound sufficiently close to
the γ-phosphate in StTdcD complexes with</P>
<P STYLE="margin-bottom: 0cm">triphosphate nucleotides supports
direct in-line phosphoryl transfer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2013 Elsevier B.V. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 23747922 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Biol Chem. 2011 May
13;286(19):17351-8. doi: 10.1074/jbc.M111.231258. Epub 2011</P>
<P STYLE="margin-bottom: 0cm">Mar 23.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structural basis for ligand recognition
and discrimination of a quorum-quenching 
</P>
<P STYLE="margin-bottom: 0cm">antibody.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Kirchdoerfer RN(1), Garner AL, Flack
CE, Mee JM, Horswill AR, Janda KD, Kaufmann 
</P>
<P STYLE="margin-bottom: 0cm">GF, Wilson IA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Molecular Biology, The
Scripps Research Institute, La Jolla,</P>
<P STYLE="margin-bottom: 0cm">California 92037, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">In the postantibiotic era, available
treatment options for severe bacterial</P>
<P STYLE="margin-bottom: 0cm">infections caused by
methicillin-resistant Staphylococcus aureus have become</P>
<P STYLE="margin-bottom: 0cm">limited. Therefore, new and innovative
approaches are needed to combat such</P>
<P STYLE="margin-bottom: 0cm">life-threatening infections. Virulence
factor expression in S. aureus is</P>
<P STYLE="margin-bottom: 0cm">regulated in a cell density-dependent
manner using &quot;quorum sensing,&quot; which</P>
<P STYLE="margin-bottom: 0cm">involves generation and secretion of
autoinducing peptides (AIPs) into the</P>
<P STYLE="margin-bottom: 0cm">surrounding environment to activate a
bacterial sensor kinase at a particular</P>
<P STYLE="margin-bottom: 0cm">threshold concentration. Mouse
monoclonal antibody AP4-24H11 was shown previously</P>
<P STYLE="margin-bottom: 0cm">to blunt quorum sensing-mediated
changes in gene expression in vitro and protect 
</P>
<P STYLE="margin-bottom: 0cm">mice from a lethal dose of S. aureus by
sequestering the AIP signal. We have</P>
<P STYLE="margin-bottom: 0cm">elucidated the crystal structure of the
AP4-24H11 Fab in complex with AIP-4 at</P>
<P STYLE="margin-bottom: 0cm">2.5 Å resolution to determine its
mechanism of ligand recognition. A key Glu(H95)</P>
<P STYLE="margin-bottom: 0cm">provides much of the binding
specificity through formation of hydrogen bonds with</P>
<P STYLE="margin-bottom: 0cm">each of the four amide nitrogens in the
AIP-4 macrocyclic ring. Importantly,</P>
<P STYLE="margin-bottom: 0cm">these structural data give clues as to
the interactions between the cognate</P>
<P STYLE="margin-bottom: 0cm">staphylococcal AIP receptors AgrC and
the AIPs, as AP4-24H11·AIP-4 binding</P>
<P STYLE="margin-bottom: 0cm">recapitulates features that have been
proposed for AgrC-AIP recognition.</P>
<P STYLE="margin-bottom: 0cm">Additionally, these structural insights
may enable the engineering of AIP</P>
<P STYLE="margin-bottom: 0cm">cross-reactive antibodies or quorum
quenching vaccines for use in active or</P>
<P STYLE="margin-bottom: 0cm">passive immunotherapy for prevention or
treatment of S. aureus infections.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3089576</P>
<P STYLE="margin-bottom: 0cm">PMID: 21454495 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Biol Chem. 2011 May
13;286(19):17351-8. doi: 10.1074/jbc.M111.231258. Epub 2011</P>
<P STYLE="margin-bottom: 0cm">Mar 23.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structural basis for ligand recognition
and discrimination of a quorum-quenching 
</P>
<P STYLE="margin-bottom: 0cm">antibody.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Kirchdoerfer RN(1), Garner AL, Flack
CE, Mee JM, Horswill AR, Janda KD, Kaufmann 
</P>
<P STYLE="margin-bottom: 0cm">GF, Wilson IA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Molecular Biology, The
Scripps Research Institute, La Jolla,</P>
<P STYLE="margin-bottom: 0cm">California 92037, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">In the postantibiotic era, available
treatment options for severe bacterial</P>
<P STYLE="margin-bottom: 0cm">infections caused by
methicillin-resistant Staphylococcus aureus have become</P>
<P STYLE="margin-bottom: 0cm">limited. Therefore, new and innovative
approaches are needed to combat such</P>
<P STYLE="margin-bottom: 0cm">life-threatening infections. Virulence
factor expression in S. aureus is</P>
<P STYLE="margin-bottom: 0cm">regulated in a cell density-dependent
manner using &quot;quorum sensing,&quot; which</P>
<P STYLE="margin-bottom: 0cm">involves generation and secretion of
autoinducing peptides (AIPs) into the</P>
<P STYLE="margin-bottom: 0cm">surrounding environment to activate a
bacterial sensor kinase at a particular</P>
<P STYLE="margin-bottom: 0cm">threshold concentration. Mouse
monoclonal antibody AP4-24H11 was shown previously</P>
<P STYLE="margin-bottom: 0cm">to blunt quorum sensing-mediated
changes in gene expression in vitro and protect 
</P>
<P STYLE="margin-bottom: 0cm">mice from a lethal dose of S. aureus by
sequestering the AIP signal. We have</P>
<P STYLE="margin-bottom: 0cm">elucidated the crystal structure of the
AP4-24H11 Fab in complex with AIP-4 at</P>
<P STYLE="margin-bottom: 0cm">2.5 Å resolution to determine its
mechanism of ligand recognition. A key Glu(H95)</P>
<P STYLE="margin-bottom: 0cm">provides much of the binding
specificity through formation of hydrogen bonds with</P>
<P STYLE="margin-bottom: 0cm">each of the four amide nitrogens in the
AIP-4 macrocyclic ring. Importantly,</P>
<P STYLE="margin-bottom: 0cm">these structural data give clues as to
the interactions between the cognate</P>
<P STYLE="margin-bottom: 0cm">staphylococcal AIP receptors AgrC and
the AIPs, as AP4-24H11·AIP-4 binding</P>
<P STYLE="margin-bottom: 0cm">recapitulates features that have been
proposed for AgrC-AIP recognition.</P>
<P STYLE="margin-bottom: 0cm">Additionally, these structural insights
may enable the engineering of AIP</P>
<P STYLE="margin-bottom: 0cm">cross-reactive antibodies or quorum
quenching vaccines for use in active or</P>
<P STYLE="margin-bottom: 0cm">passive immunotherapy for prevention or
treatment of S. aureus infections.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3089576</P>
<P STYLE="margin-bottom: 0cm">PMID: 21454495 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm">1. Biochem J. 2014 Sep
15;462(3):441-52. doi: 10.1042/BJ20140382.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structural and functional
characterization of ochratoxinase, a novel</P>
<P STYLE="margin-bottom: 0cm">mycotoxin-degrading enzyme.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Dobritzsch D, Wang H, Schneider G(1),
Yu S.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)*Department of Medical Biochemistry
and Biophysics, Karolinska Institutet,</P>
<P STYLE="margin-bottom: 0cm">SE-17177 Stockholm, Sweden.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ochratoxin, with ochratoxin A as the
dominant form, is one of the five major</P>
<P STYLE="margin-bottom: 0cm">mycotoxins most harmful to humans and
animals. It is produced by Aspergillus and 
</P>
<P STYLE="margin-bottom: 0cm">Penicillium species and occurs in a
wide range of agricultural products.</P>
<P STYLE="margin-bottom: 0cm">Detoxification of contaminated food is
a challenging health issue. In the present</P>
<P STYLE="margin-bottom: 0cm">paper we report the identification,
characterization and crystal structure (at</P>
<P STYLE="margin-bottom: 0cm">2.2 Å) of a novel microbial
ochratoxinase from Aspergillus niger. A putative</P>
<P STYLE="margin-bottom: 0cm">amidase gene encoding a 480 amino acid
polypeptide was cloned and homologously</P>
<P STYLE="margin-bottom: 0cm">expressed in A. niger. The recombinant
protein is N-terminally truncated,</P>
<P STYLE="margin-bottom: 0cm">thermostable, has optimal activity at
pH ~6 and 66°C, and is more efficient in</P>
<P STYLE="margin-bottom: 0cm">ochratoxin A hydrolysis than
carboxypeptidase A and Y, the two previously known</P>
<P STYLE="margin-bottom: 0cm">enzymes capable of degrading this
mycotoxin. The subunit of the homo-octameric</P>
<P STYLE="margin-bottom: 0cm">enzyme folds into a two-domain
structure characteristic of a metal dependent</P>
<P STYLE="margin-bottom: 0cm">amidohydrolase, with a twisted TIM
(triosephosphateisomerase)-barrel and a</P>
<P STYLE="margin-bottom: 0cm">smaller β-sandwich domain. The active
site contains an aspartate residue for</P>
<P STYLE="margin-bottom: 0cm">acid-base catalysis, and a carboxylated
lysine and four histidine residues for</P>
<P STYLE="margin-bottom: 0cm">binding of a binuclear metal centre.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24947135 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Appl Environ Microbiol. 2015
Apr;81(7):2612-24. doi: 10.1128/AEM.04016-14. Epub</P>
<P STYLE="margin-bottom: 0cm">2015 Jan 30.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Evolutionary expansion of the
amidohydrolase superfamily in bacteria in response 
</P>
<P STYLE="margin-bottom: 0cm">to the synthetic compounds molinate and
diuron.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sugrue E(1), Fraser NJ(1), Hopkins
DH(1), Carr PD(1), Khurana JL(2), Oakeshott</P>
<P STYLE="margin-bottom: 0cm">JG(2), Scott C(2), Jackson CJ(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Research School of Chemistry,
Australian National University, Canberra, ACT,</P>
<P STYLE="margin-bottom: 0cm">Australia. (2)CSIRO, Canberra, ACT,
Australia. (3)Research School of Chemistry,</P>
<P STYLE="margin-bottom: 0cm">Australian National University,
Canberra, ACT, Australia CSIRO, Canberra, ACT,</P>
<P STYLE="margin-bottom: 0cm">Australia colin.jackson@anu.edu.au.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The amidohydrolase superfamily has
remarkable functional diversity, with</P>
<P STYLE="margin-bottom: 0cm">considerable structural and functional
annotation of known sequences. In</P>
<P STYLE="margin-bottom: 0cm">microbes, the recent evolution of
several members of this family to catalyze the 
</P>
<P STYLE="margin-bottom: 0cm">breakdown of environmental xenobiotics
is not well understood. An evolutionary</P>
<P STYLE="margin-bottom: 0cm">transition from binuclear to
mononuclear metal ion coordination at the active</P>
<P STYLE="margin-bottom: 0cm">sites of these enzymes could produce
large functional changes such as those</P>
<P STYLE="margin-bottom: 0cm">observed in nature, but there are few
clear examples available to support this</P>
<P STYLE="margin-bottom: 0cm">hypothesis. To investigate the role of
binuclear-mononuclear active-site</P>
<P STYLE="margin-bottom: 0cm">transitions in the evolution of new
function in this superfamily, we have</P>
<P STYLE="margin-bottom: 0cm">characterized two recently evolved
enzymes that catalyze the hydrolysis of the</P>
<P STYLE="margin-bottom: 0cm">synthetic herbicides molinate (MolA)
and phenylurea (PuhB). In this work, the</P>
<P STYLE="margin-bottom: 0cm">crystal structures, mutagenesis, metal
ion analysis, and enzyme kinetics of both 
</P>
<P STYLE="margin-bottom: 0cm">MolA and PuhB establish that these
enzymes utilize a mononuclear active site.</P>
<P STYLE="margin-bottom: 0cm">However, bioinformatics and structural
comparisons reveal that the closest</P>
<P STYLE="margin-bottom: 0cm">putative ancestor of these enzymes had
a binuclear active site, indicating that a</P>
<P STYLE="margin-bottom: 0cm">binuclear-mononuclear transition has
occurred. These proteins may represent</P>
<P STYLE="margin-bottom: 0cm">examples of evolution modifying the
characteristics of existing catalysts to</P>
<P STYLE="margin-bottom: 0cm">satisfy new requirements, specifically,
metal ion rearrangement leading to large 
</P>
<P STYLE="margin-bottom: 0cm">leaps in activity that would not
otherwise be possible.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Society for
Microbiology. All Rights Reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4357960 [Available on
2015-10-01]</P>
<P STYLE="margin-bottom: 0cm">PMID: 25636851 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. EMBO J. 1994 Jan 1;13(1):180-9.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structure and function of the b/HLH/Z
domain of USF.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ferré-D'Amaré AR(1), Pognonec P,
Roeder RG, Burley SK.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Laboratories of Molecular
Biophysics, Rockefeller University, New York, NY</P>
<P STYLE="margin-bottom: 0cm">10021.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The basic/helix-loop-helix/leucine
zipper (b/HLH/Z) transcription factor upstream</P>
<P STYLE="margin-bottom: 0cm">stimulatory factor (USF) and its
isolated DNA binding domain undergo a random</P>
<P STYLE="margin-bottom: 0cm">coil to alpha-helix folding transition
on recognizing their cognate DNA. The USF 
</P>
<P STYLE="margin-bottom: 0cm">b/HLH cocrystal structure resembles the
structure of the b/HLH/Z domain of the</P>
<P STYLE="margin-bottom: 0cm">homologous protein Max and reveals (i)
that the truncated, b/HLH DNA binding</P>
<P STYLE="margin-bottom: 0cm">domain homodimerizes, forming a
parallel, left-handed four-helix bundle, and (ii)</P>
<P STYLE="margin-bottom: 0cm">that the basic region becomes
alpha-helical on binding to the major groove of the</P>
<P STYLE="margin-bottom: 0cm">DNA sequence CACGTG. Hydrodynamic
measurements show that the b/HLH/Z DNA binding 
</P>
<P STYLE="margin-bottom: 0cm">domain of USF exists as a bivalent
homotetramer. This tetramer forms at the USF</P>
<P STYLE="margin-bottom: 0cm">physiological intranuclear
concentration, and depends on the integrity of the</P>
<P STYLE="margin-bottom: 0cm">leucine zipper motif. The ability to
bind simultaneously to two independent sites</P>
<P STYLE="margin-bottom: 0cm">suggests a role in DNA looping for the
b/HLH/Z and Myc-related families of</P>
<P STYLE="margin-bottom: 0cm">eukaryotic transcription factors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC394791</P>
<P STYLE="margin-bottom: 0cm">PMID: 8306960 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Science. 2012 Jun 8;336(6086):1274.
doi: 10.1126/science.1218713. Epub 2012 Mar</P>
<P STYLE="margin-bottom: 0cm">1.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Crystal structure of human enterovirus
71.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Plevka P(1), Perera R, Cardosa J, Kuhn
RJ, Rossmann MG.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biological Sciences,
Purdue University, West Lafayette, IN</P>
<P STYLE="margin-bottom: 0cm">47907, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Enterovirus 71 is a picornavirus
associated with fatal neurological illness in</P>
<P STYLE="margin-bottom: 0cm">infants and young children. Here, we
report the crystal structure of enterovirus 
</P>
<P STYLE="margin-bottom: 0cm">71 and show that, unlike in other
enteroviruses, the &quot;pocket factor,&quot; a small</P>
<P STYLE="margin-bottom: 0cm">molecule that stabilizes the virus, is
partly exposed on the floor of the</P>
<P STYLE="margin-bottom: 0cm">&quot;canyon.&quot; Thus, the structure
of antiviral compounds may require a hydrophilic</P>
<P STYLE="margin-bottom: 0cm">head group designed to interact with
residues at the entrance of the pocket.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3448362</P>
<P STYLE="margin-bottom: 0cm">PMID: 22383808 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Nature. 1998 Apr
16;392(6677):677-84.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Electron transfer by domain movement in
cytochrome bc1.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zhang Z(1), Huang L, Shulmeister VM,
Chi YI, Kim KK, Hung LW, Crofts AR, Berry</P>
<P STYLE="margin-bottom: 0cm">EA, Kim SH.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)E. O. Lawrence Berkeley National
Laboratory, University of California, 94720, 
</P>
<P STYLE="margin-bottom: 0cm">USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The cytochrome bc1 is one of the three
major respiratory enzyme complexes</P>
<P STYLE="margin-bottom: 0cm">residing in the inner mitochondrial
membrane. Cytochrome bc1 transfers electrons 
</P>
<P STYLE="margin-bottom: 0cm">from ubiquinol to cytochrome c and uses
the energy thus released to form an</P>
<P STYLE="margin-bottom: 0cm">electrochemical gradient across the
inner membrane. Our X-ray crystal structures 
</P>
<P STYLE="margin-bottom: 0cm">of the complex from chicken, cow and
rabbit in both the presence and absence of</P>
<P STYLE="margin-bottom: 0cm">inhibitors of quinone oxidation, reveal
two different locations for the extrinsic</P>
<P STYLE="margin-bottom: 0cm">domain of one component of the enzyme,
an iron-sulphur protein. One location is</P>
<P STYLE="margin-bottom: 0cm">close enough to the supposed quinol
oxidation site to allow reduction of the Fe-S</P>
<P STYLE="margin-bottom: 0cm">protein by ubiquinol. The other site is
close enough to cytochrome c1 to allow</P>
<P STYLE="margin-bottom: 0cm">oxidation of the Fe-S protein by the
cytochrome. As neither location will allow</P>
<P STYLE="margin-bottom: 0cm">both reactions to proceed at a suitable
rate, the reaction mechanism must involve</P>
<P STYLE="margin-bottom: 0cm">movement of the extrinsic domain of the
Fe-S component in order to shuttle</P>
<P STYLE="margin-bottom: 0cm">electrons from ubiquinol to cytochrome
c1. Such a mechanism has not previously</P>
<P STYLE="margin-bottom: 0cm">been observed in redox protein
complexes.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 9565029 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Nat Struct Mol Biol. 2010
May;17(5):555-60. doi: 10.1038/nsmb.1790. Epub 2010 Apr</P>
<P STYLE="margin-bottom: 0cm">18.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structural aspects of messenger RNA
reading frame maintenance by the ribosome.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Jenner LB(1), Demeshkina N, Yusupova G,
Yusupov M.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Institut de Génétique et de
Biologie Moléculaire et Cellulaire, Département de</P>
<P STYLE="margin-bottom: 0cm">Biologie et de Génomique Structurales,
Illkirch, France.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">One key question in protein
biosynthesis is how the ribosome couples mRNA and</P>
<P STYLE="margin-bottom: 0cm">tRNA movements to prevent disruption of
weak codon-anticodon interactions and</P>
<P STYLE="margin-bottom: 0cm">loss of the translational reading frame
during translocation. Here we report the 
</P>
<P STYLE="margin-bottom: 0cm">complete path of mRNA on the 70S
ribosome at the atomic level (3.1-A resolution),</P>
<P STYLE="margin-bottom: 0cm">and we show that one of the
conformational rearrangements that occurs upon</P>
<P STYLE="margin-bottom: 0cm">transition from initiation to
elongation is a narrowing of the downstream mRNA</P>
<P STYLE="margin-bottom: 0cm">tunnel. This rearrangement triggers
formation of a network of interactions</P>
<P STYLE="margin-bottom: 0cm">between the mRNA downstream of the
A-site codon and the elongating ribosome. Our 
</P>
<P STYLE="margin-bottom: 0cm">data elucidate the mechanism by which
hypermodified nucleoside 2-methylthio-N6</P>
<P STYLE="margin-bottom: 0cm">isopentenyl adenosine at position 37
(ms(2)i(6)A37) in tRNA(Phe)(GAA) stabilizes 
</P>
<P STYLE="margin-bottom: 0cm">mRNA-tRNA interactions in all three
tRNA binding sites. Another network of</P>
<P STYLE="margin-bottom: 0cm">contacts is formed between this tRNA
modification and ribosomal elements</P>
<P STYLE="margin-bottom: 0cm">surrounding the mRNA E/P kink,
resulting in the anchoring of P-site tRNA. These</P>
<P STYLE="margin-bottom: 0cm">data allow rationalization of how
modification deficiencies of ms(2)i(6)A37 in</P>
<P STYLE="margin-bottom: 0cm">tRNAs may lead to shifts of the
translational reading frame.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 20400952 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Science. 2014 Mar
7;343(6175):1137-40. doi: 10.1126/science.1246729.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Crystal structures of nucleotide-free
and glutathione-bound mitochondrial ABC</P>
<P STYLE="margin-bottom: 0cm">transporter Atm1.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Srinivasan V(1), Pierik AJ, Lill R.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Institut für Zytobiologie,
Philipps-Universität Marburg, Robert-Koch-Strasse</P>
<P STYLE="margin-bottom: 0cm">6, 35032 Marburg, Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The yeast mitochondrial ABC transporter
Atm1, in concert with glutathione,</P>
<P STYLE="margin-bottom: 0cm">functions in the export of a substrate
required for cytosolic-nuclear iron-sulfur</P>
<P STYLE="margin-bottom: 0cm">protein biogenesis and cellular iron
regulation. Defects in the human ortholog</P>
<P STYLE="margin-bottom: 0cm">ABCB7 cause the sideroblastic anemia
XLSA/A. Here, we report the crystal</P>
<P STYLE="margin-bottom: 0cm">structures of free and
glutathione-bound Atm1 in inward-facing, open</P>
<P STYLE="margin-bottom: 0cm">conformations at 3.06- and
3.38-angstrom resolution, respectively. The</P>
<P STYLE="margin-bottom: 0cm">glutathione binding site includes a
residue mutated in XLSA/A and is located</P>
<P STYLE="margin-bottom: 0cm">close to the inner membrane surface in
a large cavity. The two nucleotide-free</P>
<P STYLE="margin-bottom: 0cm">adenosine 5'-triphosphate binding
domains do not interact yet are kept in close</P>
<P STYLE="margin-bottom: 0cm">vicinity through tight interaction of
the two C-terminal α-helices of the Atm1</P>
<P STYLE="margin-bottom: 0cm">dimer. The resulting protein
stabilization may be a common structural feature of 
</P>
<P STYLE="margin-bottom: 0cm">all ABC exporters.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24604199 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Nat Struct Mol Biol. 2014
Jun;21(6):513-21. doi: 10.1038/nsmb.2822. Epub 2014 May</P>
<P STYLE="margin-bottom: 0cm">4.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structural basis of starvation-induced
assembly of the autophagy initiation</P>
<P STYLE="margin-bottom: 0cm">complex.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Fujioka Y(1), Suzuki SW(2), Yamamoto
H(3), Kondo-Kakuta C(4), Kimura Y(5), Hirano</P>
<P STYLE="margin-bottom: 0cm">H(5), Akada R(6), Inagaki F(7), Ohsumi
Y(4), Noda NN(8).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)1] Institute of Microbial Chemistry
(BIKAKEN), Tokyo, Japan. [2]. (2)1]</P>
<P STYLE="margin-bottom: 0cm">Frontier Research Center, Tokyo
Institute of Technology, Yokohama, Japan. [2]</P>
<P STYLE="margin-bottom: 0cm">Graduate School of Bioscience and
Biotechnology, Tokyo Institute of Technology,</P>
<P STYLE="margin-bottom: 0cm">Yokohama, Japan. [3]. (3)1] Frontier
Research Center, Tokyo Institute of</P>
<P STYLE="margin-bottom: 0cm">Technology, Yokohama, Japan. [2].
(4)Frontier Research Center, Tokyo Institute of</P>
<P STYLE="margin-bottom: 0cm">Technology, Yokohama, Japan.
(5)Graduate School of Medical Life Science and</P>
<P STYLE="margin-bottom: 0cm">Advanced Medical Research Center,
Yokohama City University, Yokohama, Japan.</P>
<P STYLE="margin-bottom: 0cm">(6)Department of Applied Molecular
Bioscience, Graduate School of Medicine,</P>
<P STYLE="margin-bottom: 0cm">Yamaguchi University, Ube, Japan. (7)1]
Department of Structural Biology, Faculty</P>
<P STYLE="margin-bottom: 0cm">of Advanced Life Science, Hokkaido
University, Sapporo, Japan. [2] Core Research 
</P>
<P STYLE="margin-bottom: 0cm">for Evolutionary Science and Technology
(CREST), Japan Science and Technology</P>
<P STYLE="margin-bottom: 0cm">Agency, Tokyo, Japan. (8)1] Institute
of Microbial Chemistry (BIKAKEN), Tokyo,</P>
<P STYLE="margin-bottom: 0cm">Japan. [2] Core Research for
Evolutionary Science and Technology (CREST), Japan</P>
<P STYLE="margin-bottom: 0cm">Science and Technology Agency, Tokyo,
Japan.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Assembly of the preautophagosomal
structure (PAS) is essential for autophagy</P>
<P STYLE="margin-bottom: 0cm">initiation in yeast. Starvation-induced
dephosphorylation of Atg13 is required</P>
<P STYLE="margin-bottom: 0cm">for the formation of the
Atg1-Atg13-Atg17-Atg29-Atg31 complex (Atg1 complex), a</P>
<P STYLE="margin-bottom: 0cm">prerequisite for PAS assembly. However,
molecular details underlying these events</P>
<P STYLE="margin-bottom: 0cm">have not been established. Here we
studied the interactions of yeast Atg13 with</P>
<P STYLE="margin-bottom: 0cm">Atg1 and Atg17 by X-ray
crystallography. Atg13 binds tandem microtubule</P>
<P STYLE="margin-bottom: 0cm">interacting and transport domains in
Atg1, using an elongated helix-loop-helix</P>
<P STYLE="margin-bottom: 0cm">region. Atg13 also binds Atg17, using a
short region, thereby bridging Atg1 and</P>
<P STYLE="margin-bottom: 0cm">Atg17 and leading to Atg1-complex
formation. Dephosphorylation of specific</P>
<P STYLE="margin-bottom: 0cm">serines in Atg13 enhanced its
interaction with not only Atg1 but also Atg17.</P>
<P STYLE="margin-bottom: 0cm">These observations update the
autophagy-initiation model as follows: upon</P>
<P STYLE="margin-bottom: 0cm">starvation, dephosphorylated Atg13
binds both Atg1 and Atg17, and this promotes</P>
<P STYLE="margin-bottom: 0cm">PAS assembly and autophagy progression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 24793651 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Biol Chem. 2000 Nov
10;275(45):35242-7.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The structure of a CREB
bZIP.somatostatin CRE complex reveals the basis for</P>
<P STYLE="margin-bottom: 0cm">selective dimerization and divalent
cation-enhanced DNA binding.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Schumacher MA(1), Goodman RH, Brennan
RG.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biochemistry and
Molecular Biology and the Vollum Institute,</P>
<P STYLE="margin-bottom: 0cm">Oregon Health Sciences University,
Portland, Oregon 97201-3098, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The cAMP responsive element-binding
protein (CREB) is central to second messenger</P>
<P STYLE="margin-bottom: 0cm">regulated transcription. To elucidate
the structural mechanisms of DNA binding</P>
<P STYLE="margin-bottom: 0cm">and selective dimerization of CREB, we
determined to 3.0 A resolution, the</P>
<P STYLE="margin-bottom: 0cm">structure of the CREB bZIP (residues
283-341) bound to a 21-base pair</P>
<P STYLE="margin-bottom: 0cm">deoxynucleotide that encompasses the
canonical 8-base pair somatostatin cAMP</P>
<P STYLE="margin-bottom: 0cm">response element (SSCRE). The CREB
dimer is stabilized in part by ionic</P>
<P STYLE="margin-bottom: 0cm">interactions from Arg(314) to Glu(319')
and Glu(328) to Lys(333') as well as a</P>
<P STYLE="margin-bottom: 0cm">hydrogen bond network that links the
carboxamide side chains of</P>
<P STYLE="margin-bottom: 0cm">Gln(322')-Asn(321)-Asn(321')-Gln(322).
Critical to family selective dimerization 
</P>
<P STYLE="margin-bottom: 0cm">are intersubunit hydrogen bonds between
basic region residue Tyr(307) and leucine</P>
<P STYLE="margin-bottom: 0cm">zipper residue Glu(312), which are
conserved in all CREB/CREM/ATF-1 family</P>
<P STYLE="margin-bottom: 0cm">members. Strikingly, the structure
reveals a hexahydrated Mg(2+) ion bound in the</P>
<P STYLE="margin-bottom: 0cm">cavity between the basic region and
SSCRE that makes a water-mediated DNA</P>
<P STYLE="margin-bottom: 0cm">contact. DNA binding studies
demonstrate that Mg(2+) ions enhance CREB bZIP:SSCRE</P>
<P STYLE="margin-bottom: 0cm">binding by more than 25-fold and
suggest a possible physiological role for this</P>
<P STYLE="margin-bottom: 0cm">ion in somatostatin cAMP response
element and potentially other CRE-mediated gene</P>
<P STYLE="margin-bottom: 0cm">expression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 10952992 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Chem Biol. 2006 Jan;13(1):81-90.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Target structure-based discovery of
small molecules that block human p53 and CREB</P>
<P STYLE="margin-bottom: 0cm">binding protein association.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sachchidanand(1), Resnick-Silverman L,
Yan S, Mutjaba S, Liu WJ, Zeng L, Manfredi</P>
<P STYLE="margin-bottom: 0cm">JJ, Zhou MM.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Structural Biology Program,
Department of Physiology and Biophysics, Mount</P>
<P STYLE="margin-bottom: 0cm">Sinai School of Medicine, New York
University, New York 10029, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Lysine acetylation of human tumor
suppressor p53 in response to cellular stress</P>
<P STYLE="margin-bottom: 0cm">signals is required for its function as
a transcription factor that regulates</P>
<P STYLE="margin-bottom: 0cm">cell cycle arrest, senescence, or
apoptosis. Here, we report small molecules that</P>
<P STYLE="margin-bottom: 0cm">block lysine 382-acetylated p53
association with the bromodomain of the</P>
<P STYLE="margin-bottom: 0cm">coactivator CBP, an interaction
essential for p53-induced transcription of the</P>
<P STYLE="margin-bottom: 0cm">cell cycle inhibitor p21 in response to
DNA damage. These chemicals were</P>
<P STYLE="margin-bottom: 0cm">discovered in target structure-guided
nuclear magnetic resonance spectroscopy</P>
<P STYLE="margin-bottom: 0cm">screening of a focused chemical library
constructed based on the structural</P>
<P STYLE="margin-bottom: 0cm">knowledge of CBP bromodomain/p53-AcK382
binding. Structural characterization</P>
<P STYLE="margin-bottom: 0cm">shows that these chemicals inhibit
CBP/p53 association by binding to the</P>
<P STYLE="margin-bottom: 0cm">acetyl-lysine binding site of the
bromodomain. Cell-based functional assays</P>
<P STYLE="margin-bottom: 0cm">demonstrate that the lead chemicals can
modulate p53 stability and function in</P>
<P STYLE="margin-bottom: 0cm">response to DNA damage.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 16426974 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Cell. 1997 Dec 12;91(6):741-52.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Solution structure of the KIX domain of
CBP bound to the transactivation domain</P>
<P STYLE="margin-bottom: 0cm">of CREB: a model for
activator:coactivator interactions.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Radhakrishnan I(1), Pérez-Alvarado GC,
Parker D, Dyson HJ, Montminy MR, Wright</P>
<P STYLE="margin-bottom: 0cm">PE.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Molecular Biology, and
the Skaggs Institute for Chemical</P>
<P STYLE="margin-bottom: 0cm">Biology, The Scripps Research
Institute, La Jolla, California 92037, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The nuclear factor CREB activates
transcription of target genes in part through</P>
<P STYLE="margin-bottom: 0cm">direct interactions with the KIX domain
of the coactivator CBP in a</P>
<P STYLE="margin-bottom: 0cm">phosphorylation-dependent manner. The
solution structure of the complex formed by</P>
<P STYLE="margin-bottom: 0cm">the phosphorylated kinase-inducible
domain (pKID) of CREB with KIX reveals that</P>
<P STYLE="margin-bottom: 0cm">pKID undergoes a coil--&gt;helix
folding transition upon binding to KIX, forming two</P>
<P STYLE="margin-bottom: 0cm">alpha helices. The amphipathic helix
alphaB of pKID interacts with a hydrophobic 
</P>
<P STYLE="margin-bottom: 0cm">groove defined by helices alpha1 and
alpha3 of KIX. The other pKID helix, alphaA,</P>
<P STYLE="margin-bottom: 0cm">contacts a different face of the alpha3
helix. The phosphate group of the</P>
<P STYLE="margin-bottom: 0cm">critical phosphoserine residue of pKID
forms a hydrogen bond to the side chain of</P>
<P STYLE="margin-bottom: 0cm">Tyr-658 of KIX. The structure provides
a model for interactions between other</P>
<P STYLE="margin-bottom: 0cm">transactivation domains and their
targets.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 9413984 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Chem Biol. 2011 Apr 22;18(4):531-41.
doi: 10.1016/j.chembiol.2010.12.021.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A small molecule binding to the
coactivator CREB-binding protein blocks apoptosis</P>
<P STYLE="margin-bottom: 0cm">in cardiomyocytes.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Borah JC(1), Mujtaba S, Karakikes I,
Zeng L, Muller M, Patel J, Moshkina N,</P>
<P STYLE="margin-bottom: 0cm">Morohashi K, Zhang W, Gerona-Navarro G,
Hajjar RJ, Zhou MM.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Structural and
Chemical Biology, Mount Sinai School of Medicine,</P>
<P STYLE="margin-bottom: 0cm">One Gustave L. Levy Place, New York, NY
10029, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">As a master transcription factor in
cellular responses to external stress, tumor 
</P>
<P STYLE="margin-bottom: 0cm">suppressor p53 is tightly regulated.
Excessive p53 activity during myocardial</P>
<P STYLE="margin-bottom: 0cm">ischemia causes irreversible cellular
injury and cardiomyocyte death. p53</P>
<P STYLE="margin-bottom: 0cm">activation is dependent on lysine
acetylation by the lysine acetyltransferase and</P>
<P STYLE="margin-bottom: 0cm">transcriptional coactivator
CREB-binding protein (CBP) and on</P>
<P STYLE="margin-bottom: 0cm">acetylation-directed CBP recruitment
for p53 target gene expression. Here, we</P>
<P STYLE="margin-bottom: 0cm">report a small molecule ischemin,
developed with a structure-guided approach to</P>
<P STYLE="margin-bottom: 0cm">inhibit the acetyl-lysine binding
activity of the bromodomain of CBP. We show</P>
<P STYLE="margin-bottom: 0cm">that ischemin alters post-translational
modifications on p53 and histones,</P>
<P STYLE="margin-bottom: 0cm">inhibits p53 interaction with CBP and
transcriptional activity in cells, and</P>
<P STYLE="margin-bottom: 0cm">prevents apoptosis in ischemic
cardiomyocytes. Our study suggests small molecule 
</P>
<P STYLE="margin-bottom: 0cm">modulation of acetylation-mediated
interactions in gene transcription as a new</P>
<P STYLE="margin-bottom: 0cm">approach to therapeutic interventions
of human disorders such as myocardial</P>
<P STYLE="margin-bottom: 0cm">ischemia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2011 Elsevier Ltd. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3103858</P>
<P STYLE="margin-bottom: 0cm">PMID: 21513889 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Biofactors. 2009
Mar-Apr;35(2):193-9. doi: 10.1002/biof.29.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Physiological factors that regulate
skin pigmentation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Yamaguchi Y(1), Hearing VJ.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Geriatric and
Environmental Dermatology, Nagoya City University 
</P>
<P STYLE="margin-bottom: 0cm">Graduate School of Medical Sciences,
Nagoya, Japan. yujin@med.nagoya-cu.ac.jp</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">More than 150 genes have been
identified that affect skin color either directly</P>
<P STYLE="margin-bottom: 0cm">or indirectly, and we review current
understanding of physiological factors that 
</P>
<P STYLE="margin-bottom: 0cm">regulate skin pigmentation. We focus on
melanosome biogenesis, transport and</P>
<P STYLE="margin-bottom: 0cm">transfer, melanogenic regulators in
melanocytes, and factors derived from</P>
<P STYLE="margin-bottom: 0cm">keratinocytes, fibroblasts, endothelial
cells, hormones, inflammatory cells, and 
</P>
<P STYLE="margin-bottom: 0cm">nerves. Enzymatic components of
melanosomes include tyrosinase,</P>
<P STYLE="margin-bottom: 0cm">tyrosinase-related protein 1, and
dopachrome tautomerase, which depend on the</P>
<P STYLE="margin-bottom: 0cm">functions of OA1, P, MATP, ATP7A, and
BLOC-1 to synthesize eumelanins and</P>
<P STYLE="margin-bottom: 0cm">pheomelanins. The main structural
component of melanosomes is Pmel17/gp100/Silv, 
</P>
<P STYLE="margin-bottom: 0cm">whose sorting involves adaptor protein
1A (AP1A), AP1B, AP2, and spectrin, as</P>
<P STYLE="margin-bottom: 0cm">well as a chaperone-like component,
MART-1. During their maturation, melanosomes 
</P>
<P STYLE="margin-bottom: 0cm">move from the perinuclear area toward
the plasma membrane. Microtubules, dynein, 
</P>
<P STYLE="margin-bottom: 0cm">kinesin, actin filaments, Rab27a,
melanophilin, myosin Va, and Slp2-a are</P>
<P STYLE="margin-bottom: 0cm">involved in melanosome transport. Foxn1
and p53 up-regulate skin pigmentation via</P>
<P STYLE="margin-bottom: 0cm">bFGF and POMC derivatives including
alpha-MSH and ACTH, respectively. Other</P>
<P STYLE="margin-bottom: 0cm">critical factors that affect skin
pigmentation include MC1R, CREB, ASP, MITF,</P>
<P STYLE="margin-bottom: 0cm">PAX3, SOX9/10, LEF-1/TCF, PAR-2, DKK1,
SCF, HGF, GM-CSF, endothelin-1,</P>
<P STYLE="margin-bottom: 0cm">prostaglandins, leukotrienes,
thromboxanes, neurotrophins, and neuropeptides. UV 
</P>
<P STYLE="margin-bottom: 0cm">radiation up-regulates most factors
that increase melanogenesis. Further studies 
</P>
<P STYLE="margin-bottom: 0cm">will elucidate the currently unknown
functions of many other pigment</P>
<P STYLE="margin-bottom: 0cm">genes/proteins. (c) 2009 International
Union of Biochemistry and Molecular</P>
<P STYLE="margin-bottom: 0cm">Biology, Inc.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC2793097</P>
<P STYLE="margin-bottom: 0cm">PMID: 19449448 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Biochemistry. 2009 Aug
25;48(33):7849-55. doi: 10.1021/bi901003k.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Solution structures of the actuator
domain of ATP7A and ATP7B, the Menkes and</P>
<P STYLE="margin-bottom: 0cm">Wilson disease proteins.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Banci L(1), Bertini I, Cantini F,
Migliardi M, Natile G, Nushi F, Rosato A.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Magnetic Resonance Center
(CERM)-University of Florence, Via L. Sacconi 6,</P>
<P STYLE="margin-bottom: 0cm">50019 Sesto Fiorentino, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">ATP7A and ATP7B are two human
P(1B)-type ATPases that have a crucial role in</P>
<P STYLE="margin-bottom: 0cm">maintaining copper(I) homeostasis.
Among the various domains of these enzymes,</P>
<P STYLE="margin-bottom: 0cm">one, called the Actuator or A-domain,
has a regulatory function and is required</P>
<P STYLE="margin-bottom: 0cm">for the phosphatase step of the
catalytic cycle (dephosphorylation of the</P>
<P STYLE="margin-bottom: 0cm">intermediate formed during ATP
hydrolysis). Here we report the solution</P>
<P STYLE="margin-bottom: 0cm">structures of the A-domain of both
proteins, solved by heteronuclear NMR</P>
<P STYLE="margin-bottom: 0cm">spectroscopy and a characterization of
the dynamics of the A-domain of ATP7A. We 
</P>
<P STYLE="margin-bottom: 0cm">observed that the catalytically
important TGE loop protrudes from the structure</P>
<P STYLE="margin-bottom: 0cm">ready for interaction with the
phosphorylated site in the ATP-binding domain. The</P>
<P STYLE="margin-bottom: 0cm">loop is rigid, suggesting that the
catalytic step does not require substantial</P>
<P STYLE="margin-bottom: 0cm">structural flexibility or
rearrangements. The present structures were useful to</P>
<P STYLE="margin-bottom: 0cm">rationalize the molecular effects of
disease-causing mutations. In particular, it</P>
<P STYLE="margin-bottom: 0cm">can be concluded that mutations
occurring in the A-domain either destabilize the 
</P>
<P STYLE="margin-bottom: 0cm">fold of the domain (such as Gly860Val
in ATP7A) or affect the network of</P>
<P STYLE="margin-bottom: 0cm">communication within the domain (such
as Leu873Arg in ATP7A) or with the other</P>
<P STYLE="margin-bottom: 0cm">domains of the enzyme (such as
Gly853Arg in ATP7A).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 19645496 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Biol Chem. 2006 Sep
29;281(39):29141-7. Epub 2006 Jul 26.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Solution structure and intermolecular
interactions of the third metal-binding</P>
<P STYLE="margin-bottom: 0cm">domain of ATP7A, the Menkes disease
protein.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Banci L(1), Bertini I, Cantini F,
DellaMalva N, Herrmann T, Rosato A, Wüthrich K.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Magnetic Resonance Center (CERM),
University of Florence, Via L. Sacconi 6,</P>
<P STYLE="margin-bottom: 0cm">50019 Sesto Fiorentino, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The third metal-binding domain of the
human Menkes protein (MNK3), a</P>
<P STYLE="margin-bottom: 0cm">copper(I)-transporting ATPase, has been
expressed in Escherichia coli and</P>
<P STYLE="margin-bottom: 0cm">characterized in solution. The solution
structure of MNK3, its copper(I)-binding 
</P>
<P STYLE="margin-bottom: 0cm">properties, and its interaction with
the physiological partner, HAH1, have been</P>
<P STYLE="margin-bottom: 0cm">studied. MNK3 is the domain most
dissimilar in structure from the other domains</P>
<P STYLE="margin-bottom: 0cm">of the Menkes protein. This is
reflected in a significant rearrangement of the</P>
<P STYLE="margin-bottom: 0cm">last strand of the four-stranded
beta-sheet when compared with the other known</P>
<P STYLE="margin-bottom: 0cm">homologous proteins or protein domains.
MNK3 is also peculiar with respect to its</P>
<P STYLE="margin-bottom: 0cm">interaction with the copper(I) ion, as
it was found to be a comparatively weak</P>
<P STYLE="margin-bottom: 0cm">binder. Copper(I) transfer from
metal-loaded HAH1 was observed experimentally,</P>
<P STYLE="margin-bottom: 0cm">but the metal distribution was shifted
toward binding by HAH1. This is at</P>
<P STYLE="margin-bottom: 0cm">variance with what is observed for the
other Menkes domains.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 16873374 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Biol Chem. 2006 Sep
29;281(39):29141-7. Epub 2006 Jul 26.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Solution structure and intermolecular
interactions of the third metal-binding</P>
<P STYLE="margin-bottom: 0cm">domain of ATP7A, the Menkes disease
protein.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Banci L(1), Bertini I, Cantini F,
DellaMalva N, Herrmann T, Rosato A, Wüthrich K.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Magnetic Resonance Center (CERM),
University of Florence, Via L. Sacconi 6,</P>
<P STYLE="margin-bottom: 0cm">50019 Sesto Fiorentino, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The third metal-binding domain of the
human Menkes protein (MNK3), a</P>
<P STYLE="margin-bottom: 0cm">copper(I)-transporting ATPase, has been
expressed in Escherichia coli and</P>
<P STYLE="margin-bottom: 0cm">characterized in solution. The solution
structure of MNK3, its copper(I)-binding 
</P>
<P STYLE="margin-bottom: 0cm">properties, and its interaction with
the physiological partner, HAH1, have been</P>
<P STYLE="margin-bottom: 0cm">studied. MNK3 is the domain most
dissimilar in structure from the other domains</P>
<P STYLE="margin-bottom: 0cm">of the Menkes protein. This is
reflected in a significant rearrangement of the</P>
<P STYLE="margin-bottom: 0cm">last strand of the four-stranded
beta-sheet when compared with the other known</P>
<P STYLE="margin-bottom: 0cm">homologous proteins or protein domains.
MNK3 is also peculiar with respect to its</P>
<P STYLE="margin-bottom: 0cm">interaction with the copper(I) ion, as
it was found to be a comparatively weak</P>
<P STYLE="margin-bottom: 0cm">binder. Copper(I) transfer from
metal-loaded HAH1 was observed experimentally,</P>
<P STYLE="margin-bottom: 0cm">but the metal distribution was shifted
toward binding by HAH1. This is at</P>
<P STYLE="margin-bottom: 0cm">variance with what is observed for the
other Menkes domains.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 16873374 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Biochemistry. 2004 Mar
30;43(12):3396-403.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Solution structure and backbone
dynamics of the Cu(I) and apo forms of the second</P>
<P STYLE="margin-bottom: 0cm">metal-binding domain of the Menkes
protein ATP7A.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Banci L(1), Bertini I, Del Conte R,
D'Onofrio M, Rosato A.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Magnetic Resonance Center,
University of Florence, Via L. Sacconi 6, 50019</P>
<P STYLE="margin-bottom: 0cm">Sesto Fiorentino, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The second domain of the human Menkes
protein (MNK2), formed by 72 residues, has 
</P>
<P STYLE="margin-bottom: 0cm">been expressed in Escherichia coli, and
its structure has been determined by NMR 
</P>
<P STYLE="margin-bottom: 0cm">in both the apo and copper-loaded
forms. The structures, obtained with (13)C- and</P>
<P STYLE="margin-bottom: 0cm">(15)N-labeled samples, are of high
quality with backbone rmsd values of 0.51 and 
</P>
<P STYLE="margin-bottom: 0cm">0.41 A and CYANA target functions of
0.39 and 0.38 A(2), respectively. The loop</P>
<P STYLE="margin-bottom: 0cm">involved in copper binding is part of a
hydrophobic patch, which is maintained in</P>
<P STYLE="margin-bottom: 0cm">both forms. Conformational mobility is
observed in the apo form in the same loop.</P>
<P STYLE="margin-bottom: 0cm">A comparison with metallochaperones and
soluble domains of P-type ATPases allows 
</P>
<P STYLE="margin-bottom: 0cm">us to relate the primary structure to
the occurrence of structural rearrangements</P>
<P STYLE="margin-bottom: 0cm">upon copper binding.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 15035611 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Biofactors. 2009
Mar-Apr;35(2):193-9. doi: 10.1002/biof.29.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Physiological factors that regulate
skin pigmentation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Yamaguchi Y(1), Hearing VJ.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Geriatric and
Environmental Dermatology, Nagoya City University 
</P>
<P STYLE="margin-bottom: 0cm">Graduate School of Medical Sciences,
Nagoya, Japan. yujin@med.nagoya-cu.ac.jp</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">More than 150 genes have been
identified that affect skin color either directly</P>
<P STYLE="margin-bottom: 0cm">or indirectly, and we review current
understanding of physiological factors that 
</P>
<P STYLE="margin-bottom: 0cm">regulate skin pigmentation. We focus on
melanosome biogenesis, transport and</P>
<P STYLE="margin-bottom: 0cm">transfer, melanogenic regulators in
melanocytes, and factors derived from</P>
<P STYLE="margin-bottom: 0cm">keratinocytes, fibroblasts, endothelial
cells, hormones, inflammatory cells, and 
</P>
<P STYLE="margin-bottom: 0cm">nerves. Enzymatic components of
melanosomes include tyrosinase,</P>
<P STYLE="margin-bottom: 0cm">tyrosinase-related protein 1, and
dopachrome tautomerase, which depend on the</P>
<P STYLE="margin-bottom: 0cm">functions of OA1, P, MATP, ATP7A, and
BLOC-1 to synthesize eumelanins and</P>
<P STYLE="margin-bottom: 0cm">pheomelanins. The main structural
component of melanosomes is Pmel17/gp100/Silv, 
</P>
<P STYLE="margin-bottom: 0cm">whose sorting involves adaptor protein
1A (AP1A), AP1B, AP2, and spectrin, as</P>
<P STYLE="margin-bottom: 0cm">well as a chaperone-like component,
MART-1. During their maturation, melanosomes 
</P>
<P STYLE="margin-bottom: 0cm">move from the perinuclear area toward
the plasma membrane. Microtubules, dynein, 
</P>
<P STYLE="margin-bottom: 0cm">kinesin, actin filaments, Rab27a,
melanophilin, myosin Va, and Slp2-a are</P>
<P STYLE="margin-bottom: 0cm">involved in melanosome transport. Foxn1
and p53 up-regulate skin pigmentation via</P>
<P STYLE="margin-bottom: 0cm">bFGF and POMC derivatives including
alpha-MSH and ACTH, respectively. Other</P>
<P STYLE="margin-bottom: 0cm">critical factors that affect skin
pigmentation include MC1R, CREB, ASP, MITF,</P>
<P STYLE="margin-bottom: 0cm">PAX3, SOX9/10, LEF-1/TCF, PAR-2, DKK1,
SCF, HGF, GM-CSF, endothelin-1,</P>
<P STYLE="margin-bottom: 0cm">prostaglandins, leukotrienes,
thromboxanes, neurotrophins, and neuropeptides. UV 
</P>
<P STYLE="margin-bottom: 0cm">radiation up-regulates most factors
that increase melanogenesis. Further studies 
</P>
<P STYLE="margin-bottom: 0cm">will elucidate the currently unknown
functions of many other pigment</P>
<P STYLE="margin-bottom: 0cm">genes/proteins. (c) 2009 International
Union of Biochemistry and Molecular</P>
<P STYLE="margin-bottom: 0cm">Biology, Inc.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC2793097</P>
<P STYLE="margin-bottom: 0cm">PMID: 19449448 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. J Biol Chem. 2010 Jan
22;285(4):2537-44. doi: 10.1074/jbc.M109.054262. Epub 2009 
</P>
<P STYLE="margin-bottom: 0cm">Nov 16.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The binding mode of ATP revealed by the
solution structure of the N-domain of</P>
<P STYLE="margin-bottom: 0cm">human ATP7A.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Banci L(1), Bertini I, Cantini F,
Inagaki S, Migliardi M, Rosato A.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Magnetic Resonance Center (CERM) and
Department of Chemistry, University of</P>
<P STYLE="margin-bottom: 0cm">Florence, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">We report the solution NMR structures
of the N-domain of the Menkes protein</P>
<P STYLE="margin-bottom: 0cm">(ATP7A) in the ATP-free and ATP-bound
forms. The structures consist of a twisted 
</P>
<P STYLE="margin-bottom: 0cm">antiparallel six-stranded beta-sheet
flanked by two pairs of alpha-helices. A</P>
<P STYLE="margin-bottom: 0cm">protein loop of 50 amino acids located
between beta 3 and beta 4 is disordered</P>
<P STYLE="margin-bottom: 0cm">and mobile on the subnanosecond time
scale. ATP binds with an affinity constant</P>
<P STYLE="margin-bottom: 0cm">of (1.2 +/- 0.1) x 10(4) m(-1) and
exchanges with a rate of the order of 1 x</P>
<P STYLE="margin-bottom: 0cm">10(3) s(-1). The ATP-binding cavity is
considerably affected by the presence of</P>
<P STYLE="margin-bottom: 0cm">the ligand, resulting in a more compact
conformation in the ATP-bound than in the</P>
<P STYLE="margin-bottom: 0cm">ATP-free form. This structural
variation is due to the movement of the</P>
<P STYLE="margin-bottom: 0cm">alpha1-alpha2 and beta2-beta 3 loops,
both of which are highly conserved in</P>
<P STYLE="margin-bottom: 0cm">copper(I)-transporting P(IB)-type
ATPases. The present structure reveals a</P>
<P STYLE="margin-bottom: 0cm">characteristic binding mode of ATP
within the protein scaffold of the</P>
<P STYLE="margin-bottom: 0cm">copper(I)-transporting P(IB)-type
ATPases with respect to the other P-type</P>
<P STYLE="margin-bottom: 0cm">ATPases. In particular, the binding
cavity contains mainly hydrophobic aliphatic 
</P>
<P STYLE="margin-bottom: 0cm">residues, which are involved in van der
Waal's interactions with the adenine ring</P>
<P STYLE="margin-bottom: 0cm">of ATP, and a Glu side chain, which
forms a crucial hydrogen bond to the amino</P>
<P STYLE="margin-bottom: 0cm">group of ATP.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC2807310</P>
<P STYLE="margin-bottom: 0cm">PMID: 19917612 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Biochem Pharmacol. 2013 Oct
1;86(7):872-87. doi: 10.1016/j.bcp.2013.07.025. Epub 
</P>
<P STYLE="margin-bottom: 0cm">2013 Aug 8.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gene expression profiling for analysis
acquired oxaliplatin resistant factors in 
</P>
<P STYLE="margin-bottom: 0cm">human gastric carcinoma TSGH-S3 cells:
the role of IL-6 signaling and Nrf2/AKR1C 
</P>
<P STYLE="margin-bottom: 0cm">axis identification.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Chen CC(1), Chu CB, Liu KJ, Huang CY,
Chang JY, Pan WY, Chen HH, Cheng YH, Lee</P>
<P STYLE="margin-bottom: 0cm">KD, Chen MF, Kuo CC, Chen LT.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Hematology and
Oncology, Chang Gung Memorial Hospital at Chiayi,</P>
<P STYLE="margin-bottom: 0cm">Chiayi, Taiwan, ROC; Chang Gung
University, College of Medicine, Chang Gung</P>
<P STYLE="margin-bottom: 0cm">Institute of Technology, Chiayi,
Taiwan, ROC; Graduate Institute of Clinical</P>
<P STYLE="margin-bottom: 0cm">Medical Sciences, Chang Gung
University, Tao-Yuan, Taiwan, ROC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Oxaliplatin treatment is a mainstay of
treatment for advanced gastrointestinal</P>
<P STYLE="margin-bottom: 0cm">tract cancer, but the underlying
mechanisms of acquired oxaliplatin resistance</P>
<P STYLE="margin-bottom: 0cm">remain largely obscured. We previously
demonstrated that increased DNA repair</P>
<P STYLE="margin-bottom: 0cm">capacity and copper-transporting ATPase
1 (ATP7A) level contributed to</P>
<P STYLE="margin-bottom: 0cm">oxaliplatin resistance in the human
gastric carcinoma cell line TSGH-S3 (S3). In 
</P>
<P STYLE="margin-bottom: 0cm">the present study, we applied gene
array technology to identify additional</P>
<P STYLE="margin-bottom: 0cm">resistance factors in S3 cells. We
found that interleukin-6 (IL-6), aldo-keto</P>
<P STYLE="margin-bottom: 0cm">reductase 1C1 (AKR1C1), and AKR1C3 are
the top 3 upregulated genes in S3 cells</P>
<P STYLE="margin-bottom: 0cm">when compared with parent TSGH cells.
Despite a higher level of endogenous IL-6</P>
<P STYLE="margin-bottom: 0cm">in S3, IL-6 receptor (IR-6R, gp-80, and
gp-130) levels were similar between TSGH 
</P>
<P STYLE="margin-bottom: 0cm">and S3 cells. The addition of exogenous
IL-6, IL-6 targeted siRNA, or</P>
<P STYLE="margin-bottom: 0cm">neutralizing antibodies neither
affected Stat3 activation, a downstream target of</P>
<P STYLE="margin-bottom: 0cm">IL-6, nor changed oxaliplatin
sensitivity in S3 cells. However, manipulation of</P>
<P STYLE="margin-bottom: 0cm">AKR1C activity with siRNA or AKR1C
inhibitors significantly reversed oxaliplatin 
</P>
<P STYLE="margin-bottom: 0cm">resistance. AKR1Cs are classical
antioxidant response element (ARE) genes that</P>
<P STYLE="margin-bottom: 0cm">can be transcriptionally upregulated by
nuclear factor erythroid 2-related factor</P>
<P STYLE="margin-bottom: 0cm">2 (Nrf2). Knockdown of Nrf2 not only
decreased the levels of AKR1C1, AKR1C2, and 
</P>
<P STYLE="margin-bottom: 0cm">AKR1C3 mRNA and protein but also
reversed oxaliplatin resistance in S3 cells.</P>
<P STYLE="margin-bottom: 0cm">Taken together, these results suggest
that activation of the Nrf2/AKR1C axis may 
</P>
<P STYLE="margin-bottom: 0cm">contribute to oxaliplatin resistance in
S3 cells but that the IL-6 signaling</P>
<P STYLE="margin-bottom: 0cm">pathway did not contribute to
resistance. Manipulation of Nrf2/AKR1Cs activity</P>
<P STYLE="margin-bottom: 0cm">may be useful for management of
oxaliplatin-refractory gastric cancers.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2013 Elsevier Inc. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 23933386 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. Cytokine. 2011 Dec;56(3):699-707.
doi: 10.1016/j.cyto.2011.09.007. Epub 2011 Oct 
</P>
<P STYLE="margin-bottom: 0cm">10.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">CCL27 expression is regulated by both
p38 MAPK and IKKβ signalling pathways.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Riis JL(1), Johansen C, Vestergaard C,
Otkjaer K, Kragballe K, Iversen L.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Dermatology, Aarhus
Sygehus, Aarhus University Hospital, Aarhus 
</P>
<P STYLE="margin-bottom: 0cm">C, Denmark.
jette.lindorff.riis@ki.au.dk</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The skin-specific chemokine CCL27 is
believed to play a pivotal role in</P>
<P STYLE="margin-bottom: 0cm">establishing the inflammatory
infiltrate characteristic for common inflammatory</P>
<P STYLE="margin-bottom: 0cm">skin diseases. Through binding to the
chemokine receptor 10 (CCR10), CCL27</P>
<P STYLE="margin-bottom: 0cm">mediates inflammation by promoting
lymphocyte migration into the skin. Little is 
</P>
<P STYLE="margin-bottom: 0cm">known about the regulation of CCL27
gene expression. The purpose of our study was</P>
<P STYLE="margin-bottom: 0cm">to investigate the regulation of the
IL-1β-induced CCL27 gene expression in</P>
<P STYLE="margin-bottom: 0cm">normal human keratinocytes (NHEK).
Preincubation of NHEK with the inhibitory κB</P>
<P STYLE="margin-bottom: 0cm">(IκB) kinase (IKK) inhibitor, SC-514,
or the p38 mitogen-activated protein kinase</P>
<P STYLE="margin-bottom: 0cm">(MAPK) inhibitor, SB202190, revealed a
profound reduction in both CCL27 mRNA and 
</P>
<P STYLE="margin-bottom: 0cm">CCL27 protein expression indicating the
significance of these pathways in the</P>
<P STYLE="margin-bottom: 0cm">regulation of CCL27 expression.
Furthermore, the impact of inhibitors of mitogen-</P>
<P STYLE="margin-bottom: 0cm">and stress-activated kinase 1 (MSK1) or
the mitogen-activated protein</P>
<P STYLE="margin-bottom: 0cm">kinase-interacting kinases (Mnk1+2),
downstream kinases of p38 MAPK, on</P>
<P STYLE="margin-bottom: 0cm">IL-1β-induced CCL27 expression in NHEK
were investigated. We identified seven</P>
<P STYLE="margin-bottom: 0cm">NF-κB binding elements upstream from
the CCL27 gene start codon using</P>
<P STYLE="margin-bottom: 0cm">electrophoretic mobility shift assay
(EMSA). Supershift analyses demonstrated the</P>
<P STYLE="margin-bottom: 0cm">involvement of the p50/p65 NF-κB
heterodimer. We conclude that IL-1β-induced</P>
<P STYLE="margin-bottom: 0cm">CCL27 gene expression in NHEK is
regulated through the p38 MAPK/MSK1/Mnk1+2 as</P>
<P STYLE="margin-bottom: 0cm">well as the IKKβ/NF-κB signalling
pathways.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2011 Elsevier Ltd. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 21993219 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. Carcinogenesis. 2008
Dec;29(12):2279-88. doi: 10.1093/carcin/bgn221. Epub 2008</P>
<P STYLE="margin-bottom: 0cm">Sep 22.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Phosphorylation of eIF4E by MNKs
supports protein synthesis, cell cycle</P>
<P STYLE="margin-bottom: 0cm">progression and proliferation in
prostate cancer cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Bianchini A(1), Loiarro M, Bielli P,
Busà R, Paronetto MP, Loreni F, Geremia R,</P>
<P STYLE="margin-bottom: 0cm">Sette C.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Public Health and Cell
Biology, University of Rome Tor Vergata, 
</P>
<P STYLE="margin-bottom: 0cm">Rome, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Deregulation of the phosphatidyl
inositol trisphosphate kinase/AKT/mammalian</P>
<P STYLE="margin-bottom: 0cm">target of rapamycin (mTOR) and
RAS/mitogen-activated protein kinase (MAPK)/MNK</P>
<P STYLE="margin-bottom: 0cm">pathways frequently occurs in human
prostate carcinomas (PCas) and leads to</P>
<P STYLE="margin-bottom: 0cm">aberrant modulation of messenger RNA
(mRNA) translation. We have investigated the</P>
<P STYLE="margin-bottom: 0cm">relative contribution of these pathways
to translational regulation and</P>
<P STYLE="margin-bottom: 0cm">proliferation of PCa cells.
MNK-dependent phosphorylation of eIF4E is elevated in</P>
<P STYLE="margin-bottom: 0cm">DU145 cells, which have low basal
levels of AKT/mTOR activity due to the</P>
<P STYLE="margin-bottom: 0cm">expression of the tumor suppressor
PTEN. In contrast, eIF4E phosphorylation is</P>
<P STYLE="margin-bottom: 0cm">low in PC3 and LNCaP cells with mutated
PTEN and constitutively active AKT/mTOR</P>
<P STYLE="margin-bottom: 0cm">pathway, but it can be strongly induced
through inhibition of mTOR activity by</P>
<P STYLE="margin-bottom: 0cm">rapamycin or serum depletion.
Remarkably, we found that inhibition of MNKs</P>
<P STYLE="margin-bottom: 0cm">strongly reduced the polysomal
recruitment of terminal oligopyrimidine messenger 
</P>
<P STYLE="margin-bottom: 0cm">RNAs (TOP mRNAs), which are known
targets of mTOR-dependent translational</P>
<P STYLE="margin-bottom: 0cm">control. Pull-down assays of the eIF4F
complex indicated that translation</P>
<P STYLE="margin-bottom: 0cm">initiation was differently affected by
inhibition of MNKs and mTOR. In addition, 
</P>
<P STYLE="margin-bottom: 0cm">concomitant treatment with MNK
inhibitor and rapamycin exerted additive effects</P>
<P STYLE="margin-bottom: 0cm">on polysomal recruitment of TOP mRNAs
and protein synthesis. The MNK inhibitor</P>
<P STYLE="margin-bottom: 0cm">was more effective than rapamycin in
blocking proliferation of PTEN-expressing</P>
<P STYLE="margin-bottom: 0cm">cells, whereas combination of the two
inhibitors suppressed cell cycle</P>
<P STYLE="margin-bottom: 0cm">progression in both cell lines.
Microarray analysis showed that MNK affected</P>
<P STYLE="margin-bottom: 0cm">translation of mRNAs involved in cell
cycle progression. Thus, our results</P>
<P STYLE="margin-bottom: 0cm">indicate that a balance between the
activity of the AKT/mTO1. Cancer. 2015 Jul 28. doi:
10.1002/cncr.29586. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Clinicopathologic features associated
with efficacy and long-term survival in</P>
<P STYLE="margin-bottom: 0cm">metastatic melanoma patients treated
with BRAF or combined BRAF and MEK</P>
<P STYLE="margin-bottom: 0cm">inhibitors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Menzies AM(1,)(2,)(3), Wilmott
JS(1,)(2), Drummond M(1,)(2), Lo S(1,)(2), Lyle</P>
<P STYLE="margin-bottom: 0cm">M(1,)(2), Chan MM(4), Thompson
JF(1,)(2,)(5,)(6), Guminski A(1,)(2,)(3), Carlino 
</P>
<P STYLE="margin-bottom: 0cm">MS(1,)(2,)(4), Scolyer RA(1,)(2,)(5),
Kefford RF(1,)(2,)(4,)(7), Long GV(1,)(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Melanoma Institute Australia,
Sydney, Australia. (2)The University of Sydney, 
</P>
<P STYLE="margin-bottom: 0cm">Sydney, Australia. (3)Royal North Shore
Hospital, Sydney, Australia. (4)Crown</P>
<P STYLE="margin-bottom: 0cm">Princess Mary Cancer Centre, Westmead
Hospital, Sydney, Australia. (5)Royal</P>
<P STYLE="margin-bottom: 0cm">Prince Alfred Hospital, Sydney,
Australia. (6)Mater Hospital, Sydney, Australia. 
</P>
<P STYLE="margin-bottom: 0cm">(7)Macquarie University, Sydney,
Australia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: The degree of response and
the duration of survival of patients</P>
<P STYLE="margin-bottom: 0cm">treated with mitogen-activated protein
kinase (MAPK) inhibitors are highly</P>
<P STYLE="margin-bottom: 0cm">variable. Whether baseline
clinicopathologic factors can predict the clinical</P>
<P STYLE="margin-bottom: 0cm">course with treatment is largely
unknown.</P>
<P STYLE="margin-bottom: 0cm">METHODS: For 142 consecutive
immunotherapy- and MAPK inhibitor-naive patients</P>
<P STYLE="margin-bottom: 0cm">with BRAF-mutant metastatic melanoma
who were treated during clinical trials with</P>
<P STYLE="margin-bottom: 0cm">BRAF inhibitors (n = 111) or a
combination of dabrafenib and trametinib (n = 31),</P>
<P STYLE="margin-bottom: 0cm">clinicopathologic factors were
correlated with the response to MAPK inhibitors</P>
<P STYLE="margin-bottom: 0cm">and survival.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: The median follow-up was 15.7
months (range, 0.6-60.5 months). The 2-,</P>
<P STYLE="margin-bottom: 0cm">3-, and 4-year overall survival (OS)
rates were 43%, 24%, and 24%, respectively. 
</P>
<P STYLE="margin-bottom: 0cm">A multivariate analysis demonstrated
that the only clinicopathologic factors</P>
<P STYLE="margin-bottom: 0cm">associated with longer progression-free
survival (PFS) and OS were female sex and</P>
<P STYLE="margin-bottom: 0cm">a normal pretreatment serum lactate
dehydrogenase (LDH) level. The BRAF V600E</P>
<P STYLE="margin-bottom: 0cm">genotype and an absence of primary
melanoma ulceration were also independently</P>
<P STYLE="margin-bottom: 0cm">associated with longer PFS but not OS.
The median OS was 23.5 months for patients</P>
<P STYLE="margin-bottom: 0cm">with normal LDH levels and 7.3 months
for those with elevated LDH levels (hazard 
</P>
<P STYLE="margin-bottom: 0cm">ratio, 0.31; P &lt; .001). Complete
responders had the best survival, but disease</P>
<P STYLE="margin-bottom: 0cm">progression still occurred in 2 of 7
patients.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Long-term survival occurs
for a minority of patients receiving MAPK 
</P>
<P STYLE="margin-bottom: 0cm">inhibitor treatment alone. Sex, serum
LDH, BRAF genotype, and primary melanoma</P>
<P STYLE="margin-bottom: 0cm">ulceration status are independent
factors associated with treatment outcomes.</P>
<P STYLE="margin-bottom: 0cm">Patients with a complete response to
treatment have the best survival, but</P>
<P STYLE="margin-bottom: 0cm">relapses still occur. Cancer 2015. ©
2015 American Cancer Society.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2015 American Cancer Society.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26218930 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. BMC Syst Biol. 2015 Jul 25;9:41.
doi: 10.1186/s12918-015-0187-6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Regulation of ERK-MAPK signaling in
human epidermis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cursons J(1,)(2,)(3,)(4,)(5), Gao J(6),
Hurley DG(7,)(8,)(9,)(10,)(11,)(12),</P>
<P STYLE="margin-bottom: 0cm">Print CG(13,)(14,)(15), Dunbar
PR(16,)(17), Jacobs MD(18), Crampin</P>
<P STYLE="margin-bottom: 0cm">EJ(19,)(20,)(21,)(22,)(23,)(24).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Systems Biology Laboratory,
Melbourne School of Engineering, University of</P>
<P STYLE="margin-bottom: 0cm">Melbourne, Melbourne, Australia.
joseph.cursons@unimelb.edu.au. (2)NICTA Victoria</P>
<P STYLE="margin-bottom: 0cm">Research Lab, Melbourne, Australia.
joseph.cursons@unimelb.edu.au. (3)ARC Centre 
</P>
<P STYLE="margin-bottom: 0cm">of Excellence in Convergent Bio-Nano
Science and Technology, Melbourne School of 
</P>
<P STYLE="margin-bottom: 0cm">Engineering, University of Melbourne,
Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">joseph.cursons@unimelb.edu.au.
(4)Auckland Bioengineering Institute, University</P>
<P STYLE="margin-bottom: 0cm">of Auckland, Auckland, New Zealand.
joseph.cursons@unimelb.edu.au. (5)Maurice</P>
<P STYLE="margin-bottom: 0cm">Wilkins Centre, University of Auckland,
Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">joseph.cursons@unimelb.edu.au.
(6)Systems Biology Laboratory, Melbourne School of</P>
<P STYLE="margin-bottom: 0cm">Engineering, University of Melbourne,
Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">jerry.gao@unimelb.edu.au. (7)Systems
Biology Laboratory, Melbourne School of</P>
<P STYLE="margin-bottom: 0cm">Engineering, University of Melbourne,
Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">daniel.hurley@unimelb.edu.au. (8)NICTA
Victoria Research Lab, Melbourne,</P>
<P STYLE="margin-bottom: 0cm">Australia.
daniel.hurley@unimelb.edu.au. (9)Auckland Bioengineering Institute,</P>
<P STYLE="margin-bottom: 0cm">University of Auckland, Auckland, New
Zealand. daniel.hurley@unimelb.edu.au.</P>
<P STYLE="margin-bottom: 0cm">(10)Maurice Wilkins Centre, University
of Auckland, Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">daniel.hurley@unimelb.edu.au.
(11)Bioinformatics Institute, University of</P>
<P STYLE="margin-bottom: 0cm">Auckland, Auckland, New Zealand.
daniel.hurley@unimelb.edu.au. (12)Faculty of</P>
<P STYLE="margin-bottom: 0cm">Medical and Health Sciences, University
of Auckland, Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">daniel.hurley@unimelb.edu.au.
(13)Maurice Wilkins Centre, University of Auckland,</P>
<P STYLE="margin-bottom: 0cm">Auckland, New Zealand.
c.print@auckland.ac.nz. (14)Bioinformatics Institute,</P>
<P STYLE="margin-bottom: 0cm">University of Auckland, Auckland, New
Zealand. c.print@auckland.ac.nz.</P>
<P STYLE="margin-bottom: 0cm">(15)Faculty of Medical and Health
Sciences, University of Auckland, Auckland, New</P>
<P STYLE="margin-bottom: 0cm">Zealand. c.print@auckland.ac.nz.
(16)Maurice Wilkins Centre, University of</P>
<P STYLE="margin-bottom: 0cm">Auckland, Auckland, New Zealand.
r.dunbar@auckland.ac.nz. (17)School of</P>
<P STYLE="margin-bottom: 0cm">Biological Sciences, University of
Auckland, Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">r.dunbar@auckland.ac.nz. (18)Department
of Biology, New Zealand International</P>
<P STYLE="margin-bottom: 0cm">College, ACG New Zealand, Auckland, New
Zealand. marc.jacobs@gmx.com. (19)Systems</P>
<P STYLE="margin-bottom: 0cm">Biology Laboratory, Melbourne School of
Engineering, University of Melbourne,</P>
<P STYLE="margin-bottom: 0cm">Melbourne, Australia.
edmund.crampin@unimelb.edu.au. (20)ARC Centre of Excellence</P>
<P STYLE="margin-bottom: 0cm">in Convergent Bio-Nano Science and
Technology, Melbourne School of Engineering,</P>
<P STYLE="margin-bottom: 0cm">University of Melbourne, Melbourne,
Australia. edmund.crampin@unimelb.edu.au.</P>
<P STYLE="margin-bottom: 0cm">(21)Auckland Bioengineering Institute,
University of Auckland, Auckland, New</P>
<P STYLE="margin-bottom: 0cm">Zealand. edmund.crampin@unimelb.edu.au.
(22)Maurice Wilkins Centre, University of</P>
<P STYLE="margin-bottom: 0cm">Auckland, Auckland, New Zealand.
edmund.crampin@unimelb.edu.au. (23)School of</P>
<P STYLE="margin-bottom: 0cm">Mathematics and Statistics, University
of Melbourne, Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">edmund.crampin@unimelb.edu.au.
(24)School of Medicine, University of Melbourne,</P>
<P STYLE="margin-bottom: 0cm">Melbourne, Australia.
edmund.crampin@unimelb.edu.au.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: The skin is largely
comprised of keratinocytes within the</P>
<P STYLE="margin-bottom: 0cm">interfollicular epidermis. Over
approximately two weeks these cells differentiate</P>
<P STYLE="margin-bottom: 0cm">and traverse the thickness of the skin.
The stage of differentiation is therefore</P>
<P STYLE="margin-bottom: 0cm">reflected in the positions of cells
within the tissue, providing a convenient</P>
<P STYLE="margin-bottom: 0cm">axis along which to study the signaling
events that occur in situ during</P>
<P STYLE="margin-bottom: 0cm">keratinocyte terminal differentiation,
over this extended two-week timescale. The</P>
<P STYLE="margin-bottom: 0cm">canonical ERK-MAPK signaling cascade
(Raf-1, MEK-1/2 and ERK-1/2) has been</P>
<P STYLE="margin-bottom: 0cm">implicated in controlling diverse
cellular behaviors, including proliferation and</P>
<P STYLE="margin-bottom: 0cm">differentiation. While the molecular
interactions involved in signal transduction</P>
<P STYLE="margin-bottom: 0cm">through this cascade have been well
characterized in cell culture experiments,</P>
<P STYLE="margin-bottom: 0cm">our understanding of how this sequence
of events unfolds to determine cell fate</P>
<P STYLE="margin-bottom: 0cm">within a homeostatic tissue environment
has not been fully characterized.</P>
<P STYLE="margin-bottom: 0cm">METHODS: We measured the abundance of
total and phosphorylated ERK-MAPK signaling</P>
<P STYLE="margin-bottom: 0cm">proteins within interfollicular
keratinocytes in transverse cross-sections of</P>
<P STYLE="margin-bottom: 0cm">human epidermis using
immunofluorescence microscopy. To investigate these data we</P>
<P STYLE="margin-bottom: 0cm">developed a mathematical model of the
signaling cascade using a normalized-Hill</P>
<P STYLE="margin-bottom: 0cm">differential equation formalism.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: These data show coordinated
variation in the abundance of phosphorylated</P>
<P STYLE="margin-bottom: 0cm">ERK-MAPK components across the
epidermis. Statistical analysis of these data</P>
<P STYLE="margin-bottom: 0cm">shows that associations between
phosphorylated ERK-MAPK components which</P>
<P STYLE="margin-bottom: 0cm">correspond to canonical molecular
interactions are dependent upon spatial</P>
<P STYLE="margin-bottom: 0cm">position within the epidermis. The
model demonstrates that the spatial profile of</P>
<P STYLE="margin-bottom: 0cm">activation for ERK-MAPK signaling
components across the epidermis may be</P>
<P STYLE="margin-bottom: 0cm">maintained in a cell-autonomous fashion
by an underlying spatial gradient in</P>
<P STYLE="margin-bottom: 0cm">calcium signaling.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Our data demonstrate an
extended phospho-protein profile of ERK-MAPK</P>
<P STYLE="margin-bottom: 0cm">signaling cascade components across the
epidermis in situ, and statistical</P>
<P STYLE="margin-bottom: 0cm">associations in these data indicate
canonical ERK-MAPK interactions underlie this</P>
<P STYLE="margin-bottom: 0cm">spatial profile of ERK-MAPK activation.
Using mathematical modelling we have</P>
<P STYLE="margin-bottom: 0cm">demonstrated that spatially varying
calcium signaling components across the</P>
<P STYLE="margin-bottom: 0cm">epidermis may be sufficient to maintain
the spatial profile of ERK-MAPK signaling</P>
<P STYLE="margin-bottom: 0cm">cascade components in a cell-autonomous
manner. These findings may have</P>
<P STYLE="margin-bottom: 0cm">significant implications for the wide
range of cancer drugs which therapeutically</P>
<P STYLE="margin-bottom: 0cm">target ERK-MAPK signaling components.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4514964</P>
<P STYLE="margin-bottom: 0cm">PMID: 26209520 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. Cell Adh Migr. 2015 Jul 24:1-10.
[Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Snail promotes cell migration through
PI3K/AKT-dependent Rac1 activation as well 
</P>
<P STYLE="margin-bottom: 0cm">as PI3K/AKT-independent pathways during
prostate cancer progression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Henderson V(1), Smith B, Burton LJ,
Randle D, Morris M, Odero-Marah VA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)a Center for Cancer Research and
Therapeutic Development; Department of</P>
<P STYLE="margin-bottom: 0cm">Biological Sciences ; Clark Atlanta
University ; Atlanta , GA USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Snail, a zinc-finger transcription
factor, induces epithelial-mesenchymal</P>
<P STYLE="margin-bottom: 0cm">transition (EMT), which is associated
with increased cell migration and</P>
<P STYLE="margin-bottom: 0cm">metastasis in cancer cells. Rac1 is a
small G-protein which upon activation</P>
<P STYLE="margin-bottom: 0cm">results in formation of lamellipodia,
the first protrusions formed by migrating</P>
<P STYLE="margin-bottom: 0cm">cells. We have previously shown that
Snail promotes cell migration through</P>
<P STYLE="margin-bottom: 0cm">down-regulation of maspin tumor
suppressor. We hypothesized that Snail's</P>
<P STYLE="margin-bottom: 0cm">regulation of cell migration may also
involve Rac1 signaling regulated by</P>
<P STYLE="margin-bottom: 0cm">PI3K/AKT and/or MAPK pathways. We found
that Snail overexpression in LNCaP and</P>
<P STYLE="margin-bottom: 0cm">22Rv1 prostate cancer cells increased
Rac1 activity associated with increased</P>
<P STYLE="margin-bottom: 0cm">cell migration, and the Rac1 inhibitor,
NSC23766, could inhibit Snail-mediated</P>
<P STYLE="margin-bottom: 0cm">cell migration. Conversely, Snail
downregulation using shRNA in the aggressive</P>
<P STYLE="margin-bottom: 0cm">C4-2 prostate cancer cells decreased
Rac1 activity and cell migration. Moreover, 
</P>
<P STYLE="margin-bottom: 0cm">Snail overexpression increased ERK and
PI3K/AKT activity in 22Rv1 prostate cancer</P>
<P STYLE="margin-bottom: 0cm">cells. Treatment of
Snail-overexpressing 22Rv1 cells with LY294002, PI3K/AKT</P>
<P STYLE="margin-bottom: 0cm">inhibitor or U0126, MEK inhibitor,
decreased cell migration significantly, but</P>
<P STYLE="margin-bottom: 0cm">only LY294002 significantly reduced
Rac1 activity, suggesting that Snail promotes</P>
<P STYLE="margin-bottom: 0cm">Rac1 activation via the PI3K/AKT
pathway. Furthermore, 22Rv1 cells overexpressing</P>
<P STYLE="margin-bottom: 0cm">Snail displayed decreased maspin
levels, while inhibition of maspin expression in</P>
<P STYLE="margin-bottom: 0cm">22Rv1 cells with siRNA, led to
increased PI3K/AKT, Rac1 activity and cell</P>
<P STYLE="margin-bottom: 0cm">migration, without affecting ERK
activity, suggesting that maspin is upstream of 
</P>
<P STYLE="margin-bottom: 0cm">PI3K/AKT. Overall, we have dissected
signaling pathways by which Snail may</P>
<P STYLE="margin-bottom: 0cm">promote cell migration through MAPK
signaling or alternatively through</P>
<P STYLE="margin-bottom: 0cm">PI3K/AKT-Rac1 signaling that involves
Snail inhibition of maspin tumor</P>
<P STYLE="margin-bottom: 0cm">suppressor. This may contribute to
prostate cancer progression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26207671 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">4. Mol Cancer Ther. 2015 Jul 23. pii:
molcanther.0223.2015. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Assessment of the in vivo activity of
PI3K and MEK inhibitors in genetically</P>
<P STYLE="margin-bottom: 0cm">defined models of colorectal cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Raja M(1), Zverev M(1), Seipel K(2),
Williams GT(3), Clarke AR(4), Shaw PH(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)European Cancer Stem Cell Research
Institute, Cardiff University. (2)Oncology,</P>
<P STYLE="margin-bottom: 0cm">University Hospital Bern. (3)School of
Medicine, Cardiff University. (4)Cardiff</P>
<P STYLE="margin-bottom: 0cm">University, European Cancer Stem Cell
Research Institute ClarkeAR@cardiff.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The objective of tailoring medicines
for cancer patients according to the</P>
<P STYLE="margin-bottom: 0cm">molecular profile of their disease
holds great promise for the improvement of</P>
<P STYLE="margin-bottom: 0cm">cancer therapy. Nevertheless, this
approach has been limited, in part due to the 
</P>
<P STYLE="margin-bottom: 0cm">lack of predictive and informative
pre-clinical studies. Herein, we describe an</P>
<P STYLE="margin-bottom: 0cm">assessment of the therapeutic potential
of targeting PI3K/mTOR and MAPK</P>
<P STYLE="margin-bottom: 0cm">signalling in genetically defined mouse
models of colorectal cancer (CRC)</P>
<P STYLE="margin-bottom: 0cm">mirroring disease subtypes targeted for
novel therapy in the FOCUS4 trial. Our</P>
<P STYLE="margin-bottom: 0cm">studies demonstrate that dual PI3K/mTOR
inhibition is highly effective in</P>
<P STYLE="margin-bottom: 0cm">invasive adenocarcinoma models
characterised by combinatorial mutations in Apc</P>
<P STYLE="margin-bottom: 0cm">and Pten; Apc and Kras; and Apc, Pten
and Kras. MEK inhibition was effective in</P>
<P STYLE="margin-bottom: 0cm">the combinatorial Apc and Kras setting,
but had no impact in either Apc Pten</P>
<P STYLE="margin-bottom: 0cm">mutants or in Apc Pten Kras triple
mutants. Furthermore, we describe the</P>
<P STYLE="margin-bottom: 0cm">importance of scheduling for
combination studies and show that although no</P>
<P STYLE="margin-bottom: 0cm">additional benefit is gained in Apc
Pten mice, combination of PI3K/mTOR and MAPK 
</P>
<P STYLE="margin-bottom: 0cm">inhibition leads to an additive benefit
in survival in Apc Kras mice and a</P>
<P STYLE="margin-bottom: 0cm">synergistic increase in survival in Apc
Pten Kras mice. This is the first study</P>
<P STYLE="margin-bottom: 0cm">utilising robust CRC GEMMs to support
the validity of PI3K/mTOR and MEK</P>
<P STYLE="margin-bottom: 0cm">inhibitors as tailored therapies for
CRC and highlight the potential importance</P>
<P STYLE="margin-bottom: 0cm">of drug scheduling in the clinic.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Association
for Cancer Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26206338 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">5. Mol Cancer Ther. 2015 Jul 23. pii:
molcanther.0429.2015. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Inhibition of wild-type p53-expressing
AML by novel small molecule HDM2</P>
<P STYLE="margin-bottom: 0cm">inhibitor, CGM097.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Weisberg EL(1), Halilovic E(2), Cooke
VG(2), Nonami A(3), Ren T(4), Sanda T(3),</P>
<P STYLE="margin-bottom: 0cm">Simkin I(5), Yuan J(2), Antonakos B(2),
Barys L(6), Ito M(6), Stone RM(3),</P>
<P STYLE="margin-bottom: 0cm">Galinsky I(3), Cowens K(3), Nelson
E(3), Sattler M(3), Jeay S(7), Wuerthner</P>
<P STYLE="margin-bottom: 0cm">JU(6), McDonough S(3), Wiesmann M(6),
Griffin JD(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Medical Oncology, Dana Farber Cancer
Institute</P>
<P STYLE="margin-bottom: 0cm">ellen_weisberg@dfci.harvard.edu.
(2)Oncology, Novartis Institutes for BioMedical 
</P>
<P STYLE="margin-bottom: 0cm">Research, Inc. (3)Medical Oncology,
Dana Farber Cancer Institute. (4)National</P>
<P STYLE="margin-bottom: 0cm">Screening Laboratory for the Regional
Centers of Excellence in Biodefense and</P>
<P STYLE="margin-bottom: 0cm">Emerging Infectious Diseases Research,
Harvard Medical School. (5)Molecular</P>
<P STYLE="margin-bottom: 0cm">Genetics Core, Boston University School
of Medicine. (6)Disease Area Oncology,</P>
<P STYLE="margin-bottom: 0cm">Novartis Institutes for BioMedical
Research, Inc. (7)Oncology, Novartis</P>
<P STYLE="margin-bottom: 0cm">Institutes for BioMedical Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The tumor suppressor, p53, is a key
regulator of apoptosis and functions upstream</P>
<P STYLE="margin-bottom: 0cm">in the apoptotic cascade by both
indirectly and directly regulating Bcl-2 family 
</P>
<P STYLE="margin-bottom: 0cm">proteins. In cells expressing wild-type
(wt) p53, the HDM2 protein binds to p53</P>
<P STYLE="margin-bottom: 0cm">and blocks its activity. Inhibition of
HDM2:p53 interaction activates p53 and</P>
<P STYLE="margin-bottom: 0cm">causes apoptosis or cell cycle arrest.
Here, we investigated the ability of the</P>
<P STYLE="margin-bottom: 0cm">novel HDM2 inhibitor, CGM097, to
potently and selectively kill wt p53-expressing 
</P>
<P STYLE="margin-bottom: 0cm">AML cells. The anti-leukemic effects of
CGM097 were studied using cell-based</P>
<P STYLE="margin-bottom: 0cm">proliferation assays (human AML cell
lines, primary AML patient cells and normal 
</P>
<P STYLE="margin-bottom: 0cm">bone marrow samples), apoptosis and
cell cycle assays, ELISA, immunoblotting, and</P>
<P STYLE="margin-bottom: 0cm">an AML patient-derived in vivo mouse
model. CGM097 potently and selectively</P>
<P STYLE="margin-bottom: 0cm">inhibited the proliferation of human
AML cell lines and the majority of primary</P>
<P STYLE="margin-bottom: 0cm">AML cells expressing wt p53, but not
mutant p53, in a target-specific manner.</P>
<P STYLE="margin-bottom: 0cm">Several patient samples that harbored
mutant p53 were comparatively unresponsive 
</P>
<P STYLE="margin-bottom: 0cm">to CGM097. Synergy was observed when
CGM097 was combined with FLT3 inhibition</P>
<P STYLE="margin-bottom: 0cm">against oncogenic FLT3-expressing cells
cultured both in the absence as well as</P>
<P STYLE="margin-bottom: 0cm">the presence of cytoprotective
stromal-secreted cytokines, as well as when</P>
<P STYLE="margin-bottom: 0cm">combined with MEK inhibition in cells
with activated MAPK signaling. Finally,</P>
<P STYLE="margin-bottom: 0cm">CGM097 was effective in reducing
leukemia burden in vivo. These data suggest that</P>
<P STYLE="margin-bottom: 0cm">CGM097 is a promising treatment for AML
characterized as harboring wt p53 as a</P>
<P STYLE="margin-bottom: 0cm">single agent, as well as in combination
with other therapies targeting</P>
<P STYLE="margin-bottom: 0cm">oncogene-activated pathways that drive
AML.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Association
for Cancer Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26206331 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">6. Expert Opin Biol Ther. 2015 Jul
24:1-10. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Synergy of molecular targeted
approaches and immunotherapy in melanoma:</P>
<P STYLE="margin-bottom: 0cm">preclinical basis and clinical
perspectives.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sanlorenzo M(1), Vujic I, Moy A,
Quaglino P, Fierro MT, Gammaitoni L,</P>
<P STYLE="margin-bottom: 0cm">Carnevale-Schianca F, Aglietta M,
Sangiolo D.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)University of Turin, Department of
Medical Sciences, Section of Dermatology , 
</P>
<P STYLE="margin-bottom: 0cm">Via Cherasco 23, Torino , Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">INTRODUCTION: Targeted therapy and
immunotherapies are the novel pharmacologic</P>
<P STYLE="margin-bottom: 0cm">treatment strategies for metastatic
melanoma. BRAF and MEK inhibitors effectively</P>
<P STYLE="margin-bottom: 0cm">block the hyperactivation of the MAPK
pathway in BRAF mutant melanomas and also</P>
<P STYLE="margin-bottom: 0cm">have several other effects on melanoma
cells and on the immune response. The aim 
</P>
<P STYLE="margin-bottom: 0cm">of this work is to discuss the
rationale, evidence and perspectives of approaches</P>
<P STYLE="margin-bottom: 0cm">combining target and immunotherapy
against melanoma. Areas covered: We first</P>
<P STYLE="margin-bottom: 0cm">review the effects of BRAF and MEK
inhibitors on melanoma cells and on the</P>
<P STYLE="margin-bottom: 0cm">different components of the immune
system. Afterwards, we summarize the results</P>
<P STYLE="margin-bottom: 0cm">of the preclinical and clinical studies
that have combined targeted therapy and</P>
<P STYLE="margin-bottom: 0cm">immunotherapy for the treatment of
melanoma. Expert opinion: Clinical</P>
<P STYLE="margin-bottom: 0cm">applications of immunotherapy
strategies have recently changed the therapeutic</P>
<P STYLE="margin-bottom: 0cm">mainstay for metastatic melanoma.
Biologic and initial preclinical data support</P>
<P STYLE="margin-bottom: 0cm">their integration with innovative
molecular targeted therapies, opening enormous 
</P>
<P STYLE="margin-bottom: 0cm">perspectives for researchers in the
effort of finding a definitive cure. Main</P>
<P STYLE="margin-bottom: 0cm">open challenges are the definition of
reliable research models, assessment of</P>
<P STYLE="margin-bottom: 0cm">effective schedules, safety issues and
designing of personalized approaches.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26206099 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">7. Int J Cancer. 2015 Jul 23. doi:
10.1002/ijc.29698. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Inhibition of class I histone
deacetylases by romidepsin potently induces</P>
<P STYLE="margin-bottom: 0cm">Epstein-Barr virus lytic cycle and
mediates enhanced cell death with ganciclovir.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hui KF(1), Cheung AK(2), Choi CK(1),
Yeung PL(1), Middeldorp JM(3), Lung</P>
<P STYLE="margin-bottom: 0cm">ML(2,)(4), Tsao SW(5,)(4), Chiang
AK(1,)(4).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Paediatrics and
Adolescent Medicine, The University of Hong</P>
<P STYLE="margin-bottom: 0cm">Kong, Queen Mary Hospital, Pokfulam,
Hong Kong SAR, China. (2)Department of</P>
<P STYLE="margin-bottom: 0cm">Clinical Oncology, Li Ka Shing Faculty
of Medicine, The University of Hong Kong, 
</P>
<P STYLE="margin-bottom: 0cm">Queen Mary Hospital, Pokfulam, Hong
Kong SAR, China. (3)Department of Pathology, 
</P>
<P STYLE="margin-bottom: 0cm">VU University Medical Center,
Amsterdam, The Netherlands. (4)Center for</P>
<P STYLE="margin-bottom: 0cm">Nasopharyngeal Carcinoma Research, The
University of Hong Kong, Hong Kong SAR,</P>
<P STYLE="margin-bottom: 0cm">China. (5)Department of Anatomy, Li Ka
Shing Faculty of Medicine, The University 
</P>
<P STYLE="margin-bottom: 0cm">of Hong Kong, Pokfulam, Hong Kong SAR,
China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Pan-histone deacetylase (HDAC)
inhibitors, which inhibit eleven HDAC isoforms,</P>
<P STYLE="margin-bottom: 0cm">are widely used to induce EBV lytic
cycle in EBV-associated cancers in vitro and 
</P>
<P STYLE="margin-bottom: 0cm">in clinical trials. Here, we
hypothesized that inhibition of one or several</P>
<P STYLE="margin-bottom: 0cm">specific HDAC isoforms by selective
HDAC inhibitors could potently induce EBV</P>
<P STYLE="margin-bottom: 0cm">lytic cycle in EBV-associated
malignancies such as nasopharyngeal carcinoma (NPC)</P>
<P STYLE="margin-bottom: 0cm">and gastric carcinoma (GC). We found
that inhibition of class I HDACs,</P>
<P STYLE="margin-bottom: 0cm">particularly HDAC-1, -2 and -3, was
sufficient to induce EBV lytic cycle in NPC</P>
<P STYLE="margin-bottom: 0cm">and GC cells in vitro and in vivo.
Among a panel of selective HDAC inhibitors,</P>
<P STYLE="margin-bottom: 0cm">the FDA-approved HDAC inhibitor
romidepsin was found to be the most potent lytic 
</P>
<P STYLE="margin-bottom: 0cm">inducer, which could activate EBV lytic
cycle at ∼0.5 to 5 nM (versus ∼800 nM</P>
<P STYLE="margin-bottom: 0cm">achievable concentration in patients'
plasma) in more than 75% of cells.</P>
<P STYLE="margin-bottom: 0cm">Up-regulation of p21(WAF1) , which is
negatively regulated by class I HDACs was</P>
<P STYLE="margin-bottom: 0cm">observed prior to the induction of EBV
lytic cycle. The up-regulation of</P>
<P STYLE="margin-bottom: 0cm">p21(WAF1) and induction of lytic cycle
were abrogated by a specific inhibitor of 
</P>
<P STYLE="margin-bottom: 0cm">PKC-δ but not the inhibitors of PI3K,
MEK, p38 MAPK, JNK, or ATM pathways.</P>
<P STYLE="margin-bottom: 0cm">Interestingly, inhibition of HDAC-1, -2
and -3 by romidepsin or shRNA knockdown</P>
<P STYLE="margin-bottom: 0cm">could confer susceptibility of
EBV-positive epithelial cells to the treatment</P>
<P STYLE="margin-bottom: 0cm">with ganciclovir. In conclusion, we
demonstrated that inhibition of class I HDACs</P>
<P STYLE="margin-bottom: 0cm">by romidepsin could potently induce EBV
lytic cycle and mediate enhanced cell</P>
<P STYLE="margin-bottom: 0cm">death with ganciclovir, suggesting
potential application of romidepsin for the</P>
<P STYLE="margin-bottom: 0cm">treatment of EBV-associated cancers.
This article is protected by copyright. All 
</P>
<P STYLE="margin-bottom: 0cm">rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2015 UICC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26205347 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">8. Clin Cancer Res. 2015 Jul 22. pii:
clincanres.0393.2015. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cellular mechanisms underlying complete
hematological response of chronic myeloid</P>
<P STYLE="margin-bottom: 0cm">leukemia to BRAF/MEK inhibition in a
patient with concomitant metastatic</P>
<P STYLE="margin-bottom: 0cm">melanoma.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Andrews MC(1), Turner N(2), Boyd J(3),
Roberts AW(4), Grigg A(5), Behren A(1),</P>
<P STYLE="margin-bottom: 0cm">Cebon JS(6).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Cancer Immunobiology Laboratory,
Olivia Newton-John Cancer Research Institute.</P>
<P STYLE="margin-bottom: 0cm">(2)Systems Biology and Personalized
Medicine, Walter and Eliza Hall Institute of 
</P>
<P STYLE="margin-bottom: 0cm">Medical Research. (3)Clinical
Haematology and Bone Marrow Transplantation, Royal 
</P>
<P STYLE="margin-bottom: 0cm">Melbourne Hospital. (4)Clinical
Haematology and BMT service, The Royal Melbourne 
</P>
<P STYLE="margin-bottom: 0cm">Hospital. (5)Haematology, Austin
Health. (6)Cancer Immunobiology Laboratory,</P>
<P STYLE="margin-bottom: 0cm">Olivia Newton-John Cancer Research
Institute jonathan.cebon@onjcri.org.au.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PURPOSE: Targeted MEK inhibition is an
emerging therapy in a number of solid</P>
<P STYLE="margin-bottom: 0cm">tumors. It holds particular promise in
BRAF V600E mutation-positive malignant</P>
<P STYLE="margin-bottom: 0cm">melanoma, where constitutive activation
and cell growth through the MAP kinase</P>
<P STYLE="margin-bottom: 0cm">(MAPK) pathway is well established. In
vitro and pre-clinical research indicates 
</P>
<P STYLE="margin-bottom: 0cm">that MAPK pathway activation is
important in chronic myeloid leukemia (CML)</P>
<P STYLE="margin-bottom: 0cm">leukemogenesis however the potential of
MEK inhibition has not yet been</P>
<P STYLE="margin-bottom: 0cm">investigated clinically in the setting
of such hematological malignancies.</P>
<P STYLE="margin-bottom: 0cm">EXPERIMENTAL DESIGN: We report a case
of complete hematological response of CML</P>
<P STYLE="margin-bottom: 0cm">to MEK inhibition in a patient with
synchronous metastatic melanoma, who received</P>
<P STYLE="margin-bottom: 0cm">treatment with combination BRAF and
MEK1/2 inhibitors. We studied the effects of 
</P>
<P STYLE="margin-bottom: 0cm">these agents on proliferation and
outgrowth of myeloid precursors, and</P>
<P STYLE="margin-bottom: 0cm">longitudinal shifts in peripheral blood
phenotyping during the course of</P>
<P STYLE="margin-bottom: 0cm">treatment. A model cell line system was
used to examine the effects of dabrafenib</P>
<P STYLE="margin-bottom: 0cm">and trametinib on MAPK and
BCR-ABL1-signalling.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: After 35 weeks on treatment
with BRAF and MEK inhibitors, complete</P>
<P STYLE="margin-bottom: 0cm">hematologic response was observed
without recourse to BCR-ABL1-targeted therapy. 
</P>
<P STYLE="margin-bottom: 0cm">MEK inhibition was principally
responsible for impaired proliferation of both</P>
<P STYLE="margin-bottom: 0cm">mature and primitive myeloid
precursors, as well as growth and hemoglobinization 
</P>
<P STYLE="margin-bottom: 0cm">of erythroid precursors. Paradoxical
activation of the MAPK pathway was seen in</P>
<P STYLE="margin-bottom: 0cm">response to BRAF inhibitor therapy but
this was easily overcome by</P>
<P STYLE="margin-bottom: 0cm">clinically-relevant doses of concurrent
MEK inhibitor.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: These studies suggest that
further evaluation of the optimal MAPK</P>
<P STYLE="margin-bottom: 0cm">targeting approach is warranted to
extend therapeutic options in CML.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Association
for Cancer Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26202951 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">9. J Exp Med. 2015 Jul
27;212(8):1323-36. doi: 10.1084/jem.20150110. Epub 2015 Jul</P>
<P STYLE="margin-bottom: 0cm">20.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">T cell development involves
TRAF3IP3-mediated ERK signaling in the Golgi.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zou Q(1), Jin J(1), Xiao Y(1), Hu H(1),
Zhou X(1), Jie Z(1), Xie X(1), Li JY(2), 
</P>
<P STYLE="margin-bottom: 0cm">Cheng X(1), Sun SC(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Immunology, The
University of Texas MD Anderson Cancer Center,</P>
<P STYLE="margin-bottom: 0cm">Houston, TX 77030. (2)Department of
Genetics and Developmental Biology,</P>
<P STYLE="margin-bottom: 0cm">University of Connecticut Health
Center, Farmington, CT 06030. (3)Department of</P>
<P STYLE="margin-bottom: 0cm">Immunology, The University of Texas MD
Anderson Cancer Center, Houston, TX 77030 
</P>
<P STYLE="margin-bottom: 0cm">The University of Texas Graduate School
of Biomedical Sciences, Houston, TX 77030</P>
<P STYLE="margin-bottom: 0cm">ssun@mdanderson.org.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Generation of T lymphocytes in the
thymus is guided by signal transduction from</P>
<P STYLE="margin-bottom: 0cm">the T cell receptor (TCR), but the
underlying mechanism is incompletely</P>
<P STYLE="margin-bottom: 0cm">understood. Here we have identified a
Golgi-associated factor, TRAF3-interacting 
</P>
<P STYLE="margin-bottom: 0cm">protein 3 (TRAF3IP3), as a crucial
mediator of thymocyte development. TRAF3IP3</P>
<P STYLE="margin-bottom: 0cm">deficiency in mice attenuates the
generation of mature thymocytes caused by</P>
<P STYLE="margin-bottom: 0cm">impaired thymocyte-positive selection.
TRAF3IP3 mediates TCR-stimulated</P>
<P STYLE="margin-bottom: 0cm">activation of the mitogen-activated
protein kinase (MAPK) extracellular</P>
<P STYLE="margin-bottom: 0cm">signal-regulated kinase (ERK) and its
upstream kinase mitogen/extracellular</P>
<P STYLE="margin-bottom: 0cm">signal-regulated kinase (MEK).
Interestingly, TRAF3IP3 exerts this signaling</P>
<P STYLE="margin-bottom: 0cm">function through recruiting MEK to the
Golgi and, thereby, facilitating the</P>
<P STYLE="margin-bottom: 0cm">interaction of MEK with its activator
BRAF. Transgenic expression of a</P>
<P STYLE="margin-bottom: 0cm">constitutively active MEK rescues the T
cell development block in Traf3ip3</P>
<P STYLE="margin-bottom: 0cm">knockout mice. These findings establish
TRAF3IP3 as a novel regulator of T cell</P>
<P STYLE="margin-bottom: 0cm">development and suggest a
Golgi-specific ERK signaling mechanism that regulates</P>
<P STYLE="margin-bottom: 0cm">thymocyte development.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2015 Zou et al.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26195727 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">10. Discov Med. 2015
Jun;19(107):455-61.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Novel mechanisms and therapeutic
approaches in melanoma: targeting the MAPK</P>
<P STYLE="margin-bottom: 0cm">pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Grimaldi AM(1), Simeone E, Festino L,
Vanella V, Palla M, Ascierto PA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)O.U. Melanoma, Cancer Immunotherapy
and Innovative Therapies, National Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Institute of Naples &quot;G. Pascale&quot;
Foundation, Naples, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The development of novel treatments
that selectively inhibit the RAS-RAF-MAPK</P>
<P STYLE="margin-bottom: 0cm">pathway represents a milestone in the
history of melanoma treatment. BRAF</P>
<P STYLE="margin-bottom: 0cm">mutations occur in approximately 45% of
cutaneous melanomas, while mutations in</P>
<P STYLE="margin-bottom: 0cm">NRAS occur in 15-25%. Vemurafenib was
the first BRAF inhibitor to be approved in 
</P>
<P STYLE="margin-bottom: 0cm">2011, based on the results of a phase
III trial (BRIM-3) that showed higher</P>
<P STYLE="margin-bottom: 0cm">progression-free survival and overall
survival compared with dacarbazine</P>
<P STYLE="margin-bottom: 0cm">chemotherapy in metastatic BRAF-mutated
melanoma. Dabrafenib, another BRAF</P>
<P STYLE="margin-bottom: 0cm">inhibitor, has shown similar results
and was approved in 2013. Preclinical</P>
<P STYLE="margin-bottom: 0cm">studies suggested that another novel
group of agents, the MEK inhibitors, showed 
</P>
<P STYLE="margin-bottom: 0cm">stronger inhibition of both mutated
BRAF and NRAS cell cultures than vemurafenib.</P>
<P STYLE="margin-bottom: 0cm">Trametinib was the first MEK inhibitor
approved in 2014, both as a single agent</P>
<P STYLE="margin-bottom: 0cm">and in combination with dabrafenib for
the treatment of advanced BRAF-mutated</P>
<P STYLE="margin-bottom: 0cm">melanoma. Other MEK inhibitors are also
in development. Concomitant inhibition of</P>
<P STYLE="margin-bottom: 0cm">both MEK and BRAF has shown more
durable and greater tumor response than BRAF</P>
<P STYLE="margin-bottom: 0cm">monotherapy, by overcoming the multiple
genetic mechanisms of escape. Combined</P>
<P STYLE="margin-bottom: 0cm">therapy prevents the development of
acquired resistance as well as decreasing</P>
<P STYLE="margin-bottom: 0cm">cutaneous toxicity secondary to
paradoxical activation of the MAPK pathway</P>
<P STYLE="margin-bottom: 0cm">induced by BRAF inhibitors. Various
combinations of BRAF and MEK inhibitors have 
</P>
<P STYLE="margin-bottom: 0cm">shown promising results. Moreover,
triple combination therapies involved other</P>
<P STYLE="margin-bottom: 0cm">agents with novel mechanisms of action
are also being evaluated. These and other 
</P>
<P STYLE="margin-bottom: 0cm">combination strategies involving
immunotherapies and targeted therapies offer the</P>
<P STYLE="margin-bottom: 0cm">hope of improving outcomes beyond those
already achieved with anti-BRAF</P>
<P STYLE="margin-bottom: 0cm">treatments.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26175403 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">11. Oncol Lett. 2015 Jul;10(1):502-508.
Epub 2015 May 4.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Type II cyclic guanosine
monophosphate-dependent protein kinase inhibits Rac1</P>
<P STYLE="margin-bottom: 0cm">activation in gastric cancer cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Wang Y(1), Chen Y(1), Wu M(1), Lan
T(1), Wu Y(1), Li Y(1), Qian H(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Physiology, School of
Medicine, Jiangsu University, Zhenjiang,</P>
<P STYLE="margin-bottom: 0cm">Jiangsu 212013, P.R. China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Enhanced motility of cancer cells is a
critical step in promoting tumor</P>
<P STYLE="margin-bottom: 0cm">metastasis, which remains the major
cause of gastric cancer-associated mortality.</P>
<P STYLE="margin-bottom: 0cm">The small GTPase Rac1 is a key
signaling component in the regulation of cell</P>
<P STYLE="margin-bottom: 0cm">migration. Previous studies have
demonstrated that Rac1 activity may be regulated</P>
<P STYLE="margin-bottom: 0cm">by protein kinase G (PKG); however, the
underlying mechanism is not yet clear.</P>
<P STYLE="margin-bottom: 0cm">The current study aimed to investigate
the effect of type II cyclic guanosine</P>
<P STYLE="margin-bottom: 0cm">monophosphate (cGMP)-dependent protein
kinase (PKG II) on Rac1 activity. The</P>
<P STYLE="margin-bottom: 0cm">human gastric cancer cell line AGS was
infected with adenoviral constructs</P>
<P STYLE="margin-bottom: 0cm">encoding PKG II to increase the
expression of this enzyme, and treated with a</P>
<P STYLE="margin-bottom: 0cm">cGMP analog (8-pCPT-cGMP) to induce its
activation. A Transwell assay was</P>
<P STYLE="margin-bottom: 0cm">employed to measure cell migration, and
the activity of Rac1 was assessed using a</P>
<P STYLE="margin-bottom: 0cm">pull-down assay. Immunoprecipitation
was used to isolate the Rac1 protein.</P>
<P STYLE="margin-bottom: 0cm">Phosphorylation of phosphatidylinositol
4,5 bisphosphate 3 kinase (PI3K) and its 
</P>
<P STYLE="margin-bottom: 0cm">downstream effecter protein kinase B
(Akt) are associated with lysophosphatidic</P>
<P STYLE="margin-bottom: 0cm">acid (LPA)-induced motility/migration
of cancer cells. Extracellular signal</P>
<P STYLE="margin-bottom: 0cm">regulated kinase (ERK) is the major
signaling molecule of the Mitogen activated</P>
<P STYLE="margin-bottom: 0cm">protein kinase (MAPK) mediated
signaling pathway. ERK and its upstream activator 
</P>
<P STYLE="margin-bottom: 0cm">MAPK kinase (MEK) are also involved in
LPA-induced motility/migration of cancer</P>
<P STYLE="margin-bottom: 0cm">cells. Phosphorylation of PI3K/Akt,
MEK/ERK and enriched Rac1 were detected by</P>
<P STYLE="margin-bottom: 0cm">western blotting. The results revealed
that blocking the activation of Rac1 by</P>
<P STYLE="margin-bottom: 0cm">ectopically expressing an inactive Rac1
mutant (T17N) impeded LPA-induced cell</P>
<P STYLE="margin-bottom: 0cm">migration. Increased PKG II activity
inhibited LPA-induced migration and</P>
<P STYLE="margin-bottom: 0cm">LPA-induced activation of Rac1;
however, it had no effect on the phosphorylation 
</P>
<P STYLE="margin-bottom: 0cm">of Rac1. PKG II also inhibited the
activation of PI3K/Akt and MEK/ERK mediated</P>
<P STYLE="margin-bottom: 0cm">signaling, which is important for
LPA-induced Rac1 activation. These results</P>
<P STYLE="margin-bottom: 0cm">suggest that PKG II affects
LPA-stimulated migration of AGS cells by blocking</P>
<P STYLE="margin-bottom: 0cm">Rac1 activation, via inhibition of
PI3K/Akt and MEK/ERK mediated signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4487129</P>
<P STYLE="margin-bottom: 0cm">PMID: 26171059 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">12. Cell Signal. 2015 Jul 11. pii:
S0898-6568(15)00199-0. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.cellsig.2015.06.007. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The mechanism and function of
mitogen-activated protein kinase activation by</P>
<P STYLE="margin-bottom: 0cm">ARF1.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zhou F(1), Dong C(1), Davis JE(2), Wu
WH(2), Surrao K(2), Wu G(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Pharmacology and
Experimental Therapeutics, Louisiana State</P>
<P STYLE="margin-bottom: 0cm">University Health Sciences Center, 1901
Perdido St, New Orleans, LA 70112, United</P>
<P STYLE="margin-bottom: 0cm">States. (2)Department of Pharmacology
and Toxicology, Medical College of Georgia,</P>
<P STYLE="margin-bottom: 0cm">Georgia Regents University, 1459 Laney
Walker Blvd., Augusta, GA 30912, United</P>
<P STYLE="margin-bottom: 0cm">States. (3)Department of Pharmacology
and Experimental Therapeutics, Louisiana</P>
<P STYLE="margin-bottom: 0cm">State University Health Sciences
Center, 1901 Perdido St, New Orleans, LA 70112, 
</P>
<P STYLE="margin-bottom: 0cm">United States; Department of
Pharmacology and Toxicology, Medical College of</P>
<P STYLE="margin-bottom: 0cm">Georgia, Georgia Regents University,
1459 Laney Walker Blvd., Augusta, GA 30912, 
</P>
<P STYLE="margin-bottom: 0cm">United States. Electronic address:
guwu@gru.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Mitogen-activated protein kinases
(MAPK) can be activated by a number of</P>
<P STYLE="margin-bottom: 0cm">biochemical pathways through distinct
signaling molecules. We have recently</P>
<P STYLE="margin-bottom: 0cm">revealed a novel function for the
Ras-like small GTPase ADP-ribosylation factor 1</P>
<P STYLE="margin-bottom: 0cm">(ARF1) in mediating the activation of
Raf1-MEK-ERK1/2 pathway by G</P>
<P STYLE="margin-bottom: 0cm">protein-coupled receptors [Dong C, Li C
and Wu G (2011) J Biol Chem 286,</P>
<P STYLE="margin-bottom: 0cm">43,361-43,369]. Here, we have further
defined the underlying mechanism and the</P>
<P STYLE="margin-bottom: 0cm">possible function of ARF1-mediated MAPK
pathway. We demonstrated that the</P>
<P STYLE="margin-bottom: 0cm">blockage of ARF1 activation and the
disruption of ARF1 localization to the Golgi 
</P>
<P STYLE="margin-bottom: 0cm">by mutating Thr48, a highly conserved
residue involved in the exchange of GDP for</P>
<P STYLE="margin-bottom: 0cm">GTP, and the myristoylation site Gly2
abolished ARF1's ability to activate</P>
<P STYLE="margin-bottom: 0cm">ERK1/2. In addition, treatment with
Golgi structure disrupting agents markedly</P>
<P STYLE="margin-bottom: 0cm">attenuated ARF1-mediated ERK1/2
activation. Furthermore, ARF1 significantly</P>
<P STYLE="margin-bottom: 0cm">promoted cell proliferation. More
interestingly, ARF1 activated 90kDa ribosomal</P>
<P STYLE="margin-bottom: 0cm">S6 kinase 1 (RSK1) without influencing
Elk-1 activation and ERK2 translocation to</P>
<P STYLE="margin-bottom: 0cm">the nuclei. These data demonstrate
that, once activated, ARF1 activates the MAPK 
</P>
<P STYLE="margin-bottom: 0cm">pathway likely using the Golgi as a
main platform, which in turn activates the</P>
<P STYLE="margin-bottom: 0cm">cytoplasmic RSK1, leading to cell
proliferation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015 Elsevier Inc. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26169956 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">13. Radiother Oncol. 2015 Jul 8. pii:
S0167-8140(15)00323-0. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.radonc.2015.06.026. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Trametinib radiosensitises RAS- and
BRAF-mutated melanoma by perturbing cell</P>
<P STYLE="margin-bottom: 0cm">cycle and inducing senescence.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Schick U(1), Kyula J(1), Barker H(1),
Patel R(1), Zaidi S(1), Gregory C(1), Hafsi</P>
<P STYLE="margin-bottom: 0cm">H(1), Roulstone V(1), Deutsch E(2),
McLaughlin M(1), Harrington K(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Targeted Therapy Team, The Institute
of Cancer Research, London, United</P>
<P STYLE="margin-bottom: 0cm">Kingdom. (2)INSERM UMR 1030, Gustave
Roussy, Villejuif, France. (3)Targeted</P>
<P STYLE="margin-bottom: 0cm">Therapy Team, The Institute of Cancer
Research, London, United Kingdom.</P>
<P STYLE="margin-bottom: 0cm">Electronic address:
Kevin.Harrington@icr.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PURPOSE: Radiotherapy (RT) is used
frequently in patients with melanoma, but</P>
<P STYLE="margin-bottom: 0cm">results are suboptimal because the
disease is often radioresistant. This may be</P>
<P STYLE="margin-bottom: 0cm">due to constitutive activation of MAPK
pathway signalling through mutations</P>
<P STYLE="margin-bottom: 0cm">involving RAS/RAF. Thus, we studied
whether trametinib, a potent and selective</P>
<P STYLE="margin-bottom: 0cm">allosteric inhibitor of MEK1/2 could
improve the efficacy of RT.</P>
<P STYLE="margin-bottom: 0cm">METHODS AND MATERIALS: Clonogenic
survival assays were performed in human</P>
<P STYLE="margin-bottom: 0cm">BRAF-mutant (A375), NRAS-mutant (D04,
WM1631), KRAS-mutant (WM1791c) and</P>
<P STYLE="margin-bottom: 0cm">wild-type (PMWK) melanoma cell lines.
The effects of trametinib with and without 
</P>
<P STYLE="margin-bottom: 0cm">radiation on protein levels of MEK
effectors were measured by immunoblot</P>
<P STYLE="margin-bottom: 0cm">analyses. Cell cycle effects, DNA
damage repair, mitotic catastrophe and</P>
<P STYLE="margin-bottom: 0cm">senescence were measured using flow
cytometry, γH2Ax staining, nuclear</P>
<P STYLE="margin-bottom: 0cm">fragmentation and β-galactosidase
staining, respectively. Additionally, athymic</P>
<P STYLE="margin-bottom: 0cm">mice with D04 flank tumours were
treated with fractionated RT after gavage with</P>
<P STYLE="margin-bottom: 0cm">trametinib and monitored for tumour
growth.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: All cell lines, except PMWK,
exhibited enhanced cytotoxicity when RT was</P>
<P STYLE="margin-bottom: 0cm">combined with trametinib compared to
either agent alone. Sensitiser enhancement</P>
<P STYLE="margin-bottom: 0cm">ratios were 1.70, 1.32, 1.10, and 1.70
for A375, D04, WM1361 and WM1791c,</P>
<P STYLE="margin-bottom: 0cm">respectively. Trametinib efficiently
blocked RT-induced phosphorylation of ERK at</P>
<P STYLE="margin-bottom: 0cm">nanomolar concentrations. Increased
radiosensitivity correlated with prolonged G1</P>
<P STYLE="margin-bottom: 0cm">arrest and reduction in the
radioresistant S phase up to 48h following RT. A</P>
<P STYLE="margin-bottom: 0cm">larger population of
senescence-activated β-galactosidase-positive cells was seen</P>
<P STYLE="margin-bottom: 0cm">in the trametinib pretreated group, and
this correlated with activation of two of</P>
<P STYLE="margin-bottom: 0cm">the major mediators of induced
senescence, p53 and pRb. Mice receiving the</P>
<P STYLE="margin-bottom: 0cm">combination treatment (trametinib
1mg/kg and RT over 3days) showed a reduced mean</P>
<P STYLE="margin-bottom: 0cm">tumour volume compared with mice
receiving trametinib alone (p=0.016), or RT</P>
<P STYLE="margin-bottom: 0cm">alone (p=0.047). No overt signs of drug
toxicity were observed.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: Trametinib radiosensitised
RAS-/RAF-mutated melanoma cells by</P>
<P STYLE="margin-bottom: 0cm">inducing prolonged G1 arrest and
premature senescence. In this pre-clinical study</P>
<P STYLE="margin-bottom: 0cm">we demonstrate that combining
trametinib and RT is well tolerated, and reduces</P>
<P STYLE="margin-bottom: 0cm">tumour growth in vivo.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015. Published by
Elsevier Ireland Ltd.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26163092 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">14. Oncotarget. 2015 Jun
30;6(18):15814-27.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A MEK/PI3K/HDAC inhibitor combination
therapy for KRAS mutant pancreatic cancer</P>
<P STYLE="margin-bottom: 0cm">cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ischenko I(1), Petrenko O(1), Hayman
MJ(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Molecular Genetics and
Microbiology, Stony Brook University,</P>
<P STYLE="margin-bottom: 0cm">Stony Brook, NY, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Pancreatic ductal adenocarcinoma (PDAC)
is a highly aggressive, metastatic</P>
<P STYLE="margin-bottom: 0cm">disease with limited treatment options.
Factors contributing to the metastatic</P>
<P STYLE="margin-bottom: 0cm">predisposition and therapy resistance
in pancreatic cancer are not well</P>
<P STYLE="margin-bottom: 0cm">understood. Here, we used a mouse model
of KRAS-driven pancreatic carcinogenesis 
</P>
<P STYLE="margin-bottom: 0cm">to define distinct subtypes of PDAC
metastasis: epithelial, mesenchymal and</P>
<P STYLE="margin-bottom: 0cm">quasi-mesenchymal. We examined
pro-survival signals in these cells and the</P>
<P STYLE="margin-bottom: 0cm">therapeutic response differences
between them. Our data indicate that the</P>
<P STYLE="margin-bottom: 0cm">initiation and maintenance of the
transformed state are separable, and that KRAS 
</P>
<P STYLE="margin-bottom: 0cm">dependency is not a fundamental
constant of KRAS-initiated tumors. Moreover, some</P>
<P STYLE="margin-bottom: 0cm">cancer cells can shuttle between the
KRAS dependent (drug-sensitive) and</P>
<P STYLE="margin-bottom: 0cm">independent (drug-tolerant) states and
thus escape extinction. We further</P>
<P STYLE="margin-bottom: 0cm">demonstrate that inhibition of KRAS
signaling alone via co-targeting the MAPK and</P>
<P STYLE="margin-bottom: 0cm">PI3K pathways fails to induce extensive
tumor cell death and, therefore, has</P>
<P STYLE="margin-bottom: 0cm">limited efficacy against PDAC. However,
the addition of histone deacetylase</P>
<P STYLE="margin-bottom: 0cm">(HDAC) inhibitors greatly improves
outcomes, reduces the self-renewal of cancer</P>
<P STYLE="margin-bottom: 0cm">cells, and blocks cancer metastasis in
vivo. Our results suggest that targeting</P>
<P STYLE="margin-bottom: 0cm">HDACs in combination with KRAS or its
effector pathways provides an effective</P>
<P STYLE="margin-bottom: 0cm">strategy for the treatment of PDAC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26158412 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">15. Proc Natl Acad Sci U S A. 2015 Jul
21;112(29):E3855-63. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1073/pnas.1510733112. Epub 2015 Jul
6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">EGFR inhibition evokes innate drug
resistance in lung cancer cells by preventing 
</P>
<P STYLE="margin-bottom: 0cm">Akt activity and thus inactivating
Ets-1 function.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Phuchareon J(1), McCormick F(2), Eisele
DW(1), Tetsu O(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Head and Neck Cancer Research
Laboratory, Department of Otolaryngology-Head</P>
<P STYLE="margin-bottom: 0cm">and Neck Surgery, School of Medicine,
University of California, San Francisco</P>
<P STYLE="margin-bottom: 0cm">(UCSF), CA 94115; UCSF Helen Diller
Family Comprehensive Cancer Center, School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, University of California, San
Francisco, CA 94158. (2)UCSF Helen Diller</P>
<P STYLE="margin-bottom: 0cm">Family Comprehensive Cancer Center,
School of Medicine, University of California,</P>
<P STYLE="margin-bottom: 0cm">San Francisco, CA 94158
mccormic@cc.ucsf.edu osamu.tetsu@ucsf.edu. (3)Head and</P>
<P STYLE="margin-bottom: 0cm">Neck Cancer Research Laboratory,
Department of Otolaryngology-Head and Neck</P>
<P STYLE="margin-bottom: 0cm">Surgery, School of Medicine, University
of California, San Francisco (UCSF), CA</P>
<P STYLE="margin-bottom: 0cm">94115; UCSF Helen Diller Family
Comprehensive Cancer Center, School of Medicine, 
</P>
<P STYLE="margin-bottom: 0cm">University of California, San
Francisco, CA 94158 mccormic@cc.ucsf.edu</P>
<P STYLE="margin-bottom: 0cm">osamu.tetsu@ucsf.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nonsmall cell lung cancer (NSCLC) is
the leading cause of cancer death worldwide.</P>
<P STYLE="margin-bottom: 0cm">About 14% of NSCLCs harbor mutations in
epidermal growth factor receptor (EGFR). 
</P>
<P STYLE="margin-bottom: 0cm">Despite remarkable progress in
treatment with tyrosine kinase inhibitors (TKIs), 
</P>
<P STYLE="margin-bottom: 0cm">only 5% of patients achieve tumor
reduction &gt;90%. The limited primary responses</P>
<P STYLE="margin-bottom: 0cm">are attributed partly to drug
resistance inherent in the tumor cells before</P>
<P STYLE="margin-bottom: 0cm">therapy begins. Recent reports showed
that activation of receptor tyrosine</P>
<P STYLE="margin-bottom: 0cm">kinases (RTKs) is an important
determinant of this innate drug resistance. In</P>
<P STYLE="margin-bottom: 0cm">contrast, we demonstrate that EGFR
inhibition promotes innate drug resistance</P>
<P STYLE="margin-bottom: 0cm">despite blockade of RTK activity in
NSCLC cells. EGFR TKIs decrease both the</P>
<P STYLE="margin-bottom: 0cm">mitogen-activated protein kinase (MAPK)
and Akt protein kinase pathways for a</P>
<P STYLE="margin-bottom: 0cm">short time, after which the Ras/MAPK
pathway becomes reactivated. Akt inhibition 
</P>
<P STYLE="margin-bottom: 0cm">selectively blocks the transcriptional
activation of Ets-1, which inhibits its</P>
<P STYLE="margin-bottom: 0cm">target gene, dual specificity
phosphatase 6 (DUSP6), a negative regulator</P>
<P STYLE="margin-bottom: 0cm">specific for ERK1/2. As a result,
ERK1/2 is activated. Furthermore, elevated</P>
<P STYLE="margin-bottom: 0cm">c-Src stimulates Ras GTP-loading and
activates Raf and MEK kinases. These</P>
<P STYLE="margin-bottom: 0cm">observations suggest that not only
ERK1/2 but also Akt activity is essential to</P>
<P STYLE="margin-bottom: 0cm">maintain Ets-1 in an active state.
Therefore, despite high levels of ERK1/2,</P>
<P STYLE="margin-bottom: 0cm">Ets-1 target genes including DUSP6 and
cyclins D1, D3, and E2 remain suppressed</P>
<P STYLE="margin-bottom: 0cm">by Akt inhibition. Reduction of DUSP6
in combination with elevated c-Src renews</P>
<P STYLE="margin-bottom: 0cm">activation of the Ras/MAPK pathway,
which enhances cell survival by accelerating 
</P>
<P STYLE="margin-bottom: 0cm">Bim protein turnover. Thus, EGFR TKIs
evoke innate drug resistance by preventing 
</P>
<P STYLE="margin-bottom: 0cm">Akt activity and inactivating Ets-1
function in NSCLC cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26150526 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">16. J Biol Chem. 2015 Jul 2. pii:
jbc.M114.634162. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nicotinic Acetylcholine Receptors
Sensitize a MAPK-Linked Toxicity Pathway on</P>
<P STYLE="margin-bottom: 0cm">Prolonged Exposure to β-Amyloid.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Arora K(1), Cheng J(1), Nichols RA(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)University of Hawaii, United States.
(2)University of Hawaii, United States</P>
<P STYLE="margin-bottom: 0cm">robert.nichols@hawaii.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Among putative downstream synaptic
targets of β-amyloid (Aβ) are signaling</P>
<P STYLE="margin-bottom: 0cm">molecules involved in synaptic
function, memory formation and cognition, such as 
</P>
<P STYLE="margin-bottom: 0cm">the MAP kinases, MKPs, CaMKII, CREB,
Fyn and Tau. Here, we assessed the</P>
<P STYLE="margin-bottom: 0cm">activation and interaction of signaling
pathways upon prolonged exposure to Aβ in</P>
<P STYLE="margin-bottom: 0cm">model nerve cells expressing nicotinic
acetylcholine receptors (nAChRs). Our goal</P>
<P STYLE="margin-bottom: 0cm">was to characterize the steps
underlying sensitization of the nerve cells to</P>
<P STYLE="margin-bottom: 0cm">neurotoxicity when Aβ-target receptors
are present. Of particular focus was the</P>
<P STYLE="margin-bottom: 0cm">connection of the activated signaling
molecules to oxidative stress.</P>
<P STYLE="margin-bottom: 0cm">Differentiated neuroblastoma cells
expressing mouse α4β2-nAChRs were exposed to</P>
<P STYLE="margin-bottom: 0cm">Aβ1-42 for intervals from 30 min to 3
days. The cells and cell-derived protein</P>
<P STYLE="margin-bottom: 0cm">extracts were then probed for
activation of signaling pathway molecules (ERK,</P>
<P STYLE="margin-bottom: 0cm">JNK, CaMKII, CREB, MARCKS, Fyn, tau).
Our results show substantial, progressive</P>
<P STYLE="margin-bottom: 0cm">activation of ERK in response to
nanomolar Aβ exposure, starting at the earliest 
</P>
<P STYLE="margin-bottom: 0cm">time point. Increased ERK activation
was followed by JNK activation as well as an</P>
<P STYLE="margin-bottom: 0cm">increased expression of PHF-tau,
paralleled by increased levels of reactive</P>
<P STYLE="margin-bottom: 0cm">oxygen species (ROS). The impact of
prolonged Aβ on the levels of pERK, pJNK and 
</P>
<P STYLE="margin-bottom: 0cm">ROS was attenuated by MEK-selective and
JNK-selective inhibitors. In addition,</P>
<P STYLE="margin-bottom: 0cm">the MEK inhibitor as well as a JNK
inhibitor attenuated Aβ-induced nuclear</P>
<P STYLE="margin-bottom: 0cm">fragmentation, which followed the
changes in ROS levels. These results</P>
<P STYLE="margin-bottom: 0cm">demonstrate that the presence of nAChRs
sensitizes neurons to the neurotoxic</P>
<P STYLE="margin-bottom: 0cm">action of Aβ through the timed
activation of discrete intracellular signaling</P>
<P STYLE="margin-bottom: 0cm">molecules, suggesting pathways involved
in the early stages of Alzheimers</P>
<P STYLE="margin-bottom: 0cm">disease.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, The American Society
for Biochemistry and Molecular Biology.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26139609 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">17. J Transl Med. 2015 Jul 3;13(1):210.
doi: 10.1186/s12967-015-0581-2.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Vemurafenib resistance reprograms
melanoma cells towards glutamine dependence.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hernandez-Davies JE(1), Tran TQ(2),
Reid MA(3), Rosales KR(4), Lowman XH(5), Pan 
</P>
<P STYLE="margin-bottom: 0cm">M(6), Moriceau G(7,)(8), Yang Y(9), Wu
J(10), Lo RS(11,)(12), Kong M(13).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Cancer Biology,
Beckman Research Institute of City of Hope</P>
<P STYLE="margin-bottom: 0cm">Cancer Center, Duarte, CA, 91010, USA.
jedavies@coh.org. (2)Department of Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Biology, Beckman Research Institute of
City of Hope Cancer Center, Duarte, CA,</P>
<P STYLE="margin-bottom: 0cm">91010, USA. thatran@coh.org.
(3)Department of Cancer Biology, Beckman Research</P>
<P STYLE="margin-bottom: 0cm">Institute of City of Hope Cancer
Center, Duarte, CA, 91010, USA. mreida@coh.org. 
</P>
<P STYLE="margin-bottom: 0cm">(4)Department of Cancer Biology,
Beckman Research Institute of City of Hope</P>
<P STYLE="margin-bottom: 0cm">Cancer Center, Duarte, CA, 91010, USA.
krosales@coh.org. (5)Department of Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Biology, Beckman Research Institute of
City of Hope Cancer Center, Duarte, CA,</P>
<P STYLE="margin-bottom: 0cm">91010, USA. xlowman@coh.org.
(6)Department of Cancer Biology, Beckman Research</P>
<P STYLE="margin-bottom: 0cm">Institute of City of Hope Cancer
Center, Duarte, CA, 91010, USA. Minoan@coh.org. 
</P>
<P STYLE="margin-bottom: 0cm">(7)Division of Dermatology/Department
of Medicine, David Geffen School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, University of California, Los
Angeles, CA, 90095-1662, USA.</P>
<P STYLE="margin-bottom: 0cm">gmoriceau@mednet.ucla.edu. (8)Jonsson
Comprehensive Cancer Center, David Geffen</P>
<P STYLE="margin-bottom: 0cm">School of Medicine, University of
California, Los Angeles, CA, 90095-1662, USA.</P>
<P STYLE="margin-bottom: 0cm">gmoriceau@mednet.ucla.edu.
(9)Department of Cancer Biology, Beckman Research</P>
<P STYLE="margin-bottom: 0cm">Institute of City of Hope Cancer
Center, Duarte, CA, 91010, USA. yiyang@coh.org. 
</P>
<P STYLE="margin-bottom: 0cm">(10)Animal Tumor Model Program,
Division of Comparative Medicine, Beckman</P>
<P STYLE="margin-bottom: 0cm">Research Institute of City of Hope
Cancer Center, Duarte, CA, 91010, USA.</P>
<P STYLE="margin-bottom: 0cm">jwu@coh.org. (11)Division of
Dermatology/Department of Medicine, David Geffen</P>
<P STYLE="margin-bottom: 0cm">School of Medicine, University of
California, Los Angeles, CA, 90095-1662, USA.</P>
<P STYLE="margin-bottom: 0cm">rlo@mednet.ucla.edu. (12)Jonsson
Comprehensive Cancer Center, David Geffen School</P>
<P STYLE="margin-bottom: 0cm">of Medicine, University of California,
Los Angeles, CA, 90095-1662, USA.</P>
<P STYLE="margin-bottom: 0cm">rlo@mednet.ucla.edu. (13)Department of
Cancer Biology, Beckman Research Institute</P>
<P STYLE="margin-bottom: 0cm">of City of Hope Cancer Center, Duarte,
CA, 91010, USA. mekong@coh.org.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: (V600) BRAF mutations drive
approximately 50% of metastatic melanoma 
</P>
<P STYLE="margin-bottom: 0cm">which can be therapeutically targeted
by BRAF inhibitors (BRAFi) and, based on</P>
<P STYLE="margin-bottom: 0cm">resistance mechanisms, the combination
of BRAF and MEK inhibitors (BRAFi + MEKi).</P>
<P STYLE="margin-bottom: 0cm">Although the combination therapy has
been shown to provide superior clinical</P>
<P STYLE="margin-bottom: 0cm">benefits, acquired resistance is still
prevalent and limits the overall survival 
</P>
<P STYLE="margin-bottom: 0cm">benefits. Recent work has shown that
oncogenic changes can lead to alterations in</P>
<P STYLE="margin-bottom: 0cm">tumor cell metabolism rendering cells
addicted to nutrients, such as the amino</P>
<P STYLE="margin-bottom: 0cm">acid glutamine. Here, we evaluated
whether melanoma cells with acquired</P>
<P STYLE="margin-bottom: 0cm">resistance display glutamine dependence
and whether glutamine metabolism can be a</P>
<P STYLE="margin-bottom: 0cm">potential molecular target to treat
resistant cells.</P>
<P STYLE="margin-bottom: 0cm">METHODS: Isogenic BRAFi sensitive
parental (V600) BRAF mutant melanoma cell lines</P>
<P STYLE="margin-bottom: 0cm">and resistant (derived by chronic
treatment with vemurafenib) sub-lines were used</P>
<P STYLE="margin-bottom: 0cm">to assess differences in the glutamine
uptake and sensitivity to glutamine</P>
<P STYLE="margin-bottom: 0cm">deprivation. To evaluate a broader
range of resistance mechanisms, isogenic pairs</P>
<P STYLE="margin-bottom: 0cm">where the sub-lines were resistant to
BRAFi + MEKi were also studied. Since</P>
<P STYLE="margin-bottom: 0cm">resistant cells demonstrated increased
sensitivity to glutamine deficiency, we</P>
<P STYLE="margin-bottom: 0cm">used glutaminase inhibitors BPTES
[bis-2-(5 phenylacetamido-1, 2,</P>
<P STYLE="margin-bottom: 0cm">4-thiadiazol-2-yl) ethyl sulfide] and
L-L-DON (6-Diazo-5-oxo-L-norleucine) to</P>
<P STYLE="margin-bottom: 0cm">treat MAPK pathway inhibitor (MAPKi)
resistant cell populations both in vitro and</P>
<P STYLE="margin-bottom: 0cm">in vivo.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: We demonstrated that
MAPKi-acquired resistant cells uptook greater</P>
<P STYLE="margin-bottom: 0cm">amounts of glutamine and have increased
sensitivity to glutamine deprivation than</P>
<P STYLE="margin-bottom: 0cm">their MAPKi-sensitive counterparts. In
addition, it was found that both BPTES and</P>
<P STYLE="margin-bottom: 0cm">L-DON were more effective at decreasing
cell survival of MAPKi-resistant</P>
<P STYLE="margin-bottom: 0cm">sub-lines than parental cell
populations in vitro. We also showed that mutant</P>
<P STYLE="margin-bottom: 0cm">NRAS was critical for glutamine
addiction in mutant NRAS driven resistance. When 
</P>
<P STYLE="margin-bottom: 0cm">tested in vivo, we found that
xenografts derived from resistant cells were more</P>
<P STYLE="margin-bottom: 0cm">sensitive to BPTES or L-DON treatment
than those derived from parental cells.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: Our study is a
proof-of-concept for the potential of targeting</P>
<P STYLE="margin-bottom: 0cm">glutamine metabolism as an alternative
strategy to suppress acquired</P>
<P STYLE="margin-bottom: 0cm">MAPKi-resistance in melanoma.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4490757</P>
<P STYLE="margin-bottom: 0cm">PMID: 26139106 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">18. Oncotarget. 2015 Jul
10;6(19):17178-91.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Radiosensitization and downregulation
of heterogeneous nuclear ribonucleoprotein 
</P>
<P STYLE="margin-bottom: 0cm">K (hnRNP K) upon inhibition of
mitogen/extracellular signal-regulated kinase</P>
<P STYLE="margin-bottom: 0cm">(MEK) in malignant melanoma cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Eder S(1), Lamkowski A(1), Priller
M(1), Port M(1), Steinestel K(1,)(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Bundeswehr Institute of
Radiobiology, 80937 Munich, Germany.</P>
<P STYLE="margin-bottom: 0cm">(2)Gerhard-Domagk-Institute of
Pathology, University Hospital Muenster, 48149</P>
<P STYLE="margin-bottom: 0cm">Muenster, Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Heterogeneous nuclear
ribonucleoprotein K (hnRNP K) is an important</P>
<P STYLE="margin-bottom: 0cm">cofactor in the p53-mediated DNA damage
response pathway upon ionizing radiation 
</P>
<P STYLE="margin-bottom: 0cm">(IR) and exerts anti-apoptotic effects
also independent of p53 pathway</P>
<P STYLE="margin-bottom: 0cm">activation. Furthermore, hnRNP K is
overexpressed in various neoplasms including 
</P>
<P STYLE="margin-bottom: 0cm">malignant melanoma (MM). Here, we
investigate the role of hnRNP K in the</P>
<P STYLE="margin-bottom: 0cm">radioresistance of MM cells.</P>
<P STYLE="margin-bottom: 0cm">METHODS AND RESULTS: Our results show
cytoplasmic expression of hnRNP K in human 
</P>
<P STYLE="margin-bottom: 0cm">MM surgical specimens, but not in
benign nevi, and a quick dose- and</P>
<P STYLE="margin-bottom: 0cm">time-dependent upregulation in response
to IR accompanied by cytoplasmic</P>
<P STYLE="margin-bottom: 0cm">redistribution of the protein in the
IPC-298 cellular tumor model carrying an</P>
<P STYLE="margin-bottom: 0cm">activating NRAS mutation (p.Q61L).
SiRNA-based knockdown of hnRNP K induced a</P>
<P STYLE="margin-bottom: 0cm">delayed decline in γH2AX/53BP1-positive
DNA repair foci upon IR. Pharmacological 
</P>
<P STYLE="margin-bottom: 0cm">interference with MAPK signaling
abrogated ERK phosphorylation, diminished</P>
<P STYLE="margin-bottom: 0cm">cellular hnRNP K levels, impaired
γH2AX/53BP1-foci repair and proliferative</P>
<P STYLE="margin-bottom: 0cm">capability and increased apoptosis
comparable to the observed hnRNP K knockdown</P>
<P STYLE="margin-bottom: 0cm">phenotype in IPC-298 cells.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Our results indicate that
pharmacological interference with MAPK</P>
<P STYLE="margin-bottom: 0cm">signaling increases vulnerability of
NRAS-mutant malignant melanoma cells to</P>
<P STYLE="margin-bottom: 0cm">ionizing radiation along with
downregulation of endogenous hnRNP K and point</P>
<P STYLE="margin-bottom: 0cm">towards a possible use for combined MEK
inhibition and localized radiation</P>
<P STYLE="margin-bottom: 0cm">therapy of MM in the NRAS-mutant
setting where BRAF inhibitors offer no clinical 
</P>
<P STYLE="margin-bottom: 0cm">benefit.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26136337 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">19. Immunology. 2015 Jul 1. doi:
10.1111/imm.12501. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">H-ficolin binds Aspergillus fumigatus
leading to activation of the lectin</P>
<P STYLE="margin-bottom: 0cm">complement pathway and modulation of
lung epithelial immune responses.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Bidula S(1,)(2), Sexton DW(1,)(3),
Yates M(1), Abdolrasouli A(4), Shah A(4),</P>
<P STYLE="margin-bottom: 0cm">Wallis R(5), Reed A(6), Armstrong-James
D(4), Schelenz S(1,)(7).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Biomedical Research Centre, Norwich
Medical School, University of East Anglia,</P>
<P STYLE="margin-bottom: 0cm">Norwich Research Park, Norwich, NR4
7TJ, UK. (2)Aberdeen Fungal Group, School of 
</P>
<P STYLE="margin-bottom: 0cm">Medical Sciences, Institute of Medical
Sciences, University of Aberdeen,</P>
<P STYLE="margin-bottom: 0cm">Aberdeen, AB25 2ZD, UK. (3)School of
Pharmacy and Biomolecular Science, Liverpool</P>
<P STYLE="margin-bottom: 0cm">John Moores University, Byrom Street,
Liverpool, L3 3AF, UK. (4)Section of</P>
<P STYLE="margin-bottom: 0cm">Infectious Diseases and Immunity,
Imperial College London, Flowers Building,</P>
<P STYLE="margin-bottom: 0cm">Armstrong Road, London, SW7 2AZ, UK.
(5)Departments of Infection, Immunity and</P>
<P STYLE="margin-bottom: 0cm">Inflammation and Biochemistry,
University of Leicester, Henry Wellcome Building, 
</P>
<P STYLE="margin-bottom: 0cm">Lancaster Road, Leicester, LE1 9HN, UK.
(6)Department of Lung Transplantation,</P>
<P STYLE="margin-bottom: 0cm">Harefield Hospital, Hill End Road,
Middlesex, UB9 6JH, UK. (7)Department of</P>
<P STYLE="margin-bottom: 0cm">Microbiology, Royal Brompton Hospital,
Sydney Street, London, SW3 6NP, UK.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Aspergillus fumigatus is an
opportunistic fungal pathogen that typically infects 
</P>
<P STYLE="margin-bottom: 0cm">the lungs of immunocompromised patients
leading to a high mortality. H-ficolin,</P>
<P STYLE="margin-bottom: 0cm">an innate immune opsonin, is produced
by type II alveolar epithelial cells and</P>
<P STYLE="margin-bottom: 0cm">could participate in lung defences
against infections. Here, we utilised the</P>
<P STYLE="margin-bottom: 0cm">human type II alveolar epithelial cell
line, A549, to determine the involvement</P>
<P STYLE="margin-bottom: 0cm">of H-ficolin in fungal defence.
Additionally, we investigated the presence of</P>
<P STYLE="margin-bottom: 0cm">H-ficolin in bronchoalveolar lavage
fluid (BAL) from transplant patients during</P>
<P STYLE="margin-bottom: 0cm">pneumonia. H-ficolin exhibited
demonstrable binding to A. fumigatus conidia via</P>
<P STYLE="margin-bottom: 0cm">L-fucose, D-mannose and
N-acetylglucosamine residues in a calcium- and</P>
<P STYLE="margin-bottom: 0cm">pH-dependent manner. Moreover,
recognition led to lectin complement pathway</P>
<P STYLE="margin-bottom: 0cm">activation and enhanced fungal
association with A549 cells. Following</P>
<P STYLE="margin-bottom: 0cm">recognition, H-ficolin opsonization
manifested an increase in IL-8 production</P>
<P STYLE="margin-bottom: 0cm">from A549 cells which involved
activation of the intracellular signalling</P>
<P STYLE="margin-bottom: 0cm">pathways MEK 1/2, p38 MAPK and JNK.
Finally, H-ficolin concentrations were</P>
<P STYLE="margin-bottom: 0cm">significantly higher in BAL of patients
with lung infections compared to control 
</P>
<P STYLE="margin-bottom: 0cm">subjects (n=16; p=0.00726). ROC curve
analysis further highlighted the potential 
</P>
<P STYLE="margin-bottom: 0cm">of H-ficolin as a diagnostic marker for
lung infection (AUC=0.77; p&lt;0.0001).</P>
<P STYLE="margin-bottom: 0cm">Thus, H-ficolin participates in A.
fumigatus defence via activation of the lectin</P>
<P STYLE="margin-bottom: 0cm">complement pathway, enhanced
fungal-host interactions and modulated immune</P>
<P STYLE="margin-bottom: 0cm">responses. This article is protected by
copyright. All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">This article is protected by copyright.
All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26133042 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">20. Int J Clin Exp Med. 2015 Apr
15;8(4):5553-8. eCollection 2015.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The role of leptin in the ventricular
remodeling process and its mechanism.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zuo G(1), Du X(1), Zheng L(1), Wang
C(1), Wang K(1), Li Y(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Cardiology, Tianjin
Fifth Central Hospital No. 41 Zhejiang Road,</P>
<P STYLE="margin-bottom: 0cm">Tianjin 300450, P. R. China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">OBJECTIVE: This study aims to explore
the role of leptin in the ventricular</P>
<P STYLE="margin-bottom: 0cm">remodeling process and its mechanism in
the diabetic rats' model.</P>
<P STYLE="margin-bottom: 0cm">METHODS: The diabetic SD rats model
induced by streptozotocin was established.</P>
<P STYLE="margin-bottom: 0cm">The SD rats were randomly divided into
4 groups: control group (20 rats treated</P>
<P STYLE="margin-bottom: 0cm">with citric acid/sodium citrate
buffer); M0 group (10 rats treated with</P>
<P STYLE="margin-bottom: 0cm">physiological saline); M1 group (10
rats treated with 50 μg/kg LP); M2 group (10 
</P>
<P STYLE="margin-bottom: 0cm">rats treated with 100 μg/kg LP).
Ang-II was detected by ELISA. The expression</P>
<P STYLE="margin-bottom: 0cm">levels of LP and Ob-Rb were detected by
RT-PCR. MAPK phosphorylation changes were</P>
<P STYLE="margin-bottom: 0cm">detected by western blotting.
Myocardial morphology was observed.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: Compared with control group,
the blood glucose concentration and Ang-II 
</P>
<P STYLE="margin-bottom: 0cm">significantly increased in diabetic
model groups (P &lt; 0.01) and body weight</P>
<P STYLE="margin-bottom: 0cm">decreased (P &lt; 0.05). The expression
levels of LP and Ob-Rb increased and heart</P>
<P STYLE="margin-bottom: 0cm">function decreased in diabetic model
groups.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: LP may be involved in the
myocardial cell hypertrophy through the</P>
<P STYLE="margin-bottom: 0cm">neuroendocrine system and associated
with the JAK-STAT, Ras-Raf-MEK-MAPK and</P>
<P STYLE="margin-bottom: 0cm">PI-3K signaling pathway, which provides
a new concept for the pathogenesis of</P>
<P STYLE="margin-bottom: 0cm">cardiac hypertrophy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4483875</P>
<P STYLE="margin-bottom: 0cm">PMID: 26131137 [PubMed]</P>
<P STYLE="margin-bottom: 0cm">R and the MAPK/MNK</P>
<P STYLE="margin-bottom: 0cm">pathway in PCa cells maintains a
defined translational level of specific mRNAs</P>
<P STYLE="margin-bottom: 0cm">required for ribosome biogenesis, cell
proliferation and stress response and</P>
<P STYLE="margin-bottom: 0cm">might confer to these cells the ability
to overcome negative insults.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 18809972 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Nat Commun. 2013;4:1681. doi:
10.1038/ncomms2687.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Structure of ERK2 bound to PEA-15
reveals a mechanism for rapid release of</P>
<P STYLE="margin-bottom: 0cm">activated MAPK.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Mace PD(1), Wallez Y, Egger MF,
Dobaczewska MK, Robinson H, Pasquale EB, Riedl</P>
<P STYLE="margin-bottom: 0cm">SJ.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Program in Apoptosis and Cell Death
Research, Cancer Center, Sanford-Burnham</P>
<P STYLE="margin-bottom: 0cm">Medical Research Institute, 10901 North
Torrey Pines Road, La Jolla, California</P>
<P STYLE="margin-bottom: 0cm">92037, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">ERK1/2 kinases are the principal
effectors of a central signalling cascade that</P>
<P STYLE="margin-bottom: 0cm">converts extracellular stimuli into
cell proliferation and migration responses</P>
<P STYLE="margin-bottom: 0cm">and, when deregulated, can promote cell
oncogenic transformation. The scaffolding</P>
<P STYLE="margin-bottom: 0cm">protein PEA-15 is a death effector
domain protein that directly interacts with</P>
<P STYLE="margin-bottom: 0cm">ERK1/2 and affects ERK1/2 subcellular
localization and phosphorylation. Here, to 
</P>
<P STYLE="margin-bottom: 0cm">understand this ERK1/2 signalling
complex, we have solved the crystal structures 
</P>
<P STYLE="margin-bottom: 0cm">of PEA-15 bound to three different ERK2
phospho-conformers. The structures reveal</P>
<P STYLE="margin-bottom: 0cm">that PEA-15 uses a bipartite binding
mode, occupying two key docking sites of</P>
<P STYLE="margin-bottom: 0cm">ERK2. Remarkably, PEA-15 can
efficiently bind the ERK2 activation loop in the</P>
<P STYLE="margin-bottom: 0cm">critical Thr-X-Tyr region in different
phosphorylation states. PEA-15 binding</P>
<P STYLE="margin-bottom: 0cm">triggers an extended allosteric conduit
in dually phosphorylated ERK2, disrupting</P>
<P STYLE="margin-bottom: 0cm">key features of active ERK2. At the
same time PEA-15 binding protects ERK2 from</P>
<P STYLE="margin-bottom: 0cm">dephosphorylation, thus setting the
stage for immediate ERK activity upon its</P>
<P STYLE="margin-bottom: 0cm">release from the PEA-15 inhibitory
complex.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3640864</P>
<P STYLE="margin-bottom: 0cm">PMID: 23575685 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. Sci Signal. 2012 Oct 9;5(245):ra74.
doi: 10.1126/scisignal.2003004.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Specificity of linear motifs that bind
to a common mitogen-activated protein</P>
<P STYLE="margin-bottom: 0cm">kinase docking groove.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Garai Á(1), Zeke A, Gógl G, Törő I,
Fördős F, Blankenburg H, Bárkai T, Varga J,</P>
<P STYLE="margin-bottom: 0cm">Alexa A, Emig D, Albrecht M, Reményi
A.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biochemistry, Eötvös
Loránd University, Pázmány Péter sétány</P>
<P STYLE="margin-bottom: 0cm">1/C, 1117 Budapest, Hungary.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Mitogen-activated protein kinases
(MAPKs) have a docking groove that interacts</P>
<P STYLE="margin-bottom: 0cm">with linear &quot;docking&quot; motifs
in binding partners. To determine the structural</P>
<P STYLE="margin-bottom: 0cm">basis of binding specificity between
MAPKs and docking motifs, we quantitatively 
</P>
<P STYLE="margin-bottom: 0cm">analyzed the ability of 15 docking
motifs from diverse MAPK partners to bind to</P>
<P STYLE="margin-bottom: 0cm">c-Jun amino-terminal kinase 1 (JNK1),
p38α, and extracellular signal-regulated</P>
<P STYLE="margin-bottom: 0cm">kinase 2 (ERK2). Classical docking
motifs mediated highly specific binding only</P>
<P STYLE="margin-bottom: 0cm">to JNK1, and only those motifs with a
sequence pattern distinct from the</P>
<P STYLE="margin-bottom: 0cm">classical MAPK binding docking motif
consensus differentiated between the</P>
<P STYLE="margin-bottom: 0cm">topographically similar docking grooves
of ERK and p38α. Crystal structures of</P>
<P STYLE="margin-bottom: 0cm">four complexes of MAPKs with docking
peptides, representing JNK-specific,</P>
<P STYLE="margin-bottom: 0cm">ERK-specific, or ERK- and p38-selective
binding modes, revealed that the regions 
</P>
<P STYLE="margin-bottom: 0cm">located between consensus positions in
the docking motifs showed conformational</P>
<P STYLE="margin-bottom: 0cm">diversity. Although the consensus
positions in the docking motifs served as</P>
<P STYLE="margin-bottom: 0cm">anchor points that bound to common MAPK
surface features and mostly contributed</P>
<P STYLE="margin-bottom: 0cm">to docking in a nondiscriminatory
fashion, the conformation of the intervening</P>
<P STYLE="margin-bottom: 0cm">region between the anchor points mostly
determined specificity. We designed</P>
<P STYLE="margin-bottom: 0cm">peptides with tailored MAPK binding
profiles by rationally changing the length</P>
<P STYLE="margin-bottom: 0cm">and amino acid composition of
intervening regions located between anchor points. 
</P>
<P STYLE="margin-bottom: 0cm">These results suggest a coherent
structural model for MAPK docking specificity</P>
<P STYLE="margin-bottom: 0cm">that reveals how short linear motifs
binding to a common kinase docking groove</P>
<P STYLE="margin-bottom: 0cm">can mediate diverse interaction
patterns and contribute to correct MAPK partner</P>
<P STYLE="margin-bottom: 0cm">selection in signaling networks.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC3500698</P>
<P STYLE="margin-bottom: 0cm">PMID: 23047924 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. Sci Signal. 2011 Dec 20;4(204):ra88.
doi: 10.1126/scisignal.2002241.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A distinct interaction mode revealed by
the crystal structure of the kinase p38α 
</P>
<P STYLE="margin-bottom: 0cm">with the MAPK binding domain of the
phosphatase MKP5.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zhang YY(1), Wu JW, Wang ZX.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Ministry of Education Key Laboratory
for Protein Science, School of Life</P>
<P STYLE="margin-bottom: 0cm">Sciences, Tsinghua University, Beijing
100084, PR China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The mitogen-activated protein kinase
(MAPK) cascades play a pivotal role in a</P>
<P STYLE="margin-bottom: 0cm">myriad of cellular functions. The
specificity and efficiency of MAPK signaling</P>
<P STYLE="margin-bottom: 0cm">are controlled by docking interactions
between MAPKs and their cognate proteins. 
</P>
<P STYLE="margin-bottom: 0cm">Many MAPK-interacting partners,
including substrates, MAPK kinases, phosphatases,</P>
<P STYLE="margin-bottom: 0cm">and scaffolding proteins, have linear
sequence motifs that mediate the</P>
<P STYLE="margin-bottom: 0cm">interaction with the common docking
site on MAPKs. We report the crystal</P>
<P STYLE="margin-bottom: 0cm">structure of p38α in complex with the
MAPK binding domain (KBD) from MAPK</P>
<P STYLE="margin-bottom: 0cm">phosphatase 5 (MKP5) at 2.7 Å
resolution. In contrast to the well-known docking</P>
<P STYLE="margin-bottom: 0cm">mode, the KBD binds p38α in a
bipartite manner, in which two distinct helical</P>
<P STYLE="margin-bottom: 0cm">regions of KBD engage the p38α docking
site, which is situated on the back of the</P>
<P STYLE="margin-bottom: 0cm">p38α active site. We also determined
the crystal structure of the KBD of MKP7,</P>
<P STYLE="margin-bottom: 0cm">which closely resembles the MKP5 KBD,
suggesting that the mechanism of molecular 
</P>
<P STYLE="margin-bottom: 0cm">recognition by the KBD of MKP5 is
conserved in the cytoplasmic p38- and c-Jun</P>
<P STYLE="margin-bottom: 0cm">N-terminal kinase-specific MKP
subgroup. This previously unknown binding mode</P>
<P STYLE="margin-bottom: 0cm">provides new insights into how MAPKs
interact with their binding partners to</P>
<P STYLE="margin-bottom: 0cm">achieve functional specificity.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 22375048 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">4. Structure. 2003 Feb;11(2):155-64.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Solution structure of the MAPK
phosphatase PAC-1 catalytic domain. Insights into 
</P>
<P STYLE="margin-bottom: 0cm">substrate-induced enzymatic activation
of MKP.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Farooq A(1), Plotnikova O, Chaturvedi
G, Yan S, Zeng L, Zhang Q, Zhou MM.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Structural Biology Program,
Department of Physiology and Biophysics, Mount</P>
<P STYLE="margin-bottom: 0cm">Sinai School of Medicine, New York
University, One Gustave L. Levy Place, New</P>
<P STYLE="margin-bottom: 0cm">York, NY 10029, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Comment in</P>
<P STYLE="margin-bottom: 0cm">Structure. 2003 Feb;11(2):131-2.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Inactivation of mitogen-activated
protein kinases (MAPKs) by MAPK phosphatases</P>
<P STYLE="margin-bottom: 0cm">(MKPs) is accomplished via
substrate-induced activation of the latter enzymes;</P>
<P STYLE="margin-bottom: 0cm">however, the structural basis for the
underlying mechanism remains elusive. Here,</P>
<P STYLE="margin-bottom: 0cm">we report the three-dimensional
solution structure of the C-terminal phosphatase 
</P>
<P STYLE="margin-bottom: 0cm">domain of the prototypical MKP PAC-1,
determined when bound to phosphate.</P>
<P STYLE="margin-bottom: 0cm">Structural and biochemical analyses
reveal unique active site geometry of the</P>
<P STYLE="margin-bottom: 0cm">enzyme important for binding to
phosphorylated threonine and tyrosine of MAPK</P>
<P STYLE="margin-bottom: 0cm">ERK2. Our study further demonstrates
that the dynamic interaction between the</P>
<P STYLE="margin-bottom: 0cm">N-terminal kinase binding domain and
the C-terminal phosphatase domain of an MKP 
</P>
<P STYLE="margin-bottom: 0cm">is directly coupled to MAPK-induced
conformational change of the phosphatase</P>
<P STYLE="margin-bottom: 0cm">active site, which is essential for
eliciting its full enzymatic activity.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 12575935 [PubMed - indexed for
MEDLINE]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. Cancer. 2015 Jul 28. doi:
10.1002/cncr.29586. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Clinicopathologic features associated
with efficacy and long-term survival in</P>
<P STYLE="margin-bottom: 0cm">metastatic melanoma patients treated
with BRAF or combined BRAF and MEK</P>
<P STYLE="margin-bottom: 0cm">inhibitors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Menzies AM(1,)(2,)(3), Wilmott
JS(1,)(2), Drummond M(1,)(2), Lo S(1,)(2), Lyle</P>
<P STYLE="margin-bottom: 0cm">M(1,)(2), Chan MM(4), Thompson
JF(1,)(2,)(5,)(6), Guminski A(1,)(2,)(3), Carlino 
</P>
<P STYLE="margin-bottom: 0cm">MS(1,)(2,)(4), Scolyer RA(1,)(2,)(5),
Kefford RF(1,)(2,)(4,)(7), Long GV(1,)(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Melanoma Institute Australia,
Sydney, Australia. (2)The University of Sydney, 
</P>
<P STYLE="margin-bottom: 0cm">Sydney, Australia. (3)Royal North Shore
Hospital, Sydney, Australia. (4)Crown</P>
<P STYLE="margin-bottom: 0cm">Princess Mary Cancer Centre, Westmead
Hospital, Sydney, Australia. (5)Royal</P>
<P STYLE="margin-bottom: 0cm">Prince Alfred Hospital, Sydney,
Australia. (6)Mater Hospital, Sydney, Australia. 
</P>
<P STYLE="margin-bottom: 0cm">(7)Macquarie University, Sydney,
Australia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: The degree of response and
the duration of survival of patients</P>
<P STYLE="margin-bottom: 0cm">treated with mitogen-activated protein
kinase (MAPK) inhibitors are highly</P>
<P STYLE="margin-bottom: 0cm">variable. Whether baseline
clinicopathologic factors can predict the clinical</P>
<P STYLE="margin-bottom: 0cm">course with treatment is largely
unknown.</P>
<P STYLE="margin-bottom: 0cm">METHODS: For 142 consecutive
immunotherapy- and MAPK inhibitor-naive patients</P>
<P STYLE="margin-bottom: 0cm">with BRAF-mutant metastatic melanoma
who were treated during clinical trials with</P>
<P STYLE="margin-bottom: 0cm">BRAF inhibitors (n = 111) or a
combination of dabrafenib and trametinib (n = 31),</P>
<P STYLE="margin-bottom: 0cm">clinicopathologic factors were
correlated with the response to MAPK inhibitors</P>
<P STYLE="margin-bottom: 0cm">and survival.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: The median follow-up was 15.7
months (range, 0.6-60.5 months). The 2-,</P>
<P STYLE="margin-bottom: 0cm">3-, and 4-year overall survival (OS)
rates were 43%, 24%, and 24%, respectively. 
</P>
<P STYLE="margin-bottom: 0cm">A multivariate analysis demonstrated
that the only clinicopathologic factors</P>
<P STYLE="margin-bottom: 0cm">associated with longer progression-free
survival (PFS) and OS were female sex and</P>
<P STYLE="margin-bottom: 0cm">a normal pretreatment serum lactate
dehydrogenase (LDH) level. The BRAF V600E</P>
<P STYLE="margin-bottom: 0cm">genotype and an absence of primary
melanoma ulceration were also independently</P>
<P STYLE="margin-bottom: 0cm">associated with longer PFS but not OS.
The median OS was 23.5 months for patients</P>
<P STYLE="margin-bottom: 0cm">with normal LDH levels and 7.3 months
for those with elevated LDH levels (hazard 
</P>
<P STYLE="margin-bottom: 0cm">ratio, 0.31; P &lt; .001). Complete
responders had the best survival, but disease</P>
<P STYLE="margin-bottom: 0cm">progression still occurred in 2 of 7
patients.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Long-term survival occurs
for a minority of patients receiving MAPK 
</P>
<P STYLE="margin-bottom: 0cm">inhibitor treatment alone. Sex, serum
LDH, BRAF genotype, and primary melanoma</P>
<P STYLE="margin-bottom: 0cm">ulceration status are independent
factors associated with treatment outcomes.</P>
<P STYLE="margin-bottom: 0cm">Patients with a complete response to
treatment have the best survival, but</P>
<P STYLE="margin-bottom: 0cm">relapses still occur. Cancer 2015. ©
2015 American Cancer Society.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2015 American Cancer Society.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26218930 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. BMC Syst Biol. 2015 Jul 25;9:41.
doi: 10.1186/s12918-015-0187-6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Regulation of ERK-MAPK signaling in
human epidermis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cursons J(1,)(2,)(3,)(4,)(5), Gao J(6),
Hurley DG(7,)(8,)(9,)(10,)(11,)(12),</P>
<P STYLE="margin-bottom: 0cm">Print CG(13,)(14,)(15), Dunbar
PR(16,)(17), Jacobs MD(18), Crampin</P>
<P STYLE="margin-bottom: 0cm">EJ(19,)(20,)(21,)(22,)(23,)(24).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Systems Biology Laboratory,
Melbourne School of Engineering, University of</P>
<P STYLE="margin-bottom: 0cm">Melbourne, Melbourne, Australia.
joseph.cursons@unimelb.edu.au. (2)NICTA Victoria</P>
<P STYLE="margin-bottom: 0cm">Research Lab, Melbourne, Australia.
joseph.cursons@unimelb.edu.au. (3)ARC Centre 
</P>
<P STYLE="margin-bottom: 0cm">of Excellence in Convergent Bio-Nano
Science and Technology, Melbourne School of 
</P>
<P STYLE="margin-bottom: 0cm">Engineering, University of Melbourne,
Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">joseph.cursons@unimelb.edu.au.
(4)Auckland Bioengineering Institute, University</P>
<P STYLE="margin-bottom: 0cm">of Auckland, Auckland, New Zealand.
joseph.cursons@unimelb.edu.au. (5)Maurice</P>
<P STYLE="margin-bottom: 0cm">Wilkins Centre, University of Auckland,
Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">joseph.cursons@unimelb.edu.au.
(6)Systems Biology Laboratory, Melbourne School of</P>
<P STYLE="margin-bottom: 0cm">Engineering, University of Melbourne,
Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">jerry.gao@unimelb.edu.au. (7)Systems
Biology Laboratory, Melbourne School of</P>
<P STYLE="margin-bottom: 0cm">Engineering, University of Melbourne,
Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">daniel.hurley@unimelb.edu.au. (8)NICTA
Victoria Research Lab, Melbourne,</P>
<P STYLE="margin-bottom: 0cm">Australia.
daniel.hurley@unimelb.edu.au. (9)Auckland Bioengineering Institute,</P>
<P STYLE="margin-bottom: 0cm">University of Auckland, Auckland, New
Zealand. daniel.hurley@unimelb.edu.au.</P>
<P STYLE="margin-bottom: 0cm">(10)Maurice Wilkins Centre, University
of Auckland, Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">daniel.hurley@unimelb.edu.au.
(11)Bioinformatics Institute, University of</P>
<P STYLE="margin-bottom: 0cm">Auckland, Auckland, New Zealand.
daniel.hurley@unimelb.edu.au. (12)Faculty of</P>
<P STYLE="margin-bottom: 0cm">Medical and Health Sciences, University
of Auckland, Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">daniel.hurley@unimelb.edu.au.
(13)Maurice Wilkins Centre, University of Auckland,</P>
<P STYLE="margin-bottom: 0cm">Auckland, New Zealand.
c.print@auckland.ac.nz. (14)Bioinformatics Institute,</P>
<P STYLE="margin-bottom: 0cm">University of Auckland, Auckland, New
Zealand. c.print@auckland.ac.nz.</P>
<P STYLE="margin-bottom: 0cm">(15)Faculty of Medical and Health
Sciences, University of Auckland, Auckland, New</P>
<P STYLE="margin-bottom: 0cm">Zealand. c.print@auckland.ac.nz.
(16)Maurice Wilkins Centre, University of</P>
<P STYLE="margin-bottom: 0cm">Auckland, Auckland, New Zealand.
r.dunbar@auckland.ac.nz. (17)School of</P>
<P STYLE="margin-bottom: 0cm">Biological Sciences, University of
Auckland, Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">r.dunbar@auckland.ac.nz. (18)Department
of Biology, New Zealand International</P>
<P STYLE="margin-bottom: 0cm">College, ACG New Zealand, Auckland, New
Zealand. marc.jacobs@gmx.com. (19)Systems</P>
<P STYLE="margin-bottom: 0cm">Biology Laboratory, Melbourne School of
Engineering, University of Melbourne,</P>
<P STYLE="margin-bottom: 0cm">Melbourne, Australia.
edmund.crampin@unimelb.edu.au. (20)ARC Centre of Excellence</P>
<P STYLE="margin-bottom: 0cm">in Convergent Bio-Nano Science and
Technology, Melbourne School of Engineering,</P>
<P STYLE="margin-bottom: 0cm">University of Melbourne, Melbourne,
Australia. edmund.crampin@unimelb.edu.au.</P>
<P STYLE="margin-bottom: 0cm">(21)Auckland Bioengineering Institute,
University of Auckland, Auckland, New</P>
<P STYLE="margin-bottom: 0cm">Zealand. edmund.crampin@unimelb.edu.au.
(22)Maurice Wilkins Centre, University of</P>
<P STYLE="margin-bottom: 0cm">Auckland, Auckland, New Zealand.
edmund.crampin@unimelb.edu.au. (23)School of</P>
<P STYLE="margin-bottom: 0cm">Mathematics and Statistics, University
of Melbourne, Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">edmund.crampin@unimelb.edu.au.
(24)School of Medicine, University of Melbourne,</P>
<P STYLE="margin-bottom: 0cm">Melbourne, Australia.
edmund.crampin@unimelb.edu.au.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: The skin is largely
comprised of keratinocytes within the</P>
<P STYLE="margin-bottom: 0cm">interfollicular epidermis. Over
approximately two weeks these cells differentiate</P>
<P STYLE="margin-bottom: 0cm">and traverse the thickness of the skin.
The stage of differentiation is therefore</P>
<P STYLE="margin-bottom: 0cm">reflected in the positions of cells
within the tissue, providing a convenient</P>
<P STYLE="margin-bottom: 0cm">axis along which to study the signaling
events that occur in situ during</P>
<P STYLE="margin-bottom: 0cm">keratinocyte terminal differentiation,
over this extended two-week timescale. The</P>
<P STYLE="margin-bottom: 0cm">canonical ERK-MAPK signaling cascade
(Raf-1, MEK-1/2 and ERK-1/2) has been</P>
<P STYLE="margin-bottom: 0cm">implicated in controlling diverse
cellular behaviors, including proliferation and</P>
<P STYLE="margin-bottom: 0cm">differentiation. While the molecular
interactions involved in signal transduction</P>
<P STYLE="margin-bottom: 0cm">through this cascade have been well
characterized in cell culture experiments,</P>
<P STYLE="margin-bottom: 0cm">our understanding of how this sequence
of events unfolds to determine cell fate</P>
<P STYLE="margin-bottom: 0cm">within a homeostatic tissue environment
has not been fully characterized.</P>
<P STYLE="margin-bottom: 0cm">METHODS: We measured the abundance of
total and phosphorylated ERK-MAPK signaling</P>
<P STYLE="margin-bottom: 0cm">proteins within interfollicular
keratinocytes in transverse cross-sections of</P>
<P STYLE="margin-bottom: 0cm">human epidermis using
immunofluorescence microscopy. To investigate these data we</P>
<P STYLE="margin-bottom: 0cm">developed a mathematical model of the
signaling cascade using a normalized-Hill</P>
<P STYLE="margin-bottom: 0cm">differential equation formalism.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: These data show coordinated
variation in the abundance of phosphorylated</P>
<P STYLE="margin-bottom: 0cm">ERK-MAPK components across the
epidermis. Statistical analysis of these data</P>
<P STYLE="margin-bottom: 0cm">shows that associations between
phosphorylated ERK-MAPK components which</P>
<P STYLE="margin-bottom: 0cm">correspond to canonical molecular
interactions are dependent upon spatial</P>
<P STYLE="margin-bottom: 0cm">position within the epidermis. The
model demonstrates that the spatial profile of</P>
<P STYLE="margin-bottom: 0cm">activation for ERK-MAPK signaling
components across the epidermis may be</P>
<P STYLE="margin-bottom: 0cm">maintained in a cell-autonomous fashion
by an underlying spatial gradient in</P>
<P STYLE="margin-bottom: 0cm">calcium signaling.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Our data demonstrate an
extended phospho-protein profile of ERK-MAPK</P>
<P STYLE="margin-bottom: 0cm">signaling cascade components across the
epidermis in situ, and statistical</P>
<P STYLE="margin-bottom: 0cm">associations in these data indicate
canonical ERK-MAPK interactions underlie this</P>
<P STYLE="margin-bottom: 0cm">spatial profile of ERK-MAPK activation.
Using mathematical modelling we have</P>
<P STYLE="margin-bottom: 0cm">demonstrated that spatially varying
calcium signaling components across the</P>
<P STYLE="margin-bottom: 0cm">epidermis may be sufficient to maintain
the spatial profile of ERK-MAPK signaling</P>
<P STYLE="margin-bottom: 0cm">cascade components in a cell-autonomous
manner. These findings may have</P>
<P STYLE="margin-bottom: 0cm">significant implications for the wide
range of cancer drugs which therapeutically</P>
<P STYLE="margin-bottom: 0cm">target ERK-MAPK signaling components.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4514964</P>
<P STYLE="margin-bottom: 0cm">PMID: 26209520 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. Cell Adh Migr. 2015 Jul 24:1-10.
[Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Snail promotes cell migration through
PI3K/AKT-dependent Rac1 activation as well 
</P>
<P STYLE="margin-bottom: 0cm">as PI3K/AKT-independent pathways during
prostate cancer progression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Henderson V(1), Smith B, Burton LJ,
Randle D, Morris M, Odero-Marah VA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)a Center for Cancer Research and
Therapeutic Development; Department of</P>
<P STYLE="margin-bottom: 0cm">Biological Sciences ; Clark Atlanta
University ; Atlanta , GA USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Snail, a zinc-finger transcription
factor, induces epithelial-mesenchymal</P>
<P STYLE="margin-bottom: 0cm">transition (EMT), which is associated
with increased cell migration and</P>
<P STYLE="margin-bottom: 0cm">metastasis in cancer cells. Rac1 is a
small G-protein which upon activation</P>
<P STYLE="margin-bottom: 0cm">results in formation of lamellipodia,
the first protrusions formed by migrating</P>
<P STYLE="margin-bottom: 0cm">cells. We have previously shown that
Snail promotes cell migration through</P>
<P STYLE="margin-bottom: 0cm">down-regulation of maspin tumor
suppressor. We hypothesized that Snail's</P>
<P STYLE="margin-bottom: 0cm">regulation of cell migration may also
involve Rac1 signaling regulated by</P>
<P STYLE="margin-bottom: 0cm">PI3K/AKT and/or MAPK pathways. We found
that Snail overexpression in LNCaP and</P>
<P STYLE="margin-bottom: 0cm">22Rv1 prostate cancer cells increased
Rac1 activity associated with increased</P>
<P STYLE="margin-bottom: 0cm">cell migration, and the Rac1 inhibitor,
NSC23766, could inhibit Snail-mediated</P>
<P STYLE="margin-bottom: 0cm">cell migration. Conversely, Snail
downregulation using shRNA in the aggressive</P>
<P STYLE="margin-bottom: 0cm">C4-2 prostate cancer cells decreased
Rac1 activity and cell migration. Moreover, 
</P>
<P STYLE="margin-bottom: 0cm">Snail overexpression increased ERK and
PI3K/AKT activity in 22Rv1 prostate cancer</P>
<P STYLE="margin-bottom: 0cm">cells. Treatment of
Snail-overexpressing 22Rv1 cells with LY294002, PI3K/AKT</P>
<P STYLE="margin-bottom: 0cm">inhibitor or U0126, MEK inhibitor,
decreased cell migration significantly, but</P>
<P STYLE="margin-bottom: 0cm">only LY294002 significantly reduced
Rac1 activity, suggesting that Snail promotes</P>
<P STYLE="margin-bottom: 0cm">Rac1 activation via the PI3K/AKT
pathway. Furthermore, 22Rv1 cells overexpressing</P>
<P STYLE="margin-bottom: 0cm">Snail displayed decreased maspin
levels, while inhibition of maspin expression in</P>
<P STYLE="margin-bottom: 0cm">22Rv1 cells with siRNA, led to
increased PI3K/AKT, Rac1 activity and cell</P>
<P STYLE="margin-bottom: 0cm">migration, without affecting ERK
activity, suggesting that maspin is upstream of 
</P>
<P STYLE="margin-bottom: 0cm">PI3K/AKT. Overall, we have dissected
signaling pathways by which Snail may</P>
<P STYLE="margin-bottom: 0cm">promote cell migration through MAPK
signaling or alternatively through</P>
<P STYLE="margin-bottom: 0cm">PI3K/AKT-Rac1 signaling that involves
Snail inhibition of maspin tumor</P>
<P STYLE="margin-bottom: 0cm">suppressor. This may contribute to
prostate cancer progression.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26207671 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">4. Mol Cancer Ther. 2015 Jul 23. pii:
molcanther.0223.2015. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Assessment of the in vivo activity of
PI3K and MEK inhibitors in genetically</P>
<P STYLE="margin-bottom: 0cm">defined models of colorectal cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Raja M(1), Zverev M(1), Seipel K(2),
Williams GT(3), Clarke AR(4), Shaw PH(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)European Cancer Stem Cell Research
Institute, Cardiff University. (2)Oncology,</P>
<P STYLE="margin-bottom: 0cm">University Hospital Bern. (3)School of
Medicine, Cardiff University. (4)Cardiff</P>
<P STYLE="margin-bottom: 0cm">University, European Cancer Stem Cell
Research Institute ClarkeAR@cardiff.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The objective of tailoring medicines
for cancer patients according to the</P>
<P STYLE="margin-bottom: 0cm">molecular profile of their disease
holds great promise for the improvement of</P>
<P STYLE="margin-bottom: 0cm">cancer therapy. Nevertheless, this
approach has been limited, in part due to the 
</P>
<P STYLE="margin-bottom: 0cm">lack of predictive and informative
pre-clinical studies. Herein, we describe an</P>
<P STYLE="margin-bottom: 0cm">assessment of the therapeutic potential
of targeting PI3K/mTOR and MAPK</P>
<P STYLE="margin-bottom: 0cm">signalling in genetically defined mouse
models of colorectal cancer (CRC)</P>
<P STYLE="margin-bottom: 0cm">mirroring disease subtypes targeted for
novel therapy in the FOCUS4 trial. Our</P>
<P STYLE="margin-bottom: 0cm">studies demonstrate that dual PI3K/mTOR
inhibition is highly effective in</P>
<P STYLE="margin-bottom: 0cm">invasive adenocarcinoma models
characterised by combinatorial mutations in Apc</P>
<P STYLE="margin-bottom: 0cm">and Pten; Apc and Kras; and Apc, Pten
and Kras. MEK inhibition was effective in</P>
<P STYLE="margin-bottom: 0cm">the combinatorial Apc and Kras setting,
but had no impact in either Apc Pten</P>
<P STYLE="margin-bottom: 0cm">mutants or in Apc Pten Kras triple
mutants. Furthermore, we describe the</P>
<P STYLE="margin-bottom: 0cm">importance of scheduling for
combination studies and show that although no</P>
<P STYLE="margin-bottom: 0cm">additional benefit is gained in Apc
Pten mice, combination of PI3K/mTOR and MAPK 
</P>
<P STYLE="margin-bottom: 0cm">inhibition leads to an additive benefit
in survival in Apc Kras mice and a</P>
<P STYLE="margin-bottom: 0cm">synergistic increase in survival in Apc
Pten Kras mice. This is the first study</P>
<P STYLE="margin-bottom: 0cm">utilising robust CRC GEMMs to support
the validity of PI3K/mTOR and MEK</P>
<P STYLE="margin-bottom: 0cm">inhibitors as tailored therapies for
CRC and highlight the potential importance</P>
<P STYLE="margin-bottom: 0cm">of drug scheduling in the clinic.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Association
for Cancer Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26206338 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">5. Mol Cancer Ther. 2015 Jul 23. pii:
molcanther.0429.2015. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Inhibition of wild-type p53-expressing
AML by novel small molecule HDM2</P>
<P STYLE="margin-bottom: 0cm">inhibitor, CGM097.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Weisberg EL(1), Halilovic E(2), Cooke
VG(2), Nonami A(3), Ren T(4), Sanda T(3),</P>
<P STYLE="margin-bottom: 0cm">Simkin I(5), Yuan J(2), Antonakos B(2),
Barys L(6), Ito M(6), Stone RM(3),</P>
<P STYLE="margin-bottom: 0cm">Galinsky I(3), Cowens K(3), Nelson
E(3), Sattler M(3), Jeay S(7), Wuerthner</P>
<P STYLE="margin-bottom: 0cm">JU(6), McDonough S(3), Wiesmann M(6),
Griffin JD(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Medical Oncology, Dana Farber Cancer
Institute</P>
<P STYLE="margin-bottom: 0cm">ellen_weisberg@dfci.harvard.edu.
(2)Oncology, Novartis Institutes for BioMedical 
</P>
<P STYLE="margin-bottom: 0cm">Research, Inc. (3)Medical Oncology,
Dana Farber Cancer Institute. (4)National</P>
<P STYLE="margin-bottom: 0cm">Screening Laboratory for the Regional
Centers of Excellence in Biodefense and</P>
<P STYLE="margin-bottom: 0cm">Emerging Infectious Diseases Research,
Harvard Medical School. (5)Molecular</P>
<P STYLE="margin-bottom: 0cm">Genetics Core, Boston University School
of Medicine. (6)Disease Area Oncology,</P>
<P STYLE="margin-bottom: 0cm">Novartis Institutes for BioMedical
Research, Inc. (7)Oncology, Novartis</P>
<P STYLE="margin-bottom: 0cm">Institutes for BioMedical Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The tumor suppressor, p53, is a key
regulator of apoptosis and functions upstream</P>
<P STYLE="margin-bottom: 0cm">in the apoptotic cascade by both
indirectly and directly regulating Bcl-2 family 
</P>
<P STYLE="margin-bottom: 0cm">proteins. In cells expressing wild-type
(wt) p53, the HDM2 protein binds to p53</P>
<P STYLE="margin-bottom: 0cm">and blocks its activity. Inhibition of
HDM2:p53 interaction activates p53 and</P>
<P STYLE="margin-bottom: 0cm">causes apoptosis or cell cycle arrest.
Here, we investigated the ability of the</P>
<P STYLE="margin-bottom: 0cm">novel HDM2 inhibitor, CGM097, to
potently and selectively kill wt p53-expressing 
</P>
<P STYLE="margin-bottom: 0cm">AML cells. The anti-leukemic effects of
CGM097 were studied using cell-based</P>
<P STYLE="margin-bottom: 0cm">proliferation assays (human AML cell
lines, primary AML patient cells and normal 
</P>
<P STYLE="margin-bottom: 0cm">bone marrow samples), apoptosis and
cell cycle assays, ELISA, immunoblotting, and</P>
<P STYLE="margin-bottom: 0cm">an AML patient-derived in vivo mouse
model. CGM097 potently and selectively</P>
<P STYLE="margin-bottom: 0cm">inhibited the proliferation of human
AML cell lines and the majority of primary</P>
<P STYLE="margin-bottom: 0cm">AML cells expressing wt p53, but not
mutant p53, in a target-specific manner.</P>
<P STYLE="margin-bottom: 0cm">Several patient samples that harbored
mutant p53 were comparatively unresponsive 
</P>
<P STYLE="margin-bottom: 0cm">to CGM097. Synergy was observed when
CGM097 was combined with FLT3 inhibition</P>
<P STYLE="margin-bottom: 0cm">against oncogenic FLT3-expressing cells
cultured both in the absence as well as</P>
<P STYLE="margin-bottom: 0cm">the presence of cytoprotective
stromal-secreted cytokines, as well as when</P>
<P STYLE="margin-bottom: 0cm">combined with MEK inhibition in cells
with activated MAPK signaling. Finally,</P>
<P STYLE="margin-bottom: 0cm">CGM097 was effective in reducing
leukemia burden in vivo. These data suggest that</P>
<P STYLE="margin-bottom: 0cm">CGM097 is a promising treatment for AML
characterized as harboring wt p53 as a</P>
<P STYLE="margin-bottom: 0cm">single agent, as well as in combination
with other therapies targeting</P>
<P STYLE="margin-bottom: 0cm">oncogene-activated pathways that drive
AML.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Association
for Cancer Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26206331 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">6. Expert Opin Biol Ther. 2015 Jul
24:1-10. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Synergy of molecular targeted
approaches and immunotherapy in melanoma:</P>
<P STYLE="margin-bottom: 0cm">preclinical basis and clinical
perspectives.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Sanlorenzo M(1), Vujic I, Moy A,
Quaglino P, Fierro MT, Gammaitoni L,</P>
<P STYLE="margin-bottom: 0cm">Carnevale-Schianca F, Aglietta M,
Sangiolo D.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)University of Turin, Department of
Medical Sciences, Section of Dermatology , 
</P>
<P STYLE="margin-bottom: 0cm">Via Cherasco 23, Torino , Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">INTRODUCTION: Targeted therapy and
immunotherapies are the novel pharmacologic</P>
<P STYLE="margin-bottom: 0cm">treatment strategies for metastatic
melanoma. BRAF and MEK inhibitors effectively</P>
<P STYLE="margin-bottom: 0cm">block the hyperactivation of the MAPK
pathway in BRAF mutant melanomas and also</P>
<P STYLE="margin-bottom: 0cm">have several other effects on melanoma
cells and on the immune response. The aim 
</P>
<P STYLE="margin-bottom: 0cm">of this work is to discuss the
rationale, evidence and perspectives of approaches</P>
<P STYLE="margin-bottom: 0cm">combining target and immunotherapy
against melanoma. Areas covered: We first</P>
<P STYLE="margin-bottom: 0cm">review the effects of BRAF and MEK
inhibitors on melanoma cells and on the</P>
<P STYLE="margin-bottom: 0cm">different components of the immune
system. Afterwards, we summarize the results</P>
<P STYLE="margin-bottom: 0cm">of the preclinical and clinical studies
that have combined targeted therapy and</P>
<P STYLE="margin-bottom: 0cm">immunotherapy for the treatment of
melanoma. Expert opinion: Clinical</P>
<P STYLE="margin-bottom: 0cm">applications of immunotherapy
strategies have recently changed the therapeutic</P>
<P STYLE="margin-bottom: 0cm">mainstay for metastatic melanoma.
Biologic and initial preclinical data support</P>
<P STYLE="margin-bottom: 0cm">their integration with innovative
molecular targeted therapies, opening enormous 
</P>
<P STYLE="margin-bottom: 0cm">perspectives for researchers in the
effort of finding a definitive cure. Main</P>
<P STYLE="margin-bottom: 0cm">open challenges are the definition of
reliable research models, assessment of</P>
<P STYLE="margin-bottom: 0cm">effective schedules, safety issues and
designing of personalized approaches.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26206099 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">7. Int J Cancer. 2015 Jul 23. doi:
10.1002/ijc.29698. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Inhibition of class I histone
deacetylases by romidepsin potently induces</P>
<P STYLE="margin-bottom: 0cm">Epstein-Barr virus lytic cycle and
mediates enhanced cell death with ganciclovir.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hui KF(1), Cheung AK(2), Choi CK(1),
Yeung PL(1), Middeldorp JM(3), Lung</P>
<P STYLE="margin-bottom: 0cm">ML(2,)(4), Tsao SW(5,)(4), Chiang
AK(1,)(4).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Paediatrics and
Adolescent Medicine, The University of Hong</P>
<P STYLE="margin-bottom: 0cm">Kong, Queen Mary Hospital, Pokfulam,
Hong Kong SAR, China. (2)Department of</P>
<P STYLE="margin-bottom: 0cm">Clinical Oncology, Li Ka Shing Faculty
of Medicine, The University of Hong Kong, 
</P>
<P STYLE="margin-bottom: 0cm">Queen Mary Hospital, Pokfulam, Hong
Kong SAR, China. (3)Department of Pathology, 
</P>
<P STYLE="margin-bottom: 0cm">VU University Medical Center,
Amsterdam, The Netherlands. (4)Center for</P>
<P STYLE="margin-bottom: 0cm">Nasopharyngeal Carcinoma Research, The
University of Hong Kong, Hong Kong SAR,</P>
<P STYLE="margin-bottom: 0cm">China. (5)Department of Anatomy, Li Ka
Shing Faculty of Medicine, The University 
</P>
<P STYLE="margin-bottom: 0cm">of Hong Kong, Pokfulam, Hong Kong SAR,
China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Pan-histone deacetylase (HDAC)
inhibitors, which inhibit eleven HDAC isoforms,</P>
<P STYLE="margin-bottom: 0cm">are widely used to induce EBV lytic
cycle in EBV-associated cancers in vitro and 
</P>
<P STYLE="margin-bottom: 0cm">in clinical trials. Here, we
hypothesized that inhibition of one or several</P>
<P STYLE="margin-bottom: 0cm">specific HDAC isoforms by selective
HDAC inhibitors could potently induce EBV</P>
<P STYLE="margin-bottom: 0cm">lytic cycle in EBV-associated
malignancies such as nasopharyngeal carcinoma (NPC)</P>
<P STYLE="margin-bottom: 0cm">and gastric carcinoma (GC). We found
that inhibition of class I HDACs,</P>
<P STYLE="margin-bottom: 0cm">particularly HDAC-1, -2 and -3, was
sufficient to induce EBV lytic cycle in NPC</P>
<P STYLE="margin-bottom: 0cm">and GC cells in vitro and in vivo.
Among a panel of selective HDAC inhibitors,</P>
<P STYLE="margin-bottom: 0cm">the FDA-approved HDAC inhibitor
romidepsin was found to be the most potent lytic 
</P>
<P STYLE="margin-bottom: 0cm">inducer, which could activate EBV lytic
cycle at ∼0.5 to 5 nM (versus ∼800 nM</P>
<P STYLE="margin-bottom: 0cm">achievable concentration in patients'
plasma) in more than 75% of cells.</P>
<P STYLE="margin-bottom: 0cm">Up-regulation of p21(WAF1) , which is
negatively regulated by class I HDACs was</P>
<P STYLE="margin-bottom: 0cm">observed prior to the induction of EBV
lytic cycle. The up-regulation of</P>
<P STYLE="margin-bottom: 0cm">p21(WAF1) and induction of lytic cycle
were abrogated by a specific inhibitor of 
</P>
<P STYLE="margin-bottom: 0cm">PKC-δ but not the inhibitors of PI3K,
MEK, p38 MAPK, JNK, or ATM pathways.</P>
<P STYLE="margin-bottom: 0cm">Interestingly, inhibition of HDAC-1, -2
and -3 by romidepsin or shRNA knockdown</P>
<P STYLE="margin-bottom: 0cm">could confer susceptibility of
EBV-positive epithelial cells to the treatment</P>
<P STYLE="margin-bottom: 0cm">with ganciclovir. In conclusion, we
demonstrated that inhibition of class I HDACs</P>
<P STYLE="margin-bottom: 0cm">by romidepsin could potently induce EBV
lytic cycle and mediate enhanced cell</P>
<P STYLE="margin-bottom: 0cm">death with ganciclovir, suggesting
potential application of romidepsin for the</P>
<P STYLE="margin-bottom: 0cm">treatment of EBV-associated cancers.
This article is protected by copyright. All 
</P>
<P STYLE="margin-bottom: 0cm">rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2015 UICC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26205347 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">8. Clin Cancer Res. 2015 Jul 22. pii:
clincanres.0393.2015. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cellular mechanisms underlying complete
hematological response of chronic myeloid</P>
<P STYLE="margin-bottom: 0cm">leukemia to BRAF/MEK inhibition in a
patient with concomitant metastatic</P>
<P STYLE="margin-bottom: 0cm">melanoma.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Andrews MC(1), Turner N(2), Boyd J(3),
Roberts AW(4), Grigg A(5), Behren A(1),</P>
<P STYLE="margin-bottom: 0cm">Cebon JS(6).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Cancer Immunobiology Laboratory,
Olivia Newton-John Cancer Research Institute.</P>
<P STYLE="margin-bottom: 0cm">(2)Systems Biology and Personalized
Medicine, Walter and Eliza Hall Institute of 
</P>
<P STYLE="margin-bottom: 0cm">Medical Research. (3)Clinical
Haematology and Bone Marrow Transplantation, Royal 
</P>
<P STYLE="margin-bottom: 0cm">Melbourne Hospital. (4)Clinical
Haematology and BMT service, The Royal Melbourne 
</P>
<P STYLE="margin-bottom: 0cm">Hospital. (5)Haematology, Austin
Health. (6)Cancer Immunobiology Laboratory,</P>
<P STYLE="margin-bottom: 0cm">Olivia Newton-John Cancer Research
Institute jonathan.cebon@onjcri.org.au.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PURPOSE: Targeted MEK inhibition is an
emerging therapy in a number of solid</P>
<P STYLE="margin-bottom: 0cm">tumors. It holds particular promise in
BRAF V600E mutation-positive malignant</P>
<P STYLE="margin-bottom: 0cm">melanoma, where constitutive activation
and cell growth through the MAP kinase</P>
<P STYLE="margin-bottom: 0cm">(MAPK) pathway is well established. In
vitro and pre-clinical research indicates 
</P>
<P STYLE="margin-bottom: 0cm">that MAPK pathway activation is
important in chronic myeloid leukemia (CML)</P>
<P STYLE="margin-bottom: 0cm">leukemogenesis however the potential of
MEK inhibition has not yet been</P>
<P STYLE="margin-bottom: 0cm">investigated clinically in the setting
of such hematological malignancies.</P>
<P STYLE="margin-bottom: 0cm">EXPERIMENTAL DESIGN: We report a case
of complete hematological response of CML</P>
<P STYLE="margin-bottom: 0cm">to MEK inhibition in a patient with
synchronous metastatic melanoma, who received</P>
<P STYLE="margin-bottom: 0cm">treatment with combination BRAF and
MEK1/2 inhibitors. We studied the effects of 
</P>
<P STYLE="margin-bottom: 0cm">these agents on proliferation and
outgrowth of myeloid precursors, and</P>
<P STYLE="margin-bottom: 0cm">longitudinal shifts in peripheral blood
phenotyping during the course of</P>
<P STYLE="margin-bottom: 0cm">treatment. A model cell line system was
used to examine the effects of dabrafenib</P>
<P STYLE="margin-bottom: 0cm">and trametinib on MAPK and
BCR-ABL1-signalling.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: After 35 weeks on treatment
with BRAF and MEK inhibitors, complete</P>
<P STYLE="margin-bottom: 0cm">hematologic response was observed
without recourse to BCR-ABL1-targeted therapy. 
</P>
<P STYLE="margin-bottom: 0cm">MEK inhibition was principally
responsible for impaired proliferation of both</P>
<P STYLE="margin-bottom: 0cm">mature and primitive myeloid
precursors, as well as growth and hemoglobinization 
</P>
<P STYLE="margin-bottom: 0cm">of erythroid precursors. Paradoxical
activation of the MAPK pathway was seen in</P>
<P STYLE="margin-bottom: 0cm">response to BRAF inhibitor therapy but
this was easily overcome by</P>
<P STYLE="margin-bottom: 0cm">clinically-relevant doses of concurrent
MEK inhibitor.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: These studies suggest that
further evaluation of the optimal MAPK</P>
<P STYLE="margin-bottom: 0cm">targeting approach is warranted to
extend therapeutic options in CML.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, American Association
for Cancer Research.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26202951 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">9. J Exp Med. 2015 Jul
27;212(8):1323-36. doi: 10.1084/jem.20150110. Epub 2015 Jul</P>
<P STYLE="margin-bottom: 0cm">20.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">T cell development involves
TRAF3IP3-mediated ERK signaling in the Golgi.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zou Q(1), Jin J(1), Xiao Y(1), Hu H(1),
Zhou X(1), Jie Z(1), Xie X(1), Li JY(2), 
</P>
<P STYLE="margin-bottom: 0cm">Cheng X(1), Sun SC(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Immunology, The
University of Texas MD Anderson Cancer Center,</P>
<P STYLE="margin-bottom: 0cm">Houston, TX 77030. (2)Department of
Genetics and Developmental Biology,</P>
<P STYLE="margin-bottom: 0cm">University of Connecticut Health
Center, Farmington, CT 06030. (3)Department of</P>
<P STYLE="margin-bottom: 0cm">Immunology, The University of Texas MD
Anderson Cancer Center, Houston, TX 77030 
</P>
<P STYLE="margin-bottom: 0cm">The University of Texas Graduate School
of Biomedical Sciences, Houston, TX 77030</P>
<P STYLE="margin-bottom: 0cm">ssun@mdanderson.org.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Generation of T lymphocytes in the
thymus is guided by signal transduction from</P>
<P STYLE="margin-bottom: 0cm">the T cell receptor (TCR), but the
underlying mechanism is incompletely</P>
<P STYLE="margin-bottom: 0cm">understood. Here we have identified a
Golgi-associated factor, TRAF3-interacting 
</P>
<P STYLE="margin-bottom: 0cm">protein 3 (TRAF3IP3), as a crucial
mediator of thymocyte development. TRAF3IP3</P>
<P STYLE="margin-bottom: 0cm">deficiency in mice attenuates the
generation of mature thymocytes caused by</P>
<P STYLE="margin-bottom: 0cm">impaired thymocyte-positive selection.
TRAF3IP3 mediates TCR-stimulated</P>
<P STYLE="margin-bottom: 0cm">activation of the mitogen-activated
protein kinase (MAPK) extracellular</P>
<P STYLE="margin-bottom: 0cm">signal-regulated kinase (ERK) and its
upstream kinase mitogen/extracellular</P>
<P STYLE="margin-bottom: 0cm">signal-regulated kinase (MEK).
Interestingly, TRAF3IP3 exerts this signaling</P>
<P STYLE="margin-bottom: 0cm">function through recruiting MEK to the
Golgi and, thereby, facilitating the</P>
<P STYLE="margin-bottom: 0cm">interaction of MEK with its activator
BRAF. Transgenic expression of a</P>
<P STYLE="margin-bottom: 0cm">constitutively active MEK rescues the T
cell development block in Traf3ip3</P>
<P STYLE="margin-bottom: 0cm">knockout mice. These findings establish
TRAF3IP3 as a novel regulator of T cell</P>
<P STYLE="margin-bottom: 0cm">development and suggest a
Golgi-specific ERK signaling mechanism that regulates</P>
<P STYLE="margin-bottom: 0cm">thymocyte development.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">© 2015 Zou et al.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26195727 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">10. Discov Med. 2015
Jun;19(107):455-61.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Novel mechanisms and therapeutic
approaches in melanoma: targeting the MAPK</P>
<P STYLE="margin-bottom: 0cm">pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Grimaldi AM(1), Simeone E, Festino L,
Vanella V, Palla M, Ascierto PA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)O.U. Melanoma, Cancer Immunotherapy
and Innovative Therapies, National Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Institute of Naples &quot;G. Pascale&quot;
Foundation, Naples, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The development of novel treatments
that selectively inhibit the RAS-RAF-MAPK</P>
<P STYLE="margin-bottom: 0cm">pathway represents a milestone in the
history of melanoma treatment. BRAF</P>
<P STYLE="margin-bottom: 0cm">mutations occur in approximately 45% of
cutaneous melanomas, while mutations in</P>
<P STYLE="margin-bottom: 0cm">NRAS occur in 15-25%. Vemurafenib was
the first BRAF inhibitor to be approved in 
</P>
<P STYLE="margin-bottom: 0cm">2011, based on the results of a phase
III trial (BRIM-3) that showed higher</P>
<P STYLE="margin-bottom: 0cm">progression-free survival and overall
survival compared with dacarbazine</P>
<P STYLE="margin-bottom: 0cm">chemotherapy in metastatic BRAF-mutated
melanoma. Dabrafenib, another BRAF</P>
<P STYLE="margin-bottom: 0cm">inhibitor, has shown similar results
and was approved in 2013. Preclinical</P>
<P STYLE="margin-bottom: 0cm">studies suggested that another novel
group of agents, the MEK inhibitors, showed 
</P>
<P STYLE="margin-bottom: 0cm">stronger inhibition of both mutated
BRAF and NRAS cell cultures than vemurafenib.</P>
<P STYLE="margin-bottom: 0cm">Trametinib was the first MEK inhibitor
approved in 2014, both as a single agent</P>
<P STYLE="margin-bottom: 0cm">and in combination with dabrafenib for
the treatment of advanced BRAF-mutated</P>
<P STYLE="margin-bottom: 0cm">melanoma. Other MEK inhibitors are also
in development. Concomitant inhibition of</P>
<P STYLE="margin-bottom: 0cm">both MEK and BRAF has shown more
durable and greater tumor response than BRAF</P>
<P STYLE="margin-bottom: 0cm">monotherapy, by overcoming the multiple
genetic mechanisms of escape. Combined</P>
<P STYLE="margin-bottom: 0cm">therapy prevents the development of
acquired resistance as well as decreasing</P>
<P STYLE="margin-bottom: 0cm">cutaneous toxicity secondary to
paradoxical activation of the MAPK pathway</P>
<P STYLE="margin-bottom: 0cm">induced by BRAF inhibitors. Various
combinations of BRAF and MEK inhibitors have 
</P>
<P STYLE="margin-bottom: 0cm">shown promising results. Moreover,
triple combination therapies involved other</P>
<P STYLE="margin-bottom: 0cm">agents with novel mechanisms of action
are also being evaluated. These and other 
</P>
<P STYLE="margin-bottom: 0cm">combination strategies involving
immunotherapies and targeted therapies offer the</P>
<P STYLE="margin-bottom: 0cm">hope of improving outcomes beyond those
already achieved with anti-BRAF</P>
<P STYLE="margin-bottom: 0cm">treatments.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26175403 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">11. Oncol Lett. 2015 Jul;10(1):502-508.
Epub 2015 May 4.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Type II cyclic guanosine
monophosphate-dependent protein kinase inhibits Rac1</P>
<P STYLE="margin-bottom: 0cm">activation in gastric cancer cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Wang Y(1), Chen Y(1), Wu M(1), Lan
T(1), Wu Y(1), Li Y(1), Qian H(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Physiology, School of
Medicine, Jiangsu University, Zhenjiang,</P>
<P STYLE="margin-bottom: 0cm">Jiangsu 212013, P.R. China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Enhanced motility of cancer cells is a
critical step in promoting tumor</P>
<P STYLE="margin-bottom: 0cm">metastasis, which remains the major
cause of gastric cancer-associated mortality.</P>
<P STYLE="margin-bottom: 0cm">The small GTPase Rac1 is a key
signaling component in the regulation of cell</P>
<P STYLE="margin-bottom: 0cm">migration. Previous studies have
demonstrated that Rac1 activity may be regulated</P>
<P STYLE="margin-bottom: 0cm">by protein kinase G (PKG); however, the
underlying mechanism is not yet clear.</P>
<P STYLE="margin-bottom: 0cm">The current study aimed to investigate
the effect of type II cyclic guanosine</P>
<P STYLE="margin-bottom: 0cm">monophosphate (cGMP)-dependent protein
kinase (PKG II) on Rac1 activity. The</P>
<P STYLE="margin-bottom: 0cm">human gastric cancer cell line AGS was
infected with adenoviral constructs</P>
<P STYLE="margin-bottom: 0cm">encoding PKG II to increase the
expression of this enzyme, and treated with a</P>
<P STYLE="margin-bottom: 0cm">cGMP analog (8-pCPT-cGMP) to induce its
activation. A Transwell assay was</P>
<P STYLE="margin-bottom: 0cm">employed to measure cell migration, and
the activity of Rac1 was assessed using a</P>
<P STYLE="margin-bottom: 0cm">pull-down assay. Immunoprecipitation
was used to isolate the Rac1 protein.</P>
<P STYLE="margin-bottom: 0cm">Phosphorylation of phosphatidylinositol
4,5 bisphosphate 3 kinase (PI3K) and its 
</P>
<P STYLE="margin-bottom: 0cm">downstream effecter protein kinase B
(Akt) are associated with lysophosphatidic</P>
<P STYLE="margin-bottom: 0cm">acid (LPA)-induced motility/migration
of cancer cells. Extracellular signal</P>
<P STYLE="margin-bottom: 0cm">regulated kinase (ERK) is the major
signaling molecule of the Mitogen activated</P>
<P STYLE="margin-bottom: 0cm">protein kinase (MAPK) mediated
signaling pathway. ERK and its upstream activator 
</P>
<P STYLE="margin-bottom: 0cm">MAPK kinase (MEK) are also involved in
LPA-induced motility/migration of cancer</P>
<P STYLE="margin-bottom: 0cm">cells. Phosphorylation of PI3K/Akt,
MEK/ERK and enriched Rac1 were detected by</P>
<P STYLE="margin-bottom: 0cm">western blotting. The results revealed
that blocking the activation of Rac1 by</P>
<P STYLE="margin-bottom: 0cm">ectopically expressing an inactive Rac1
mutant (T17N) impeded LPA-induced cell</P>
<P STYLE="margin-bottom: 0cm">migration. Increased PKG II activity
inhibited LPA-induced migration and</P>
<P STYLE="margin-bottom: 0cm">LPA-induced activation of Rac1;
however, it had no effect on the phosphorylation 
</P>
<P STYLE="margin-bottom: 0cm">of Rac1. PKG II also inhibited the
activation of PI3K/Akt and MEK/ERK mediated</P>
<P STYLE="margin-bottom: 0cm">signaling, which is important for
LPA-induced Rac1 activation. These results</P>
<P STYLE="margin-bottom: 0cm">suggest that PKG II affects
LPA-stimulated migration of AGS cells by blocking</P>
<P STYLE="margin-bottom: 0cm">Rac1 activation, via inhibition of
PI3K/Akt and MEK/ERK mediated signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4487129</P>
<P STYLE="margin-bottom: 0cm">PMID: 26171059 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">12. Cell Signal. 2015 Jul 11. pii:
S0898-6568(15)00199-0. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.cellsig.2015.06.007. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The mechanism and function of
mitogen-activated protein kinase activation by</P>
<P STYLE="margin-bottom: 0cm">ARF1.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zhou F(1), Dong C(1), Davis JE(2), Wu
WH(2), Surrao K(2), Wu G(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Pharmacology and
Experimental Therapeutics, Louisiana State</P>
<P STYLE="margin-bottom: 0cm">University Health Sciences Center, 1901
Perdido St, New Orleans, LA 70112, United</P>
<P STYLE="margin-bottom: 0cm">States. (2)Department of Pharmacology
and Toxicology, Medical College of Georgia,</P>
<P STYLE="margin-bottom: 0cm">Georgia Regents University, 1459 Laney
Walker Blvd., Augusta, GA 30912, United</P>
<P STYLE="margin-bottom: 0cm">States. (3)Department of Pharmacology
and Experimental Therapeutics, Louisiana</P>
<P STYLE="margin-bottom: 0cm">State University Health Sciences
Center, 1901 Perdido St, New Orleans, LA 70112, 
</P>
<P STYLE="margin-bottom: 0cm">United States; Department of
Pharmacology and Toxicology, Medical College of</P>
<P STYLE="margin-bottom: 0cm">Georgia, Georgia Regents University,
1459 Laney Walker Blvd., Augusta, GA 30912, 
</P>
<P STYLE="margin-bottom: 0cm">United States. Electronic address:
guwu@gru.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Mitogen-activated protein kinases
(MAPK) can be activated by a number of</P>
<P STYLE="margin-bottom: 0cm">biochemical pathways through distinct
signaling molecules. We have recently</P>
<P STYLE="margin-bottom: 0cm">revealed a novel function for the
Ras-like small GTPase ADP-ribosylation factor 1</P>
<P STYLE="margin-bottom: 0cm">(ARF1) in mediating the activation of
Raf1-MEK-ERK1/2 pathway by G</P>
<P STYLE="margin-bottom: 0cm">protein-coupled receptors [Dong C, Li C
and Wu G (2011) J Biol Chem 286,</P>
<P STYLE="margin-bottom: 0cm">43,361-43,369]. Here, we have further
defined the underlying mechanism and the</P>
<P STYLE="margin-bottom: 0cm">possible function of ARF1-mediated MAPK
pathway. We demonstrated that the</P>
<P STYLE="margin-bottom: 0cm">blockage of ARF1 activation and the
disruption of ARF1 localization to the Golgi 
</P>
<P STYLE="margin-bottom: 0cm">by mutating Thr48, a highly conserved
residue involved in the exchange of GDP for</P>
<P STYLE="margin-bottom: 0cm">GTP, and the myristoylation site Gly2
abolished ARF1's ability to activate</P>
<P STYLE="margin-bottom: 0cm">ERK1/2. In addition, treatment with
Golgi structure disrupting agents markedly</P>
<P STYLE="margin-bottom: 0cm">attenuated ARF1-mediated ERK1/2
activation. Furthermore, ARF1 significantly</P>
<P STYLE="margin-bottom: 0cm">promoted cell proliferation. More
interestingly, ARF1 activated 90kDa ribosomal</P>
<P STYLE="margin-bottom: 0cm">S6 kinase 1 (RSK1) without influencing
Elk-1 activation and ERK2 translocation to</P>
<P STYLE="margin-bottom: 0cm">the nuclei. These data demonstrate
that, once activated, ARF1 activates the MAPK 
</P>
<P STYLE="margin-bottom: 0cm">pathway likely using the Golgi as a
main platform, which in turn activates the</P>
<P STYLE="margin-bottom: 0cm">cytoplasmic RSK1, leading to cell
proliferation.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015 Elsevier Inc. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26169956 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">13. Radiother Oncol. 2015 Jul 8. pii:
S0167-8140(15)00323-0. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.radonc.2015.06.026. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Trametinib radiosensitises RAS- and
BRAF-mutated melanoma by perturbing cell</P>
<P STYLE="margin-bottom: 0cm">cycle and inducing senescence.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Schick U(1), Kyula J(1), Barker H(1),
Patel R(1), Zaidi S(1), Gregory C(1), Hafsi</P>
<P STYLE="margin-bottom: 0cm">H(1), Roulstone V(1), Deutsch E(2),
McLaughlin M(1), Harrington K(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Targeted Therapy Team, The Institute
of Cancer Research, London, United</P>
<P STYLE="margin-bottom: 0cm">Kingdom. (2)INSERM UMR 1030, Gustave
Roussy, Villejuif, France. (3)Targeted</P>
<P STYLE="margin-bottom: 0cm">Therapy Team, The Institute of Cancer
Research, London, United Kingdom.</P>
<P STYLE="margin-bottom: 0cm">Electronic address:
Kevin.Harrington@icr.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PURPOSE: Radiotherapy (RT) is used
frequently in patients with melanoma, but</P>
<P STYLE="margin-bottom: 0cm">results are suboptimal because the
disease is often radioresistant. This may be</P>
<P STYLE="margin-bottom: 0cm">due to constitutive activation of MAPK
pathway signalling through mutations</P>
<P STYLE="margin-bottom: 0cm">involving RAS/RAF. Thus, we studied
whether trametinib, a potent and selective</P>
<P STYLE="margin-bottom: 0cm">allosteric inhibitor of MEK1/2 could
improve the efficacy of RT.</P>
<P STYLE="margin-bottom: 0cm">METHODS AND MATERIALS: Clonogenic
survival assays were performed in human</P>
<P STYLE="margin-bottom: 0cm">BRAF-mutant (A375), NRAS-mutant (D04,
WM1631), KRAS-mutant (WM1791c) and</P>
<P STYLE="margin-bottom: 0cm">wild-type (PMWK) melanoma cell lines.
The effects of trametinib with and without 
</P>
<P STYLE="margin-bottom: 0cm">radiation on protein levels of MEK
effectors were measured by immunoblot</P>
<P STYLE="margin-bottom: 0cm">analyses. Cell cycle effects, DNA
damage repair, mitotic catastrophe and</P>
<P STYLE="margin-bottom: 0cm">senescence were measured using flow
cytometry, γH2Ax staining, nuclear</P>
<P STYLE="margin-bottom: 0cm">fragmentation and β-galactosidase
staining, respectively. Additionally, athymic</P>
<P STYLE="margin-bottom: 0cm">mice with D04 flank tumours were
treated with fractionated RT after gavage with</P>
<P STYLE="margin-bottom: 0cm">trametinib and monitored for tumour
growth.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: All cell lines, except PMWK,
exhibited enhanced cytotoxicity when RT was</P>
<P STYLE="margin-bottom: 0cm">combined with trametinib compared to
either agent alone. Sensitiser enhancement</P>
<P STYLE="margin-bottom: 0cm">ratios were 1.70, 1.32, 1.10, and 1.70
for A375, D04, WM1361 and WM1791c,</P>
<P STYLE="margin-bottom: 0cm">respectively. Trametinib efficiently
blocked RT-induced phosphorylation of ERK at</P>
<P STYLE="margin-bottom: 0cm">nanomolar concentrations. Increased
radiosensitivity correlated with prolonged G1</P>
<P STYLE="margin-bottom: 0cm">arrest and reduction in the
radioresistant S phase up to 48h following RT. A</P>
<P STYLE="margin-bottom: 0cm">larger population of
senescence-activated β-galactosidase-positive cells was seen</P>
<P STYLE="margin-bottom: 0cm">in the trametinib pretreated group, and
this correlated with activation of two of</P>
<P STYLE="margin-bottom: 0cm">the major mediators of induced
senescence, p53 and pRb. Mice receiving the</P>
<P STYLE="margin-bottom: 0cm">combination treatment (trametinib
1mg/kg and RT over 3days) showed a reduced mean</P>
<P STYLE="margin-bottom: 0cm">tumour volume compared with mice
receiving trametinib alone (p=0.016), or RT</P>
<P STYLE="margin-bottom: 0cm">alone (p=0.047). No overt signs of drug
toxicity were observed.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: Trametinib radiosensitised
RAS-/RAF-mutated melanoma cells by</P>
<P STYLE="margin-bottom: 0cm">inducing prolonged G1 arrest and
premature senescence. In this pre-clinical study</P>
<P STYLE="margin-bottom: 0cm">we demonstrate that combining
trametinib and RT is well tolerated, and reduces</P>
<P STYLE="margin-bottom: 0cm">tumour growth in vivo.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015. Published by
Elsevier Ireland Ltd.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26163092 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">14. Oncotarget. 2015 Jun
30;6(18):15814-27.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A MEK/PI3K/HDAC inhibitor combination
therapy for KRAS mutant pancreatic cancer</P>
<P STYLE="margin-bottom: 0cm">cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Ischenko I(1), Petrenko O(1), Hayman
MJ(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Molecular Genetics and
Microbiology, Stony Brook University,</P>
<P STYLE="margin-bottom: 0cm">Stony Brook, NY, USA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Pancreatic ductal adenocarcinoma (PDAC)
is a highly aggressive, metastatic</P>
<P STYLE="margin-bottom: 0cm">disease with limited treatment options.
Factors contributing to the metastatic</P>
<P STYLE="margin-bottom: 0cm">predisposition and therapy resistance
in pancreatic cancer are not well</P>
<P STYLE="margin-bottom: 0cm">understood. Here, we used a mouse model
of KRAS-driven pancreatic carcinogenesis 
</P>
<P STYLE="margin-bottom: 0cm">to define distinct subtypes of PDAC
metastasis: epithelial, mesenchymal and</P>
<P STYLE="margin-bottom: 0cm">quasi-mesenchymal. We examined
pro-survival signals in these cells and the</P>
<P STYLE="margin-bottom: 0cm">therapeutic response differences
between them. Our data indicate that the</P>
<P STYLE="margin-bottom: 0cm">initiation and maintenance of the
transformed state are separable, and that KRAS 
</P>
<P STYLE="margin-bottom: 0cm">dependency is not a fundamental
constant of KRAS-initiated tumors. Moreover, some</P>
<P STYLE="margin-bottom: 0cm">cancer cells can shuttle between the
KRAS dependent (drug-sensitive) and</P>
<P STYLE="margin-bottom: 0cm">independent (drug-tolerant) states and
thus escape extinction. We further</P>
<P STYLE="margin-bottom: 0cm">demonstrate that inhibition of KRAS
signaling alone via co-targeting the MAPK and</P>
<P STYLE="margin-bottom: 0cm">PI3K pathways fails to induce extensive
tumor cell death and, therefore, has</P>
<P STYLE="margin-bottom: 0cm">limited efficacy against PDAC. However,
the addition of histone deacetylase</P>
<P STYLE="margin-bottom: 0cm">(HDAC) inhibitors greatly improves
outcomes, reduces the self-renewal of cancer</P>
<P STYLE="margin-bottom: 0cm">cells, and blocks cancer metastasis in
vivo. Our results suggest that targeting</P>
<P STYLE="margin-bottom: 0cm">HDACs in combination with KRAS or its
effector pathways provides an effective</P>
<P STYLE="margin-bottom: 0cm">strategy for the treatment of PDAC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26158412 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">15. Proc Natl Acad Sci U S A. 2015 Jul
21;112(29):E3855-63. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1073/pnas.1510733112. Epub 2015 Jul
6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">EGFR inhibition evokes innate drug
resistance in lung cancer cells by preventing 
</P>
<P STYLE="margin-bottom: 0cm">Akt activity and thus inactivating
Ets-1 function.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Phuchareon J(1), McCormick F(2), Eisele
DW(1), Tetsu O(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Head and Neck Cancer Research
Laboratory, Department of Otolaryngology-Head</P>
<P STYLE="margin-bottom: 0cm">and Neck Surgery, School of Medicine,
University of California, San Francisco</P>
<P STYLE="margin-bottom: 0cm">(UCSF), CA 94115; UCSF Helen Diller
Family Comprehensive Cancer Center, School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, University of California, San
Francisco, CA 94158. (2)UCSF Helen Diller</P>
<P STYLE="margin-bottom: 0cm">Family Comprehensive Cancer Center,
School of Medicine, University of California,</P>
<P STYLE="margin-bottom: 0cm">San Francisco, CA 94158
mccormic@cc.ucsf.edu osamu.tetsu@ucsf.edu. (3)Head and</P>
<P STYLE="margin-bottom: 0cm">Neck Cancer Research Laboratory,
Department of Otolaryngology-Head and Neck</P>
<P STYLE="margin-bottom: 0cm">Surgery, School of Medicine, University
of California, San Francisco (UCSF), CA</P>
<P STYLE="margin-bottom: 0cm">94115; UCSF Helen Diller Family
Comprehensive Cancer Center, School of Medicine, 
</P>
<P STYLE="margin-bottom: 0cm">University of California, San
Francisco, CA 94158 mccormic@cc.ucsf.edu</P>
<P STYLE="margin-bottom: 0cm">osamu.tetsu@ucsf.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nonsmall cell lung cancer (NSCLC) is
the leading cause of cancer death worldwide.</P>
<P STYLE="margin-bottom: 0cm">About 14% of NSCLCs harbor mutations in
epidermal growth factor receptor (EGFR). 
</P>
<P STYLE="margin-bottom: 0cm">Despite remarkable progress in
treatment with tyrosine kinase inhibitors (TKIs), 
</P>
<P STYLE="margin-bottom: 0cm">only 5% of patients achieve tumor
reduction &gt;90%. The limited primary responses</P>
<P STYLE="margin-bottom: 0cm">are attributed partly to drug
resistance inherent in the tumor cells before</P>
<P STYLE="margin-bottom: 0cm">therapy begins. Recent reports showed
that activation of receptor tyrosine</P>
<P STYLE="margin-bottom: 0cm">kinases (RTKs) is an important
determinant of this innate drug resistance. In</P>
<P STYLE="margin-bottom: 0cm">contrast, we demonstrate that EGFR
inhibition promotes innate drug resistance</P>
<P STYLE="margin-bottom: 0cm">despite blockade of RTK activity in
NSCLC cells. EGFR TKIs decrease both the</P>
<P STYLE="margin-bottom: 0cm">mitogen-activated protein kinase (MAPK)
and Akt protein kinase pathways for a</P>
<P STYLE="margin-bottom: 0cm">short time, after which the Ras/MAPK
pathway becomes reactivated. Akt inhibition 
</P>
<P STYLE="margin-bottom: 0cm">selectively blocks the transcriptional
activation of Ets-1, which inhibits its</P>
<P STYLE="margin-bottom: 0cm">target gene, dual specificity
phosphatase 6 (DUSP6), a negative regulator</P>
<P STYLE="margin-bottom: 0cm">specific for ERK1/2. As a result,
ERK1/2 is activated. Furthermore, elevated</P>
<P STYLE="margin-bottom: 0cm">c-Src stimulates Ras GTP-loading and
activates Raf and MEK kinases. These</P>
<P STYLE="margin-bottom: 0cm">observations suggest that not only
ERK1/2 but also Akt activity is essential to</P>
<P STYLE="margin-bottom: 0cm">maintain Ets-1 in an active state.
Therefore, despite high levels of ERK1/2,</P>
<P STYLE="margin-bottom: 0cm">Ets-1 target genes including DUSP6 and
cyclins D1, D3, and E2 remain suppressed</P>
<P STYLE="margin-bottom: 0cm">by Akt inhibition. Reduction of DUSP6
in combination with elevated c-Src renews</P>
<P STYLE="margin-bottom: 0cm">activation of the Ras/MAPK pathway,
which enhances cell survival by accelerating 
</P>
<P STYLE="margin-bottom: 0cm">Bim protein turnover. Thus, EGFR TKIs
evoke innate drug resistance by preventing 
</P>
<P STYLE="margin-bottom: 0cm">Akt activity and inactivating Ets-1
function in NSCLC cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26150526 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">16. J Biol Chem. 2015 Jul 2. pii:
jbc.M114.634162. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nicotinic Acetylcholine Receptors
Sensitize a MAPK-Linked Toxicity Pathway on</P>
<P STYLE="margin-bottom: 0cm">Prolonged Exposure to β-Amyloid.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Arora K(1), Cheng J(1), Nichols RA(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)University of Hawaii, United States.
(2)University of Hawaii, United States</P>
<P STYLE="margin-bottom: 0cm">robert.nichols@hawaii.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Among putative downstream synaptic
targets of β-amyloid (Aβ) are signaling</P>
<P STYLE="margin-bottom: 0cm">molecules involved in synaptic
function, memory formation and cognition, such as 
</P>
<P STYLE="margin-bottom: 0cm">the MAP kinases, MKPs, CaMKII, CREB,
Fyn and Tau. Here, we assessed the</P>
<P STYLE="margin-bottom: 0cm">activation and interaction of signaling
pathways upon prolonged exposure to Aβ in</P>
<P STYLE="margin-bottom: 0cm">model nerve cells expressing nicotinic
acetylcholine receptors (nAChRs). Our goal</P>
<P STYLE="margin-bottom: 0cm">was to characterize the steps
underlying sensitization of the nerve cells to</P>
<P STYLE="margin-bottom: 0cm">neurotoxicity when Aβ-target receptors
are present. Of particular focus was the</P>
<P STYLE="margin-bottom: 0cm">connection of the activated signaling
molecules to oxidative stress.</P>
<P STYLE="margin-bottom: 0cm">Differentiated neuroblastoma cells
expressing mouse α4β2-nAChRs were exposed to</P>
<P STYLE="margin-bottom: 0cm">Aβ1-42 for intervals from 30 min to 3
days. The cells and cell-derived protein</P>
<P STYLE="margin-bottom: 0cm">extracts were then probed for
activation of signaling pathway molecules (ERK,</P>
<P STYLE="margin-bottom: 0cm">JNK, CaMKII, CREB, MARCKS, Fyn, tau).
Our results show substantial, progressive</P>
<P STYLE="margin-bottom: 0cm">activation of ERK in response to
nanomolar Aβ exposure, starting at the earliest 
</P>
<P STYLE="margin-bottom: 0cm">time point. Increased ERK activation
was followed by JNK activation as well as an</P>
<P STYLE="margin-bottom: 0cm">increased expression of PHF-tau,
paralleled by increased levels of reactive</P>
<P STYLE="margin-bottom: 0cm">oxygen species (ROS). The impact of
prolonged Aβ on the levels of pERK, pJNK and 
</P>
<P STYLE="margin-bottom: 0cm">ROS was attenuated by MEK-selective and
JNK-selective inhibitors. In addition,</P>
<P STYLE="margin-bottom: 0cm">the MEK inhibitor as well as a JNK
inhibitor attenuated Aβ-induced nuclear</P>
<P STYLE="margin-bottom: 0cm">fragmentation, which followed the
changes in ROS levels. These results</P>
<P STYLE="margin-bottom: 0cm">demonstrate that the presence of nAChRs
sensitizes neurons to the neurotoxic</P>
<P STYLE="margin-bottom: 0cm">action of Aβ through the timed
activation of discrete intracellular signaling</P>
<P STYLE="margin-bottom: 0cm">molecules, suggesting pathways involved
in the early stages of Alzheimers</P>
<P STYLE="margin-bottom: 0cm">disease.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015, The American Society
for Biochemistry and Molecular Biology.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26139609 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">17. J Transl Med. 2015 Jul 3;13(1):210.
doi: 10.1186/s12967-015-0581-2.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Vemurafenib resistance reprograms
melanoma cells towards glutamine dependence.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hernandez-Davies JE(1), Tran TQ(2),
Reid MA(3), Rosales KR(4), Lowman XH(5), Pan 
</P>
<P STYLE="margin-bottom: 0cm">M(6), Moriceau G(7,)(8), Yang Y(9), Wu
J(10), Lo RS(11,)(12), Kong M(13).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Cancer Biology,
Beckman Research Institute of City of Hope</P>
<P STYLE="margin-bottom: 0cm">Cancer Center, Duarte, CA, 91010, USA.
jedavies@coh.org. (2)Department of Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Biology, Beckman Research Institute of
City of Hope Cancer Center, Duarte, CA,</P>
<P STYLE="margin-bottom: 0cm">91010, USA. thatran@coh.org.
(3)Department of Cancer Biology, Beckman Research</P>
<P STYLE="margin-bottom: 0cm">Institute of City of Hope Cancer
Center, Duarte, CA, 91010, USA. mreida@coh.org. 
</P>
<P STYLE="margin-bottom: 0cm">(4)Department of Cancer Biology,
Beckman Research Institute of City of Hope</P>
<P STYLE="margin-bottom: 0cm">Cancer Center, Duarte, CA, 91010, USA.
krosales@coh.org. (5)Department of Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Biology, Beckman Research Institute of
City of Hope Cancer Center, Duarte, CA,</P>
<P STYLE="margin-bottom: 0cm">91010, USA. xlowman@coh.org.
(6)Department of Cancer Biology, Beckman Research</P>
<P STYLE="margin-bottom: 0cm">Institute of City of Hope Cancer
Center, Duarte, CA, 91010, USA. Minoan@coh.org. 
</P>
<P STYLE="margin-bottom: 0cm">(7)Division of Dermatology/Department
of Medicine, David Geffen School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, University of California, Los
Angeles, CA, 90095-1662, USA.</P>
<P STYLE="margin-bottom: 0cm">gmoriceau@mednet.ucla.edu. (8)Jonsson
Comprehensive Cancer Center, David Geffen</P>
<P STYLE="margin-bottom: 0cm">School of Medicine, University of
California, Los Angeles, CA, 90095-1662, USA.</P>
<P STYLE="margin-bottom: 0cm">gmoriceau@mednet.ucla.edu.
(9)Department of Cancer Biology, Beckman Research</P>
<P STYLE="margin-bottom: 0cm">Institute of City of Hope Cancer
Center, Duarte, CA, 91010, USA. yiyang@coh.org. 
</P>
<P STYLE="margin-bottom: 0cm">(10)Animal Tumor Model Program,
Division of Comparative Medicine, Beckman</P>
<P STYLE="margin-bottom: 0cm">Research Institute of City of Hope
Cancer Center, Duarte, CA, 91010, USA.</P>
<P STYLE="margin-bottom: 0cm">jwu@coh.org. (11)Division of
Dermatology/Department of Medicine, David Geffen</P>
<P STYLE="margin-bottom: 0cm">School of Medicine, University of
California, Los Angeles, CA, 90095-1662, USA.</P>
<P STYLE="margin-bottom: 0cm">rlo@mednet.ucla.edu. (12)Jonsson
Comprehensive Cancer Center, David Geffen School</P>
<P STYLE="margin-bottom: 0cm">of Medicine, University of California,
Los Angeles, CA, 90095-1662, USA.</P>
<P STYLE="margin-bottom: 0cm">rlo@mednet.ucla.edu. (13)Department of
Cancer Biology, Beckman Research Institute</P>
<P STYLE="margin-bottom: 0cm">of City of Hope Cancer Center, Duarte,
CA, 91010, USA. mekong@coh.org.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: (V600) BRAF mutations drive
approximately 50% of metastatic melanoma 
</P>
<P STYLE="margin-bottom: 0cm">which can be therapeutically targeted
by BRAF inhibitors (BRAFi) and, based on</P>
<P STYLE="margin-bottom: 0cm">resistance mechanisms, the combination
of BRAF and MEK inhibitors (BRAFi + MEKi).</P>
<P STYLE="margin-bottom: 0cm">Although the combination therapy has
been shown to provide superior clinical</P>
<P STYLE="margin-bottom: 0cm">benefits, acquired resistance is still
prevalent and limits the overall survival 
</P>
<P STYLE="margin-bottom: 0cm">benefits. Recent work has shown that
oncogenic changes can lead to alterations in</P>
<P STYLE="margin-bottom: 0cm">tumor cell metabolism rendering cells
addicted to nutrients, such as the amino</P>
<P STYLE="margin-bottom: 0cm">acid glutamine. Here, we evaluated
whether melanoma cells with acquired</P>
<P STYLE="margin-bottom: 0cm">resistance display glutamine dependence
and whether glutamine metabolism can be a</P>
<P STYLE="margin-bottom: 0cm">potential molecular target to treat
resistant cells.</P>
<P STYLE="margin-bottom: 0cm">METHODS: Isogenic BRAFi sensitive
parental (V600) BRAF mutant melanoma cell lines</P>
<P STYLE="margin-bottom: 0cm">and resistant (derived by chronic
treatment with vemurafenib) sub-lines were used</P>
<P STYLE="margin-bottom: 0cm">to assess differences in the glutamine
uptake and sensitivity to glutamine</P>
<P STYLE="margin-bottom: 0cm">deprivation. To evaluate a broader
range of resistance mechanisms, isogenic pairs</P>
<P STYLE="margin-bottom: 0cm">where the sub-lines were resistant to
BRAFi + MEKi were also studied. Since</P>
<P STYLE="margin-bottom: 0cm">resistant cells demonstrated increased
sensitivity to glutamine deficiency, we</P>
<P STYLE="margin-bottom: 0cm">used glutaminase inhibitors BPTES
[bis-2-(5 phenylacetamido-1, 2,</P>
<P STYLE="margin-bottom: 0cm">4-thiadiazol-2-yl) ethyl sulfide] and
L-L-DON (6-Diazo-5-oxo-L-norleucine) to</P>
<P STYLE="margin-bottom: 0cm">treat MAPK pathway inhibitor (MAPKi)
resistant cell populations both in vitro and</P>
<P STYLE="margin-bottom: 0cm">in vivo.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: We demonstrated that
MAPKi-acquired resistant cells uptook greater</P>
<P STYLE="margin-bottom: 0cm">amounts of glutamine and have increased
sensitivity to glutamine deprivation than</P>
<P STYLE="margin-bottom: 0cm">their MAPKi-sensitive counterparts. In
addition, it was found that both BPTES and</P>
<P STYLE="margin-bottom: 0cm">L-DON were more effective at decreasing
cell survival of MAPKi-resistant</P>
<P STYLE="margin-bottom: 0cm">sub-lines than parental cell
populations in vitro. We also showed that mutant</P>
<P STYLE="margin-bottom: 0cm">NRAS was critical for glutamine
addiction in mutant NRAS driven resistance. When 
</P>
<P STYLE="margin-bottom: 0cm">tested in vivo, we found that
xenografts derived from resistant cells were more</P>
<P STYLE="margin-bottom: 0cm">sensitive to BPTES or L-DON treatment
than those derived from parental cells.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: Our study is a
proof-of-concept for the potential of targeting</P>
<P STYLE="margin-bottom: 0cm">glutamine metabolism as an alternative
strategy to suppress acquired</P>
<P STYLE="margin-bottom: 0cm">MAPKi-resistance in melanoma.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4490757</P>
<P STYLE="margin-bottom: 0cm">PMID: 26139106 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">18. Oncotarget. 2015 Jul
10;6(19):17178-91.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Radiosensitization and downregulation
of heterogeneous nuclear ribonucleoprotein 
</P>
<P STYLE="margin-bottom: 0cm">K (hnRNP K) upon inhibition of
mitogen/extracellular signal-regulated kinase</P>
<P STYLE="margin-bottom: 0cm">(MEK) in malignant melanoma cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Eder S(1), Lamkowski A(1), Priller
M(1), Port M(1), Steinestel K(1,)(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Bundeswehr Institute of
Radiobiology, 80937 Munich, Germany.</P>
<P STYLE="margin-bottom: 0cm">(2)Gerhard-Domagk-Institute of
Pathology, University Hospital Muenster, 48149</P>
<P STYLE="margin-bottom: 0cm">Muenster, Germany.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: Heterogeneous nuclear
ribonucleoprotein K (hnRNP K) is an important</P>
<P STYLE="margin-bottom: 0cm">cofactor in the p53-mediated DNA damage
response pathway upon ionizing radiation 
</P>
<P STYLE="margin-bottom: 0cm">(IR) and exerts anti-apoptotic effects
also independent of p53 pathway</P>
<P STYLE="margin-bottom: 0cm">activation. Furthermore, hnRNP K is
overexpressed in various neoplasms including 
</P>
<P STYLE="margin-bottom: 0cm">malignant melanoma (MM). Here, we
investigate the role of hnRNP K in the</P>
<P STYLE="margin-bottom: 0cm">radioresistance of MM cells.</P>
<P STYLE="margin-bottom: 0cm">METHODS AND RESULTS: Our results show
cytoplasmic expression of hnRNP K in human 
</P>
<P STYLE="margin-bottom: 0cm">MM surgical specimens, but not in
benign nevi, and a quick dose- and</P>
<P STYLE="margin-bottom: 0cm">time-dependent upregulation in response
to IR accompanied by cytoplasmic</P>
<P STYLE="margin-bottom: 0cm">redistribution of the protein in the
IPC-298 cellular tumor model carrying an</P>
<P STYLE="margin-bottom: 0cm">activating NRAS mutation (p.Q61L).
SiRNA-based knockdown of hnRNP K induced a</P>
<P STYLE="margin-bottom: 0cm">delayed decline in γH2AX/53BP1-positive
DNA repair foci upon IR. Pharmacological 
</P>
<P STYLE="margin-bottom: 0cm">interference with MAPK signaling
abrogated ERK phosphorylation, diminished</P>
<P STYLE="margin-bottom: 0cm">cellular hnRNP K levels, impaired
γH2AX/53BP1-foci repair and proliferative</P>
<P STYLE="margin-bottom: 0cm">capability and increased apoptosis
comparable to the observed hnRNP K knockdown</P>
<P STYLE="margin-bottom: 0cm">phenotype in IPC-298 cells.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Our results indicate that
pharmacological interference with MAPK</P>
<P STYLE="margin-bottom: 0cm">signaling increases vulnerability of
NRAS-mutant malignant melanoma cells to</P>
<P STYLE="margin-bottom: 0cm">ionizing radiation along with
downregulation of endogenous hnRNP K and point</P>
<P STYLE="margin-bottom: 0cm">towards a possible use for combined MEK
inhibition and localized radiation</P>
<P STYLE="margin-bottom: 0cm">therapy of MM in the NRAS-mutant
setting where BRAF inhibitors offer no clinical 
</P>
<P STYLE="margin-bottom: 0cm">benefit.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26136337 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">19. Immunology. 2015 Jul 1. doi:
10.1111/imm.12501. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">H-ficolin binds Aspergillus fumigatus
leading to activation of the lectin</P>
<P STYLE="margin-bottom: 0cm">complement pathway and modulation of
lung epithelial immune responses.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Bidula S(1,)(2), Sexton DW(1,)(3),
Yates M(1), Abdolrasouli A(4), Shah A(4),</P>
<P STYLE="margin-bottom: 0cm">Wallis R(5), Reed A(6), Armstrong-James
D(4), Schelenz S(1,)(7).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Biomedical Research Centre, Norwich
Medical School, University of East Anglia,</P>
<P STYLE="margin-bottom: 0cm">Norwich Research Park, Norwich, NR4
7TJ, UK. (2)Aberdeen Fungal Group, School of 
</P>
<P STYLE="margin-bottom: 0cm">Medical Sciences, Institute of Medical
Sciences, University of Aberdeen,</P>
<P STYLE="margin-bottom: 0cm">Aberdeen, AB25 2ZD, UK. (3)School of
Pharmacy and Biomolecular Science, Liverpool</P>
<P STYLE="margin-bottom: 0cm">John Moores University, Byrom Street,
Liverpool, L3 3AF, UK. (4)Section of</P>
<P STYLE="margin-bottom: 0cm">Infectious Diseases and Immunity,
Imperial College London, Flowers Building,</P>
<P STYLE="margin-bottom: 0cm">Armstrong Road, London, SW7 2AZ, UK.
(5)Departments of Infection, Immunity and</P>
<P STYLE="margin-bottom: 0cm">Inflammation and Biochemistry,
University of Leicester, Henry Wellcome Building, 
</P>
<P STYLE="margin-bottom: 0cm">Lancaster Road, Leicester, LE1 9HN, UK.
(6)Department of Lung Transplantation,</P>
<P STYLE="margin-bottom: 0cm">Harefield Hospital, Hill End Road,
Middlesex, UB9 6JH, UK. (7)Department of</P>
<P STYLE="margin-bottom: 0cm">Microbiology, Royal Brompton Hospital,
Sydney Street, London, SW3 6NP, UK.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Aspergillus fumigatus is an
opportunistic fungal pathogen that typically infects 
</P>
<P STYLE="margin-bottom: 0cm">the lungs of immunocompromised patients
leading to a high mortality. H-ficolin,</P>
<P STYLE="margin-bottom: 0cm">an innate immune opsonin, is produced
by type II alveolar epithelial cells and</P>
<P STYLE="margin-bottom: 0cm">could participate in lung defences
against infections. Here, we utilised the</P>
<P STYLE="margin-bottom: 0cm">human type II alveolar epithelial cell
line, A549, to determine the involvement</P>
<P STYLE="margin-bottom: 0cm">of H-ficolin in fungal defence.
Additionally, we investigated the presence of</P>
<P STYLE="margin-bottom: 0cm">H-ficolin in bronchoalveolar lavage
fluid (BAL) from transplant patients during</P>
<P STYLE="margin-bottom: 0cm">pneumonia. H-ficolin exhibited
demonstrable binding to A. fumigatus conidia via</P>
<P STYLE="margin-bottom: 0cm">L-fucose, D-mannose and
N-acetylglucosamine residues in a calcium- and</P>
<P STYLE="margin-bottom: 0cm">pH-dependent manner. Moreover,
recognition led to lectin complement pathway</P>
<P STYLE="margin-bottom: 0cm">activation and enhanced fungal
association with A549 cells. Following</P>
<P STYLE="margin-bottom: 0cm">recognition, H-ficolin opsonization
manifested an increase in IL-8 production</P>
<P STYLE="margin-bottom: 0cm">from A549 cells which involved
activation of the intracellular signalling</P>
<P STYLE="margin-bottom: 0cm">pathways MEK 1/2, p38 MAPK and JNK.
Finally, H-ficolin concentrations were</P>
<P STYLE="margin-bottom: 0cm">significantly higher in BAL of patients
with lung infections compared to control 
</P>
<P STYLE="margin-bottom: 0cm">subjects (n=16; p=0.00726). ROC curve
analysis further highlighted the potential 
</P>
<P STYLE="margin-bottom: 0cm">of H-ficolin as a diagnostic marker for
lung infection (AUC=0.77; p&lt;0.0001).</P>
<P STYLE="margin-bottom: 0cm">Thus, H-ficolin participates in A.
fumigatus defence via activation of the lectin</P>
<P STYLE="margin-bottom: 0cm">complement pathway, enhanced
fungal-host interactions and modulated immune</P>
<P STYLE="margin-bottom: 0cm">responses. This article is protected by
copyright. All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">This article is protected by copyright.
All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26133042 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">20. Int J Clin Exp Med. 2015 Apr
15;8(4):5553-8. eCollection 2015.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The role of leptin in the ventricular
remodeling process and its mechanism.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zuo G(1), Du X(1), Zheng L(1), Wang
C(1), Wang K(1), Li Y(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Cardiology, Tianjin
Fifth Central Hospital No. 41 Zhejiang Road,</P>
<P STYLE="margin-bottom: 0cm">Tianjin 300450, P. R. China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">OBJECTIVE: This study aims to explore
the role of leptin in the ventricular</P>
<P STYLE="margin-bottom: 0cm">remodeling process and its mechanism in
the diabetic rats' model.</P>
<P STYLE="margin-bottom: 0cm">METHODS: The diabetic SD rats model
induced by streptozotocin was established.</P>
<P STYLE="margin-bottom: 0cm">The SD rats were randomly divided into
4 groups: control group (20 rats treated</P>
<P STYLE="margin-bottom: 0cm">with citric acid/sodium citrate
buffer); M0 group (10 rats treated with</P>
<P STYLE="margin-bottom: 0cm">physiological saline); M1 group (10
rats treated with 50 μg/kg LP); M2 group (10 
</P>
<P STYLE="margin-bottom: 0cm">rats treated with 100 μg/kg LP).
Ang-II was detected by ELISA. The expression</P>
<P STYLE="margin-bottom: 0cm">levels of LP and Ob-Rb were detected by
RT-PCR. MAPK phosphorylation changes were</P>
<P STYLE="margin-bottom: 0cm">detected by western blotting.
Myocardial morphology was observed.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: Compared with control group,
the blood glucose concentration and Ang-II 
</P>
<P STYLE="margin-bottom: 0cm">significantly increased in diabetic
model groups (P &lt; 0.01) and body weight</P>
<P STYLE="margin-bottom: 0cm">decreased (P &lt; 0.05). The expression
levels of LP and Ob-Rb increased and heart</P>
<P STYLE="margin-bottom: 0cm">function decreased in diabetic model
groups.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: LP may be involved in the
myocardial cell hypertrophy through the</P>
<P STYLE="margin-bottom: 0cm">neuroendocrine system and associated
with the JAK-STAT, Ras-Raf-MEK-MAPK and</P>
<P STYLE="margin-bottom: 0cm">PI-3K signaling pathway, which provides
a new concept for the pathogenesis of</P>
<P STYLE="margin-bottom: 0cm">cardiac hypertrophy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4483875</P>
<P STYLE="margin-bottom: 0cm">PMID: 26131137 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">1. BMC Syst Biol. 2015 Jul 25;9:41.
doi: 10.1186/s12918-015-0187-6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Regulation of ERK-MAPK signaling in
human epidermis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cursons J(1,)(2,)(3,)(4,)(5), Gao J(6),
Hurley DG(7,)(8,)(9,)(10,)(11,)(12),</P>
<P STYLE="margin-bottom: 0cm">Print CG(13,)(14,)(15), Dunbar
PR(16,)(17), Jacobs MD(18), Crampin</P>
<P STYLE="margin-bottom: 0cm">EJ(19,)(20,)(21,)(22,)(23,)(24).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Systems Biology Laboratory,
Melbourne School of Engineering, University of</P>
<P STYLE="margin-bottom: 0cm">Melbourne, Melbourne, Australia.
joseph.cursons@unimelb.edu.au. (2)NICTA Victoria</P>
<P STYLE="margin-bottom: 0cm">Research Lab, Melbourne, Australia.
joseph.cursons@unimelb.edu.au. (3)ARC Centre 
</P>
<P STYLE="margin-bottom: 0cm">of Excellence in Convergent Bio-Nano
Science and Technology, Melbourne School of 
</P>
<P STYLE="margin-bottom: 0cm">Engineering, University of Melbourne,
Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">joseph.cursons@unimelb.edu.au.
(4)Auckland Bioengineering Institute, University</P>
<P STYLE="margin-bottom: 0cm">of Auckland, Auckland, New Zealand.
joseph.cursons@unimelb.edu.au. (5)Maurice</P>
<P STYLE="margin-bottom: 0cm">Wilkins Centre, University of Auckland,
Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">joseph.cursons@unimelb.edu.au.
(6)Systems Biology Laboratory, Melbourne School of</P>
<P STYLE="margin-bottom: 0cm">Engineering, University of Melbourne,
Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">jerry.gao@unimelb.edu.au. (7)Systems
Biology Laboratory, Melbourne School of</P>
<P STYLE="margin-bottom: 0cm">Engineering, University of Melbourne,
Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">daniel.hurley@unimelb.edu.au. (8)NICTA
Victoria Research Lab, Melbourne,</P>
<P STYLE="margin-bottom: 0cm">Australia.
daniel.hurley@unimelb.edu.au. (9)Auckland Bioengineering Institute,</P>
<P STYLE="margin-bottom: 0cm">University of Auckland, Auckland, New
Zealand. daniel.hurley@unimelb.edu.au.</P>
<P STYLE="margin-bottom: 0cm">(10)Maurice Wilkins Centre, University
of Auckland, Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">daniel.hurley@unimelb.edu.au.
(11)Bioinformatics Institute, University of</P>
<P STYLE="margin-bottom: 0cm">Auckland, Auckland, New Zealand.
daniel.hurley@unimelb.edu.au. (12)Faculty of</P>
<P STYLE="margin-bottom: 0cm">Medical and Health Sciences, University
of Auckland, Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">daniel.hurley@unimelb.edu.au.
(13)Maurice Wilkins Centre, University of Auckland,</P>
<P STYLE="margin-bottom: 0cm">Auckland, New Zealand.
c.print@auckland.ac.nz. (14)Bioinformatics Institute,</P>
<P STYLE="margin-bottom: 0cm">University of Auckland, Auckland, New
Zealand. c.print@auckland.ac.nz.</P>
<P STYLE="margin-bottom: 0cm">(15)Faculty of Medical and Health
Sciences, University of Auckland, Auckland, New</P>
<P STYLE="margin-bottom: 0cm">Zealand. c.print@auckland.ac.nz.
(16)Maurice Wilkins Centre, University of</P>
<P STYLE="margin-bottom: 0cm">Auckland, Auckland, New Zealand.
r.dunbar@auckland.ac.nz. (17)School of</P>
<P STYLE="margin-bottom: 0cm">Biological Sciences, University of
Auckland, Auckland, New Zealand.</P>
<P STYLE="margin-bottom: 0cm">r.dunbar@auckland.ac.nz. (18)Department
of Biology, New Zealand International</P>
<P STYLE="margin-bottom: 0cm">College, ACG New Zealand, Auckland, New
Zealand. marc.jacobs@gmx.com. (19)Systems</P>
<P STYLE="margin-bottom: 0cm">Biology Laboratory, Melbourne School of
Engineering, University of Melbourne,</P>
<P STYLE="margin-bottom: 0cm">Melbourne, Australia.
edmund.crampin@unimelb.edu.au. (20)ARC Centre of Excellence</P>
<P STYLE="margin-bottom: 0cm">in Convergent Bio-Nano Science and
Technology, Melbourne School of Engineering,</P>
<P STYLE="margin-bottom: 0cm">University of Melbourne, Melbourne,
Australia. edmund.crampin@unimelb.edu.au.</P>
<P STYLE="margin-bottom: 0cm">(21)Auckland Bioengineering Institute,
University of Auckland, Auckland, New</P>
<P STYLE="margin-bottom: 0cm">Zealand. edmund.crampin@unimelb.edu.au.
(22)Maurice Wilkins Centre, University of</P>
<P STYLE="margin-bottom: 0cm">Auckland, Auckland, New Zealand.
edmund.crampin@unimelb.edu.au. (23)School of</P>
<P STYLE="margin-bottom: 0cm">Mathematics and Statistics, University
of Melbourne, Melbourne, Australia.</P>
<P STYLE="margin-bottom: 0cm">edmund.crampin@unimelb.edu.au.
(24)School of Medicine, University of Melbourne,</P>
<P STYLE="margin-bottom: 0cm">Melbourne, Australia.
edmund.crampin@unimelb.edu.au.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: The skin is largely
comprised of keratinocytes within the</P>
<P STYLE="margin-bottom: 0cm">interfollicular epidermis. Over
approximately two weeks these cells differentiate</P>
<P STYLE="margin-bottom: 0cm">and traverse the thickness of the skin.
The stage of differentiation is therefore</P>
<P STYLE="margin-bottom: 0cm">reflected in the positions of cells
within the tissue, providing a convenient</P>
<P STYLE="margin-bottom: 0cm">axis along which to study the signaling
events that occur in situ during</P>
<P STYLE="margin-bottom: 0cm">keratinocyte terminal differentiation,
over this extended two-week timescale. The</P>
<P STYLE="margin-bottom: 0cm">canonical ERK-MAPK signaling cascade
(Raf-1, MEK-1/2 and ERK-1/2) has been</P>
<P STYLE="margin-bottom: 0cm">implicated in controlling diverse
cellular behaviors, including proliferation and</P>
<P STYLE="margin-bottom: 0cm">differentiation. While the molecular
interactions involved in signal transduction</P>
<P STYLE="margin-bottom: 0cm">through this cascade have been well
characterized in cell culture experiments,</P>
<P STYLE="margin-bottom: 0cm">our understanding of how this sequence
of events unfolds to determine cell fate</P>
<P STYLE="margin-bottom: 0cm">within a homeostatic tissue environment
has not been fully characterized.</P>
<P STYLE="margin-bottom: 0cm">METHODS: We measured the abundance of
total and phosphorylated ERK-MAPK signaling</P>
<P STYLE="margin-bottom: 0cm">proteins within interfollicular
keratinocytes in transverse cross-sections of</P>
<P STYLE="margin-bottom: 0cm">human epidermis using
immunofluorescence microscopy. To investigate these data we</P>
<P STYLE="margin-bottom: 0cm">developed a mathematical model of the
signaling cascade using a normalized-Hill</P>
<P STYLE="margin-bottom: 0cm">differential equation formalism.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: These data show coordinated
variation in the abundance of phosphorylated</P>
<P STYLE="margin-bottom: 0cm">ERK-MAPK components across the
epidermis. Statistical analysis of these data</P>
<P STYLE="margin-bottom: 0cm">shows that associations between
phosphorylated ERK-MAPK components which</P>
<P STYLE="margin-bottom: 0cm">correspond to canonical molecular
interactions are dependent upon spatial</P>
<P STYLE="margin-bottom: 0cm">position within the epidermis. The
model demonstrates that the spatial profile of</P>
<P STYLE="margin-bottom: 0cm">activation for ERK-MAPK signaling
components across the epidermis may be</P>
<P STYLE="margin-bottom: 0cm">maintained in a cell-autonomous fashion
by an underlying spatial gradient in</P>
<P STYLE="margin-bottom: 0cm">calcium signaling.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: Our data demonstrate an
extended phospho-protein profile of ERK-MAPK</P>
<P STYLE="margin-bottom: 0cm">signaling cascade components across the
epidermis in situ, and statistical</P>
<P STYLE="margin-bottom: 0cm">associations in these data indicate
canonical ERK-MAPK interactions underlie this</P>
<P STYLE="margin-bottom: 0cm">spatial profile of ERK-MAPK activation.
Using mathematical modelling we have</P>
<P STYLE="margin-bottom: 0cm">demonstrated that spatially varying
calcium signaling components across the</P>
<P STYLE="margin-bottom: 0cm">epidermis may be sufficient to maintain
the spatial profile of ERK-MAPK signaling</P>
<P STYLE="margin-bottom: 0cm">cascade components in a cell-autonomous
manner. These findings may have</P>
<P STYLE="margin-bottom: 0cm">significant implications for the wide
range of cancer drugs which therapeutically</P>
<P STYLE="margin-bottom: 0cm">target ERK-MAPK signaling components.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4514964</P>
<P STYLE="margin-bottom: 0cm">PMID: 26209520 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">2. Pharmacol Res. 2015 Jul 21. pii:
S1043-6618(15)00143-7. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.phrs.2015.07.010. [Epub ahead
of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A historical overview of protein
kinases and their targeted small molecule</P>
<P STYLE="margin-bottom: 0cm">inhibitors.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Roskoski R Jr(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Blue Ridge Institute for Medical
Research, 3754 Brevard Road, Suite 116, Box</P>
<P STYLE="margin-bottom: 0cm">19, Horse Shoe, NC 28742-8814, United
States. Electronic address: rrj@brimr.org.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Protein kinases play a predominant
regulatory role in nearly every aspect of cell</P>
<P STYLE="margin-bottom: 0cm">biology and they can modify the
function of a protein in almost every conceivable</P>
<P STYLE="margin-bottom: 0cm">way. Protein phosphorylation can
increase or decrease enzyme activity and it can 
</P>
<P STYLE="margin-bottom: 0cm">alter other biological activities such
as transcription and translation.</P>
<P STYLE="margin-bottom: 0cm">Moreover, some phosphorylation sites on
a given protein are stimulatory while</P>
<P STYLE="margin-bottom: 0cm">others are inhibitory. The human
protein kinase gene family consists of 518</P>
<P STYLE="margin-bottom: 0cm">members along with 106 pseudogenes.
Furthermore, about 50 of the 518 gene</P>
<P STYLE="margin-bottom: 0cm">products lack important catalytic
residues and are called protein pseudokinases. 
</P>
<P STYLE="margin-bottom: 0cm">The non-catalytic allosteric
interaction of protein kinases and pseudokinases</P>
<P STYLE="margin-bottom: 0cm">with other proteins has added an
important regulatory feature to the biochemistry</P>
<P STYLE="margin-bottom: 0cm">and cell biology of the protein kinase
superfamily. With rare exceptions, a</P>
<P STYLE="margin-bottom: 0cm">divalent cation such as Mg(2+) is
required for the reaction. All protein kinases 
</P>
<P STYLE="margin-bottom: 0cm">exist in a basal state and are
activated only as necessary by divergent</P>
<P STYLE="margin-bottom: 0cm">regulatory stimuli. The mechanisms for
switching between dormant and active</P>
<P STYLE="margin-bottom: 0cm">protein kinases can be intricate.
Phosphorylase kinase was the first protein</P>
<P STYLE="margin-bottom: 0cm">kinase to be characterized
biochemically and the mechanism of its regulation led 
</P>
<P STYLE="margin-bottom: 0cm">to the discovery of cAMP-dependent
protein kinase (protein kinase A, or PKA),</P>
<P STYLE="margin-bottom: 0cm">which catalyzes the phosphorylation and
activation of phosphorylase kinase. This 
</P>
<P STYLE="margin-bottom: 0cm">was the first protein kinase cascade or
signaling module to be elucidated. The</P>
<P STYLE="margin-bottom: 0cm">epidermal growth factor
receptor-Ras-Raf-MEK-ERK signaling module contains</P>
<P STYLE="margin-bottom: 0cm">protein-tyrosine,
protein-serine/threonine, and dual specificity protein kinases.</P>
<P STYLE="margin-bottom: 0cm">PKA has served as a prototype of this
enzyme family and more is known about this 
</P>
<P STYLE="margin-bottom: 0cm">enzyme than any other protein kinase.
The inactive PKA holoenzyme consists of two</P>
<P STYLE="margin-bottom: 0cm">regulatory and two catalytic subunits.
After binding four molecules of cAMP, the 
</P>
<P STYLE="margin-bottom: 0cm">holoenzyme dissociates into a
regulatory subunit dimer (each monomer binds two</P>
<P STYLE="margin-bottom: 0cm">cAMP) and two free and active catalytic
subunits. PKA and all other protein</P>
<P STYLE="margin-bottom: 0cm">kinase domains have a small
amino-terminal lobe and large carboxyterminal lobe as</P>
<P STYLE="margin-bottom: 0cm">determined by X-ray crystallography.
The N-lobe and C-lobe form a cleft that</P>
<P STYLE="margin-bottom: 0cm">serves as a docking site for MgATP.
Nearly all active protein kinases contain a</P>
<P STYLE="margin-bottom: 0cm">K/E/D/D signature sequence that plays
important structural and catalytic roles.</P>
<P STYLE="margin-bottom: 0cm">Protein kinases contain hydrophobic
catalytic and regulatory spines and</P>
<P STYLE="margin-bottom: 0cm">collateral shell residues that are
required to assemble the active enzyme. There 
</P>
<P STYLE="margin-bottom: 0cm">are two general kinds of conformational
changes associated with most protein</P>
<P STYLE="margin-bottom: 0cm">kinases. The first conformational
change involves the formation of an intact</P>
<P STYLE="margin-bottom: 0cm">regulatory spine to form an active
enzyme. The second conformational change</P>
<P STYLE="margin-bottom: 0cm">occurs in active kinases as they toggle
between open and closed conformations</P>
<P STYLE="margin-bottom: 0cm">during their catalytic cycles. Because
mutations and dysregulation of protein</P>
<P STYLE="margin-bottom: 0cm">kinases play causal roles in human
disease, this family of enzymes has become one</P>
<P STYLE="margin-bottom: 0cm">of the most important drug targets over
the past two decades. Imatinib was</P>
<P STYLE="margin-bottom: 0cm">approved by the United States FDA for
the treatment of chronic myelogenous</P>
<P STYLE="margin-bottom: 0cm">leukemia in 2001; this small molecule
inhibits the BCR-Abl protein kinase</P>
<P STYLE="margin-bottom: 0cm">oncoprotein that results from the
formation of the Philadelphia chromosome. More 
</P>
<P STYLE="margin-bottom: 0cm">than two dozen other orally effective
mechanism-based small molecule protein</P>
<P STYLE="margin-bottom: 0cm">kinase inhibitors have been
subsequently approved by the FDA. These drugs bind to</P>
<P STYLE="margin-bottom: 0cm">the ATP-binding site of their target
enzymes and extend into nearby hydrophobic</P>
<P STYLE="margin-bottom: 0cm">pockets. Most of these protein kinase
inhibitors prolong survival in cancer</P>
<P STYLE="margin-bottom: 0cm">patients only weeks or months longer
than standard cytotoxic therapies. In</P>
<P STYLE="margin-bottom: 0cm">contrast, the clinical effectiveness of
imatinib against chronic myelogenous</P>
<P STYLE="margin-bottom: 0cm">leukemia is vastly superior to that of
any other targeted protein kinase</P>
<P STYLE="margin-bottom: 0cm">inhibitor with overall survival lasting
a decade or more. However, the near</P>
<P STYLE="margin-bottom: 0cm">universal and expected development of
drug resistance in the treatment of</P>
<P STYLE="margin-bottom: 0cm">neoplastic disorders requires new
approaches to solve this therapeutic challenge.</P>
<P STYLE="margin-bottom: 0cm">Cancer is the predominant indication
for these drugs, but disease targets are</P>
<P STYLE="margin-bottom: 0cm">increasing. For example, we can expect
the approval of new drugs inhibiting other</P>
<P STYLE="margin-bottom: 0cm">protein kinases in the treatment of
illnesses such as hypertension, Parkinson's</P>
<P STYLE="margin-bottom: 0cm">disease, and autoimmune diseases.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015. Published by
Elsevier Ltd.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26207888 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">3. Sci Rep. 2015 Jul 20;5:12366. doi:
10.1038/srep12366.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">TMPRSS4 facilitates
epithelial-mesenchymal transition of hepatocellular carcinoma</P>
<P STYLE="margin-bottom: 0cm">and is a predictive marker for poor
prognosis of patients after curative</P>
<P STYLE="margin-bottom: 0cm">resection.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Wang CH(1), Guo ZY(2), Chen ZT(2), Zhi
XT(2), Li DK(2), Dong ZR(3), Chen ZQ(2),</P>
<P STYLE="margin-bottom: 0cm">Hu SY(2), Li T(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)1] Department of general surgery,
Qilu Hospital, Shandong University, Jinan</P>
<P STYLE="margin-bottom: 0cm">250012, P.R.China [2] Liver Cancer
Institute and Zhongshan Hospital, Fudan</P>
<P STYLE="margin-bottom: 0cm">University, Key Laboratory for
Carcinogenesis &amp;Cancer Invasion, the Chinese</P>
<P STYLE="margin-bottom: 0cm">Ministry of Education, Shanghai 200032,
P.R.China. (2)Department of general</P>
<P STYLE="margin-bottom: 0cm">surgery, Qilu Hospital, Shandong
University, Jinan 250012, P.R.China. (3)Liver</P>
<P STYLE="margin-bottom: 0cm">Cancer Institute and Zhongshan
Hospital, Fudan University, Key Laboratory for</P>
<P STYLE="margin-bottom: 0cm">Carcinogenesis &amp;Cancer Invasion,
the Chinese Ministry of Education, Shanghai</P>
<P STYLE="margin-bottom: 0cm">200032, P.R.China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">TMPRSS4 (Transmembrane protease serine
4) is up-regulated in a broad spectrum of 
</P>
<P STYLE="margin-bottom: 0cm">cancers. However, little is known about
the biological effects of TMPRSS4 on</P>
<P STYLE="margin-bottom: 0cm">hepatocellular carcinoma (HCC) and the
related mechanisms. In the present study, 
</P>
<P STYLE="margin-bottom: 0cm">we found that overexpression of TMPRSS4
significantly promoted the invasion,</P>
<P STYLE="margin-bottom: 0cm">migration, adhesion and metastasis of
HCC. Further more, TMPRSS4 induced EMT of</P>
<P STYLE="margin-bottom: 0cm">HCC, which was mediated via snail and
slug as a result of Raf/MEK/ERK1/2</P>
<P STYLE="margin-bottom: 0cm">activation, and inhibition of ERK1/2
activation by its inhibitor was associated</P>
<P STYLE="margin-bottom: 0cm">with reduced cell invasion and
reversion of EMT. In addition, we demonstrated</P>
<P STYLE="margin-bottom: 0cm">that TMPRSS4 remarkably suppressed the
expression of RECK, an inhibitor of</P>
<P STYLE="margin-bottom: 0cm">angiogenesis, and drastically induced
tumor angiogenesis and growth. More</P>
<P STYLE="margin-bottom: 0cm">important, in clinical HCC specimens,
TMPRSS4 expression was significantly</P>
<P STYLE="margin-bottom: 0cm">correlated with tumor staging and was
inversely correlated with E-cadherin and</P>
<P STYLE="margin-bottom: 0cm">RECKS expression. Expression of TMPRSS4
is significantly associated with HCC</P>
<P STYLE="margin-bottom: 0cm">progression and is an independent
prognostic factor for postoperative worse</P>
<P STYLE="margin-bottom: 0cm">survival and recurrence. In conclusion,
TMPRSS4 functions as a positive regulator</P>
<P STYLE="margin-bottom: 0cm">of Raf/MEK/ERK1/2 pathway and promotes
HCC progression by inducing EMT and</P>
<P STYLE="margin-bottom: 0cm">angiogenesis. The increase of TMPRSS4
expression may be a key event for HCC</P>
<P STYLE="margin-bottom: 0cm">progression and may be regarded as a
potential prognostic marker for HCC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4507176</P>
<P STYLE="margin-bottom: 0cm">PMID: 26190376 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">4. Blood Cancer J. 2015 Jul 17;5:e324.
doi: 10.1038/bcj.2015.52.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Peripheral blood cells from children
with RASopathies show enhanced spontaneous</P>
<P STYLE="margin-bottom: 0cm">colonies growth in vitro and
hyperactive RAS signaling.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Gaipa G(1), Bugarin C(1), Cianci P(2),
Sarno J(1), Bonaccorso P(3), Biondi A(4), 
</P>
<P STYLE="margin-bottom: 0cm">Selicorni A(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)M. Tettamanti Research Centre,
Pediatric Clinic, University of Milano-Bicocca,</P>
<P STYLE="margin-bottom: 0cm">Monza, Italy. (2)Pediatrics Clinical
Genetics, MBBM-AO San Gerardo Foundation,</P>
<P STYLE="margin-bottom: 0cm">University of Milano-Bicocca, Monza,
Italy. (3)1] M. Tettamanti Research Centre, 
</P>
<P STYLE="margin-bottom: 0cm">Pediatric Clinic, University of
Milano-Bicocca, Monza, Italy [2] Center of</P>
<P STYLE="margin-bottom: 0cm">Pediatric Hematology Oncology, Azienda
Policlinico-OVE, University of Catania,</P>
<P STYLE="margin-bottom: 0cm">Catania, Italy. (4)1] M. Tettamanti
Research Centre, Pediatric Clinic, University</P>
<P STYLE="margin-bottom: 0cm">of Milano-Bicocca, Monza, Italy [2]
Pediatrics Clinical Genetics, MBBM-AO San</P>
<P STYLE="margin-bottom: 0cm">Gerardo Foundation, University of
Milano-Bicocca, Monza, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Germline mutations in genes coding for
molecules involved in the RAS/RAF/MEK/ERK 
</P>
<P STYLE="margin-bottom: 0cm">pathway are the hallmarks of a newly
classified family of autosomal dominant</P>
<P STYLE="margin-bottom: 0cm">syndromes termed RASopathies.
Myeloproliferative disorders (MPDs), in particular,</P>
<P STYLE="margin-bottom: 0cm">juvenile myelomonocytic leukemia, can
lead to potentially severe complications in</P>
<P STYLE="margin-bottom: 0cm">children with Noonan syndrome (NS). We
studied 27 children with NS or other</P>
<P STYLE="margin-bottom: 0cm">RASopathies and 35 age-matched children
as control subjects. Peripheral blood</P>
<P STYLE="margin-bottom: 0cm">(PB) cells from these patients were
studied for in vitro colony-forming units</P>
<P STYLE="margin-bottom: 0cm">(CFUs) activity, as well as for
intracellular phosphosignaling. Higher</P>
<P STYLE="margin-bottom: 0cm">spontaneous growth of both
burst-forming units-erythroid (BFU-E) and</P>
<P STYLE="margin-bottom: 0cm">CFU-granulocyte/macrophage (CFU-GM)
colonies from RAS-mutated patients were</P>
<P STYLE="margin-bottom: 0cm">observed as compared with control
subjects. We also observed a significantly</P>
<P STYLE="margin-bottom: 0cm">higher amount of GM-colony-stimulating
factor-induced p-ERK in children with</P>
<P STYLE="margin-bottom: 0cm">RASopathies. Our findings demonstrate
for the first time that PB cells isolated</P>
<P STYLE="margin-bottom: 0cm">from children suffering from NS or
other RASopathies without MPD display enhanced</P>
<P STYLE="margin-bottom: 0cm">BFU-E and CFU-GM colony formation in
vitro. The biological significance of these 
</P>
<P STYLE="margin-bottom: 0cm">findings clearly awaits further
studies. Collectively, our data provide a basis</P>
<P STYLE="margin-bottom: 0cm">for further investigating of only
partially characterized hematological</P>
<P STYLE="margin-bottom: 0cm">alterations present in children
suffering from RASopathies, and may provide new</P>
<P STYLE="margin-bottom: 0cm">markers for progression toward
malignant MPD in these patients.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26186557 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">5. Pigment Cell Melanoma Res. 2015 Jul
14. doi: 10.1111/pcmr.12395. [Epub ahead of</P>
<P STYLE="margin-bottom: 0cm">print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">A (heat) shocking development: FBXW7
loss unleashes HSF1 to drive melanoma</P>
<P STYLE="margin-bottom: 0cm">invasion and metastasis.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Cho E, Grim JE.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Melanoma is the deadliest form of skin
cancer because of its strong tendency for 
</P>
<P STYLE="margin-bottom: 0cm">local invasion, distant metastasis, and
resistance to traditional cytotoxic</P>
<P STYLE="margin-bottom: 0cm">chemotherapy. A more complete
understanding of the genetic landscape of melanoma 
</P>
<P STYLE="margin-bottom: 0cm">will define and clarify the molecular
pathways that drive tumor growth and will</P>
<P STYLE="margin-bottom: 0cm">also reveal new therapeutic targets.
Indeed, this is already being borne out:</P>
<P STYLE="margin-bottom: 0cm">multiple studies have demonstrated that
activating mutations in components of the</P>
<P STYLE="margin-bottom: 0cm">RAS/RAF/MEK/ERK pathway occur in over
half of melanoma tumor samples and targeted</P>
<P STYLE="margin-bottom: 0cm">inhibitors of this pathway are
currently used to treat patients with these</P>
<P STYLE="margin-bottom: 0cm">cancers. This article is protected by
copyright. All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">This article is protected by copyright.
All rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26178611 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">6. Discov Med. 2015 Jun;19(107):455-61.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Novel mechanisms and therapeutic
approaches in melanoma: targeting the MAPK</P>
<P STYLE="margin-bottom: 0cm">pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Grimaldi AM(1), Simeone E, Festino L,
Vanella V, Palla M, Ascierto PA.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)O.U. Melanoma, Cancer Immunotherapy
and Innovative Therapies, National Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Institute of Naples &quot;G. Pascale&quot;
Foundation, Naples, Italy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The development of novel treatments
that selectively inhibit the RAS-RAF-MAPK</P>
<P STYLE="margin-bottom: 0cm">pathway represents a milestone in the
history of melanoma treatment. BRAF</P>
<P STYLE="margin-bottom: 0cm">mutations occur in approximately 45% of
cutaneous melanomas, while mutations in</P>
<P STYLE="margin-bottom: 0cm">NRAS occur in 15-25%. Vemurafenib was
the first BRAF inhibitor to be approved in 
</P>
<P STYLE="margin-bottom: 0cm">2011, based on the results of a phase
III trial (BRIM-3) that showed higher</P>
<P STYLE="margin-bottom: 0cm">progression-free survival and overall
survival compared with dacarbazine</P>
<P STYLE="margin-bottom: 0cm">chemotherapy in metastatic BRAF-mutated
melanoma. Dabrafenib, another BRAF</P>
<P STYLE="margin-bottom: 0cm">inhibitor, has shown similar results
and was approved in 2013. Preclinical</P>
<P STYLE="margin-bottom: 0cm">studies suggested that another novel
group of agents, the MEK inhibitors, showed 
</P>
<P STYLE="margin-bottom: 0cm">stronger inhibition of both mutated
BRAF and NRAS cell cultures than vemurafenib.</P>
<P STYLE="margin-bottom: 0cm">Trametinib was the first MEK inhibitor
approved in 2014, both as a single agent</P>
<P STYLE="margin-bottom: 0cm">and in combination with dabrafenib for
the treatment of advanced BRAF-mutated</P>
<P STYLE="margin-bottom: 0cm">melanoma. Other MEK inhibitors are also
in development. Concomitant inhibition of</P>
<P STYLE="margin-bottom: 0cm">both MEK and BRAF has shown more
durable and greater tumor response than BRAF</P>
<P STYLE="margin-bottom: 0cm">monotherapy, by overcoming the multiple
genetic mechanisms of escape. Combined</P>
<P STYLE="margin-bottom: 0cm">therapy prevents the development of
acquired resistance as well as decreasing</P>
<P STYLE="margin-bottom: 0cm">cutaneous toxicity secondary to
paradoxical activation of the MAPK pathway</P>
<P STYLE="margin-bottom: 0cm">induced by BRAF inhibitors. Various
combinations of BRAF and MEK inhibitors have 
</P>
<P STYLE="margin-bottom: 0cm">shown promising results. Moreover,
triple combination therapies involved other</P>
<P STYLE="margin-bottom: 0cm">agents with novel mechanisms of action
are also being evaluated. These and other 
</P>
<P STYLE="margin-bottom: 0cm">combination strategies involving
immunotherapies and targeted therapies offer the</P>
<P STYLE="margin-bottom: 0cm">hope of improving outcomes beyond those
already achieved with anti-BRAF</P>
<P STYLE="margin-bottom: 0cm">treatments.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26175403 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">7. Leukemia. 2015 Jul 13. doi:
10.1038/leu.2015.180. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Discovery of a BTK/MNK dual inhibitor
for lymphoma and leukemia.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Wu H(1), Hu C(2), Wang A(1), Weisberg
EL(3), Chen Y(2), Yun CH(4), Wang W(2), Liu</P>
<P STYLE="margin-bottom: 0cm">Y(3), Liu X(1), Tian B(5), Wang J(4),
Zhao Z(2), Liang Y(4), Li B(2), Wang L(2), 
</P>
<P STYLE="margin-bottom: 0cm">Wang B(2), Chen C(2), Buhrlage SJ(4),
Qi Z(2), Zou F(2), Nonami A(3), Li Y(3),</P>
<P STYLE="margin-bottom: 0cm">Fernandes SM(3), Adamia S(3), Stone
RM(3), Galinsky IA(3), Wang X(6), Yang G(3), 
</P>
<P STYLE="margin-bottom: 0cm">Griffin JD(3), Brown JR(3), Eck MJ(4),
Liu J(2), Gray NS(4), Liu Q(7).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)1] High Magnetic Field laboratory,
Chinese Academy of Sciences, Hefei, Anhui, 
</P>
<P STYLE="margin-bottom: 0cm">P. R. China [2] University of Science
and Technology of China, Anhui, Hefei, P.</P>
<P STYLE="margin-bottom: 0cm">R. China. (2)High Magnetic Field
laboratory, Chinese Academy of Sciences, Hefei, 
</P>
<P STYLE="margin-bottom: 0cm">Anhui, P. R. China. (3)Department of
Medical Oncology, Dana Farber Cancer</P>
<P STYLE="margin-bottom: 0cm">Institute, Harvard Medical School,
Boston, MA, USA. (4)Department of Biological</P>
<P STYLE="margin-bottom: 0cm">Chemistry &amp; Molecular Pharmacology,
Harvard Medical School, Boston, MA, USA.</P>
<P STYLE="margin-bottom: 0cm">(5)Beijing Tongren Eye Center, Beijing
Tongren Hospital, Capital Medical</P>
<P STYLE="margin-bottom: 0cm">University; Beijing Ophthalmology &amp;
Visual Science Key Laboratory, Beijing, P. R.</P>
<P STYLE="margin-bottom: 0cm">China. (6)Department of Lymphoma,
Sino-US Center for Lymphoma and Leukemia,</P>
<P STYLE="margin-bottom: 0cm">Tianjin Medical University Cancer
Institute and Hospital, National Clinical</P>
<P STYLE="margin-bottom: 0cm">Research Center of Cancer, Key
Laboratory of Cancer Prevention and Therapy,</P>
<P STYLE="margin-bottom: 0cm">Tianjin, China. (7)1] High Magnetic
Field laboratory, Chinese Academy of</P>
<P STYLE="margin-bottom: 0cm">Sciences, Hefei, Anhui, P. R. China [2]
University of Science and Technology of</P>
<P STYLE="margin-bottom: 0cm">China, Anhui, Hefei, P. R. China [3]
Hefei Science Center, Chinese Academy of</P>
<P STYLE="margin-bottom: 0cm">Sciences, Hefei, Anhui, P. R. China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BTK kinase is a member of the TEC
kinase family and is a key regulator of the</P>
<P STYLE="margin-bottom: 0cm">B-cell Receptor (BCR)-mediated
signaling pathway. It is important for B-cell</P>
<P STYLE="margin-bottom: 0cm">maturation, proliferation, survival and
metastasis. Pharmacological inhibition of</P>
<P STYLE="margin-bottom: 0cm">BTK is clinically effective against a
variety of B-cell malignances, such as MCL,</P>
<P STYLE="margin-bottom: 0cm">CLL, AML and ABC-DLBCL. MNK kinase is
one of the key downstream regulators in the</P>
<P STYLE="margin-bottom: 0cm">RAF-MEK-ERK signaling pathway and
controls protein synthesis via regulating the</P>
<P STYLE="margin-bottom: 0cm">activity of eIF4E. Inhibition of MNK
activity has been observed to moderately</P>
<P STYLE="margin-bottom: 0cm">inhibit the proliferation of AML cells.
Through a structure-based drug design</P>
<P STYLE="margin-bottom: 0cm">approach, we have discovered a
selective and potent BTK/MNK dual kinase inhibitor</P>
<P STYLE="margin-bottom: 0cm">(QL-X-138), which exhibits covalent
binding to BTK and non-covalent binding to</P>
<P STYLE="margin-bottom: 0cm">MNK. Compared to the BTK kinase
inhibitor (PCI-32765) and the MNK kinase</P>
<P STYLE="margin-bottom: 0cm">inhibitor (cercosporamide), QL-X-138
enhanced the anti-proliferative efficacies</P>
<P STYLE="margin-bottom: 0cm">in vitro against a variety of B-cell
cancer cell lines, as well as AML and CLL</P>
<P STYLE="margin-bottom: 0cm">primary patient cells which respond
moderately to BTK inhibitor in vitro. The</P>
<P STYLE="margin-bottom: 0cm">agent can effectively arrest the growth
of lymphoma and leukemia cells at the</P>
<P STYLE="margin-bottom: 0cm">G0-G1 stage and can induce strong
apoptotic cell death. These primary results</P>
<P STYLE="margin-bottom: 0cm">demonstrate that simultaneous
inhibition of BTK and MNK kinase activity might be 
</P>
<P STYLE="margin-bottom: 0cm">a new therapeutic strategy for B-cell
malignances.Leukemia accepted article</P>
<P STYLE="margin-bottom: 0cm">preview online, 13 July 2015.
doi:10.1038/leu.2015.180.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26165234 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">8. Cell Signal. 2015 Jul
9;27(10):1939-1948. doi: 10.1016/j.cellsig.2015.07.003.</P>
<P STYLE="margin-bottom: 0cm">[Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">ERK1/2 can feedback-regulate cellular
MEK1/2 levels.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hong SK(1), Wu PK(1), Karkhanis M(1),
Park JI(2).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Biochemistry, Medical
College of Wisconsin, Milwaukee, WI 53226,</P>
<P STYLE="margin-bottom: 0cm">USA. (2)Department of Biochemistry,
Medical College of Wisconsin, Milwaukee, WI</P>
<P STYLE="margin-bottom: 0cm">53226, USA. Electronic address:
jipark@mcw.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Signal transduction of the Raf/MEK/ERK
pathway is regulated by various feedback</P>
<P STYLE="margin-bottom: 0cm">mechanisms. Given the greater molar
ratio between Raf-MEK than between MEK-ERK in</P>
<P STYLE="margin-bottom: 0cm">cells, it may be possible that MEK1/2
levels are regulated to modulate</P>
<P STYLE="margin-bottom: 0cm">Raf/MEK/ERK activity upon pathway
stimulation. Nevertheless, it has not been</P>
<P STYLE="margin-bottom: 0cm">reported whether MEK1/2 expression can
be subject to a feedback regulation. Here,</P>
<P STYLE="margin-bottom: 0cm">we report that the Raf/MEK/ERK pathway
can feedback-regulate cellular MEK1 and</P>
<P STYLE="margin-bottom: 0cm">MEK2 levels. In different cell types,
ΔRaf-1:ER- or B-Raf(V600E)-mediated MEK/ERK</P>
<P STYLE="margin-bottom: 0cm">activation increased MEK1 but decreased
MEK2 levels. These regulations were</P>
<P STYLE="margin-bottom: 0cm">abrogated by ERK1/2 knockdown mediated
by RNA interference, suggesting the</P>
<P STYLE="margin-bottom: 0cm">presence of a feedback mechanism that
regulates MEK1/2 levels. Subsequently,</P>
<P STYLE="margin-bottom: 0cm">analyses using qPCR and luciferase
reporters of the DNA promoter and 3'</P>
<P STYLE="margin-bottom: 0cm">untranslated region revealed that the
feedback MEK1 upregulation was in part</P>
<P STYLE="margin-bottom: 0cm">attributed to increased transcription.
However, the feedback MEK2 downregulation 
</P>
<P STYLE="margin-bottom: 0cm">was only observed at protein levels,
which was blocked by the proteasome</P>
<P STYLE="margin-bottom: 0cm">inhibitors, MG132 and bortezomib,
suggesting that the MEK2 regulation is mediated</P>
<P STYLE="margin-bottom: 0cm">at a post-translational level. These
results suggest that the Raf/MEK/ERK pathway</P>
<P STYLE="margin-bottom: 0cm">can feedback-regulate cellular levels
of MEK1 and MEK2, wherein MEK1 levels are</P>
<P STYLE="margin-bottom: 0cm">upregulated at transcriptional level
whereas MEK2 levels are downregulated at</P>
<P STYLE="margin-bottom: 0cm">posttranslational level.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015 Elsevier Inc. All
rights reserved.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26163823 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">9. Radiother Oncol. 2015 Jul 8. pii:
S0167-8140(15)00323-0. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1016/j.radonc.2015.06.026. [Epub
ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Trametinib radiosensitises RAS- and
BRAF-mutated melanoma by perturbing cell</P>
<P STYLE="margin-bottom: 0cm">cycle and inducing senescence.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Schick U(1), Kyula J(1), Barker H(1),
Patel R(1), Zaidi S(1), Gregory C(1), Hafsi</P>
<P STYLE="margin-bottom: 0cm">H(1), Roulstone V(1), Deutsch E(2),
McLaughlin M(1), Harrington K(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Targeted Therapy Team, The Institute
of Cancer Research, London, United</P>
<P STYLE="margin-bottom: 0cm">Kingdom. (2)INSERM UMR 1030, Gustave
Roussy, Villejuif, France. (3)Targeted</P>
<P STYLE="margin-bottom: 0cm">Therapy Team, The Institute of Cancer
Research, London, United Kingdom.</P>
<P STYLE="margin-bottom: 0cm">Electronic address:
Kevin.Harrington@icr.ac.uk.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PURPOSE: Radiotherapy (RT) is used
frequently in patients with melanoma, but</P>
<P STYLE="margin-bottom: 0cm">results are suboptimal because the
disease is often radioresistant. This may be</P>
<P STYLE="margin-bottom: 0cm">due to constitutive activation of MAPK
pathway signalling through mutations</P>
<P STYLE="margin-bottom: 0cm">involving RAS/RAF. Thus, we studied
whether trametinib, a potent and selective</P>
<P STYLE="margin-bottom: 0cm">allosteric inhibitor of MEK1/2 could
improve the efficacy of RT.</P>
<P STYLE="margin-bottom: 0cm">METHODS AND MATERIALS: Clonogenic
survival assays were performed in human</P>
<P STYLE="margin-bottom: 0cm">BRAF-mutant (A375), NRAS-mutant (D04,
WM1631), KRAS-mutant (WM1791c) and</P>
<P STYLE="margin-bottom: 0cm">wild-type (PMWK) melanoma cell lines.
The effects of trametinib with and without 
</P>
<P STYLE="margin-bottom: 0cm">radiation on protein levels of MEK
effectors were measured by immunoblot</P>
<P STYLE="margin-bottom: 0cm">analyses. Cell cycle effects, DNA
damage repair, mitotic catastrophe and</P>
<P STYLE="margin-bottom: 0cm">senescence were measured using flow
cytometry, γH2Ax staining, nuclear</P>
<P STYLE="margin-bottom: 0cm">fragmentation and β-galactosidase
staining, respectively. Additionally, athymic</P>
<P STYLE="margin-bottom: 0cm">mice with D04 flank tumours were
treated with fractionated RT after gavage with</P>
<P STYLE="margin-bottom: 0cm">trametinib and monitored for tumour
growth.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: All cell lines, except PMWK,
exhibited enhanced cytotoxicity when RT was</P>
<P STYLE="margin-bottom: 0cm">combined with trametinib compared to
either agent alone. Sensitiser enhancement</P>
<P STYLE="margin-bottom: 0cm">ratios were 1.70, 1.32, 1.10, and 1.70
for A375, D04, WM1361 and WM1791c,</P>
<P STYLE="margin-bottom: 0cm">respectively. Trametinib efficiently
blocked RT-induced phosphorylation of ERK at</P>
<P STYLE="margin-bottom: 0cm">nanomolar concentrations. Increased
radiosensitivity correlated with prolonged G1</P>
<P STYLE="margin-bottom: 0cm">arrest and reduction in the
radioresistant S phase up to 48h following RT. A</P>
<P STYLE="margin-bottom: 0cm">larger population of
senescence-activated β-galactosidase-positive cells was seen</P>
<P STYLE="margin-bottom: 0cm">in the trametinib pretreated group, and
this correlated with activation of two of</P>
<P STYLE="margin-bottom: 0cm">the major mediators of induced
senescence, p53 and pRb. Mice receiving the</P>
<P STYLE="margin-bottom: 0cm">combination treatment (trametinib
1mg/kg and RT over 3days) showed a reduced mean</P>
<P STYLE="margin-bottom: 0cm">tumour volume compared with mice
receiving trametinib alone (p=0.016), or RT</P>
<P STYLE="margin-bottom: 0cm">alone (p=0.047). No overt signs of drug
toxicity were observed.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: Trametinib radiosensitised
RAS-/RAF-mutated melanoma cells by</P>
<P STYLE="margin-bottom: 0cm">inducing prolonged G1 arrest and
premature senescence. In this pre-clinical study</P>
<P STYLE="margin-bottom: 0cm">we demonstrate that combining
trametinib and RT is well tolerated, and reduces</P>
<P STYLE="margin-bottom: 0cm">tumour growth in vivo.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Copyright © 2015. Published by
Elsevier Ireland Ltd.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26163092 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">10. J Biomed Sci. 2015 Jul 9;22(1):52.
doi: 10.1186/s12929-015-0158-7.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The effects and mechanisms of SLC34A2
in tumorigenesis and progression of human</P>
<P STYLE="margin-bottom: 0cm">non-small cell lung cancer.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Wang Y(1), Yang W(2), Pu Q(3), Yang
Y(4), Ye S(5), Ma Q(6), Ren J(7), Cao Z(8),</P>
<P STYLE="margin-bottom: 0cm">Zhong G(9), Zhang X(10), Liu L(11), Zhu
W(12).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)State Key Laboratory of Biotherapy
and Cancer Center, West China Hospital,</P>
<P STYLE="margin-bottom: 0cm">Sichuan University, and Collaborative
Innovation Center for Biotherapy, NO. 1,</P>
<P STYLE="margin-bottom: 0cm">Keyuan 4th Road, Gaopeng Street, High
Technological Development Zone, 610041,</P>
<P STYLE="margin-bottom: 0cm">Chengdu, Sichuan, P. R. China.
wangyu_4932@163.com. (2)State Key Laboratory of</P>
<P STYLE="margin-bottom: 0cm">Biotherapy and Cancer Center, West
China Hospital, Sichuan University, and</P>
<P STYLE="margin-bottom: 0cm">Collaborative Innovation Center for
Biotherapy, NO. 1, Keyuan 4th Road, Gaopeng</P>
<P STYLE="margin-bottom: 0cm">Street, High Technological Development
Zone, 610041, Chengdu, Sichuan, P. R.</P>
<P STYLE="margin-bottom: 0cm">China. younger1030@163.com.
(3)Department of Thoracic Surgery, West China</P>
<P STYLE="margin-bottom: 0cm">Hospital, Sichuan University, No. 37
Guo Xue Xiang, 610041, Chengdu, Sichuan, P. 
</P>
<P STYLE="margin-bottom: 0cm">R. China. puqiang11@gmail.com. (4)State
Key Laboratory of Biotherapy and Cancer</P>
<P STYLE="margin-bottom: 0cm">Center, West China Hospital, Sichuan
University, and Collaborative Innovation</P>
<P STYLE="margin-bottom: 0cm">Center for Biotherapy, NO. 1, Keyuan
4th Road, Gaopeng Street, High Technological</P>
<P STYLE="margin-bottom: 0cm">Development Zone, 610041, Chengdu,
Sichuan, P. R. China. scu_yanyang@163.com.</P>
<P STYLE="margin-bottom: 0cm">(5)State Key Laboratory of Biotherapy
and Cancer Center, West China Hospital,</P>
<P STYLE="margin-bottom: 0cm">Sichuan University, and Collaborative
Innovation Center for Biotherapy, NO. 1,</P>
<P STYLE="margin-bottom: 0cm">Keyuan 4th Road, Gaopeng Street, High
Technological Development Zone, 610041,</P>
<P STYLE="margin-bottom: 0cm">Chengdu, Sichuan, P. R. China.
shiny9191@163.com. (6)State Key Laboratory of</P>
<P STYLE="margin-bottom: 0cm">Biotherapy and Cancer Center, West
China Hospital, Sichuan University, and</P>
<P STYLE="margin-bottom: 0cm">Collaborative Innovation Center for
Biotherapy, NO. 1, Keyuan 4th Road, Gaopeng</P>
<P STYLE="margin-bottom: 0cm">Street, High Technological Development
Zone, 610041, Chengdu, Sichuan, P. R.</P>
<P STYLE="margin-bottom: 0cm">China. qingpingle2008@163.com. (7)State
Key Laboratory of Biotherapy and Cancer</P>
<P STYLE="margin-bottom: 0cm">Center, West China Hospital, Sichuan
University, and Collaborative Innovation</P>
<P STYLE="margin-bottom: 0cm">Center for Biotherapy, NO. 1, Keyuan
4th Road, Gaopeng Street, High Technological</P>
<P STYLE="margin-bottom: 0cm">Development Zone, 610041, Chengdu,
Sichuan, P. R. China. rjham@126.com. (8)State 
</P>
<P STYLE="margin-bottom: 0cm">Key Laboratory of Biotherapy and Cancer
Center, West China Hospital, Sichuan</P>
<P STYLE="margin-bottom: 0cm">University, and Collaborative
Innovation Center for Biotherapy, NO. 1, Keyuan 4th</P>
<P STYLE="margin-bottom: 0cm">Road, Gaopeng Street, High
Technological Development Zone, 610041, Chengdu,</P>
<P STYLE="margin-bottom: 0cm">Sichuan, P. R. China.
caozhixing007@163.com. (9)State Key Laboratory of</P>
<P STYLE="margin-bottom: 0cm">Biotherapy and Cancer Center, West
China Hospital, Sichuan University, and</P>
<P STYLE="margin-bottom: 0cm">Collaborative Innovation Center for
Biotherapy, NO. 1, Keyuan 4th Road, Gaopeng</P>
<P STYLE="margin-bottom: 0cm">Street, High Technological Development
Zone, 610041, Chengdu, Sichuan, P. R.</P>
<P STYLE="margin-bottom: 0cm">China. guoxingzhong@gmail.com.
(10)State Key Laboratory of Biotherapy and Cancer 
</P>
<P STYLE="margin-bottom: 0cm">Center, West China Hospital, Sichuan
University, and Collaborative Innovation</P>
<P STYLE="margin-bottom: 0cm">Center for Biotherapy, NO. 1, Keyuan
4th Road, Gaopeng Street, High Technological</P>
<P STYLE="margin-bottom: 0cm">Development Zone, 610041, Chengdu,
Sichuan, P. R. China. 42539791@qq.com.</P>
<P STYLE="margin-bottom: 0cm">(11)Department of Thoracic Surgery,
West China Hospital, Sichuan University, No. 
</P>
<P STYLE="margin-bottom: 0cm">37 Guo Xue Xiang, 610041, Chengdu,
Sichuan, P. R. China. lunxu_liu@aliyun.com.</P>
<P STYLE="margin-bottom: 0cm">(12)State Key Laboratory of Biotherapy
and Cancer Center, West China Hospital,</P>
<P STYLE="margin-bottom: 0cm">Sichuan University, and Collaborative
Innovation Center for Biotherapy, NO. 1,</P>
<P STYLE="margin-bottom: 0cm">Keyuan 4th Road, Gaopeng Street, High
Technological Development Zone, 610041,</P>
<P STYLE="margin-bottom: 0cm">Chengdu, Sichuan, P. R. China.
zhuwen@scu.edu.cn.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: SLC34A2 with highest
expressions in lung, small intestine and kidney 
</P>
<P STYLE="margin-bottom: 0cm">encoded a type 2b sodium-dependent
phosphate transporter (NaPi-IIb). In lung,</P>
<P STYLE="margin-bottom: 0cm">SLC34A2 only expressed in the apical
membrane of type II alveolar epithelium</P>
<P STYLE="margin-bottom: 0cm">cells (ATII cells) and played a pivotal
role during the fetal lung development</P>
<P STYLE="margin-bottom: 0cm">and embryonic development. ATII cells
acting as multifunctional stem cells might 
</P>
<P STYLE="margin-bottom: 0cm">transform into NSCLC after undergoing
exogenous or endogenous factors. Increasing</P>
<P STYLE="margin-bottom: 0cm">evidences showed that the genes
performing critical roles during embryogenesis</P>
<P STYLE="margin-bottom: 0cm">were also expressed during the
development of cancer. In addition, recent</P>
<P STYLE="margin-bottom: 0cm">research found the expression of
SLC34A2 had a significant difference between the</P>
<P STYLE="margin-bottom: 0cm">surgical samples of NSCLC and normal
tissues, and SLC34A2 was down-regulated in</P>
<P STYLE="margin-bottom: 0cm">lung adenocarcinoma cell line A549 and
up-regulation expression of SLC34A2 could 
</P>
<P STYLE="margin-bottom: 0cm">significantly inhibit cell viability
and invasion of A549 in vitro. These results</P>
<P STYLE="margin-bottom: 0cm">suggested SLC34A2 might play an
important role in the development of NSCLC.</P>
<P STYLE="margin-bottom: 0cm">However, the role of SLC34A2 in
tumorigenesis and progression of NSCLC remains</P>
<P STYLE="margin-bottom: 0cm">unknown.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: Our study found that SLC34A2
was also significantly down-regulated in</P>
<P STYLE="margin-bottom: 0cm">14/15 of examined NSCLC tissues.
Moreover, we found that expressions of SLC34A2</P>
<P STYLE="margin-bottom: 0cm">were reduced in six NSCLC cell lines
for the first time. Our result also revealed</P>
<P STYLE="margin-bottom: 0cm">a dramatic inhibitory effects of
SLC34A2 on cell growth, migration and invasion</P>
<P STYLE="margin-bottom: 0cm">of several NSCLC cell lines. SLC34A2
also strongly inhibited tumor growth and</P>
<P STYLE="margin-bottom: 0cm">metastasis ability in A549 subcutaneous
tumor model and lung metastasis model,</P>
<P STYLE="margin-bottom: 0cm">respectively. Further studies found
that the suppressive effects of SLC34A2 on</P>
<P STYLE="margin-bottom: 0cm">tumorigenesis and progression might be
associated with the down-regulation of</P>
<P STYLE="margin-bottom: 0cm">related protein in PI3K/Akt and
Ras/Raf/MEK signal pathway.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: For the first time, our
data indicated that SLC34A2 could exert</P>
<P STYLE="margin-bottom: 0cm">significantly suppressive effects on
tumorigenesis and progression of NSCLC.</P>
<P STYLE="margin-bottom: 0cm">SLC34A2 might provide new insights for
further understanding the early</P>
<P STYLE="margin-bottom: 0cm">pathogenesis of human NSCLC.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4497375</P>
<P STYLE="margin-bottom: 0cm">PMID: 26156586 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">11. Proc Natl Acad Sci U S A. 2015 Jul
21;112(29):E3855-63. doi:</P>
<P STYLE="margin-bottom: 0cm">10.1073/pnas.1510733112. Epub 2015 Jul
6.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">EGFR inhibition evokes innate drug
resistance in lung cancer cells by preventing 
</P>
<P STYLE="margin-bottom: 0cm">Akt activity and thus inactivating
Ets-1 function.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Phuchareon J(1), McCormick F(2), Eisele
DW(1), Tetsu O(3).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Head and Neck Cancer Research
Laboratory, Department of Otolaryngology-Head</P>
<P STYLE="margin-bottom: 0cm">and Neck Surgery, School of Medicine,
University of California, San Francisco</P>
<P STYLE="margin-bottom: 0cm">(UCSF), CA 94115; UCSF Helen Diller
Family Comprehensive Cancer Center, School of</P>
<P STYLE="margin-bottom: 0cm">Medicine, University of California, San
Francisco, CA 94158. (2)UCSF Helen Diller</P>
<P STYLE="margin-bottom: 0cm">Family Comprehensive Cancer Center,
School of Medicine, University of California,</P>
<P STYLE="margin-bottom: 0cm">San Francisco, CA 94158
mccormic@cc.ucsf.edu osamu.tetsu@ucsf.edu. (3)Head and</P>
<P STYLE="margin-bottom: 0cm">Neck Cancer Research Laboratory,
Department of Otolaryngology-Head and Neck</P>
<P STYLE="margin-bottom: 0cm">Surgery, School of Medicine, University
of California, San Francisco (UCSF), CA</P>
<P STYLE="margin-bottom: 0cm">94115; UCSF Helen Diller Family
Comprehensive Cancer Center, School of Medicine, 
</P>
<P STYLE="margin-bottom: 0cm">University of California, San
Francisco, CA 94158 mccormic@cc.ucsf.edu</P>
<P STYLE="margin-bottom: 0cm">osamu.tetsu@ucsf.edu.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Nonsmall cell lung cancer (NSCLC) is
the leading cause of cancer death worldwide.</P>
<P STYLE="margin-bottom: 0cm">About 14% of NSCLCs harbor mutations in
epidermal growth factor receptor (EGFR). 
</P>
<P STYLE="margin-bottom: 0cm">Despite remarkable progress in
treatment with tyrosine kinase inhibitors (TKIs), 
</P>
<P STYLE="margin-bottom: 0cm">only 5% of patients achieve tumor
reduction &gt;90%. The limited primary responses</P>
<P STYLE="margin-bottom: 0cm">are attributed partly to drug
resistance inherent in the tumor cells before</P>
<P STYLE="margin-bottom: 0cm">therapy begins. Recent reports showed
that activation of receptor tyrosine</P>
<P STYLE="margin-bottom: 0cm">kinases (RTKs) is an important
determinant of this innate drug resistance. In</P>
<P STYLE="margin-bottom: 0cm">contrast, we demonstrate that EGFR
inhibition promotes innate drug resistance</P>
<P STYLE="margin-bottom: 0cm">despite blockade of RTK activity in
NSCLC cells. EGFR TKIs decrease both the</P>
<P STYLE="margin-bottom: 0cm">mitogen-activated protein kinase (MAPK)
and Akt protein kinase pathways for a</P>
<P STYLE="margin-bottom: 0cm">short time, after which the Ras/MAPK
pathway becomes reactivated. Akt inhibition 
</P>
<P STYLE="margin-bottom: 0cm">selectively blocks the transcriptional
activation of Ets-1, which inhibits its</P>
<P STYLE="margin-bottom: 0cm">target gene, dual specificity
phosphatase 6 (DUSP6), a negative regulator</P>
<P STYLE="margin-bottom: 0cm">specific for ERK1/2. As a result,
ERK1/2 is activated. Furthermore, elevated</P>
<P STYLE="margin-bottom: 0cm">c-Src stimulates Ras GTP-loading and
activates Raf and MEK kinases. These</P>
<P STYLE="margin-bottom: 0cm">observations suggest that not only
ERK1/2 but also Akt activity is essential to</P>
<P STYLE="margin-bottom: 0cm">maintain Ets-1 in an active state.
Therefore, despite high levels of ERK1/2,</P>
<P STYLE="margin-bottom: 0cm">Ets-1 target genes including DUSP6 and
cyclins D1, D3, and E2 remain suppressed</P>
<P STYLE="margin-bottom: 0cm">by Akt inhibition. Reduction of DUSP6
in combination with elevated c-Src renews</P>
<P STYLE="margin-bottom: 0cm">activation of the Ras/MAPK pathway,
which enhances cell survival by accelerating 
</P>
<P STYLE="margin-bottom: 0cm">Bim protein turnover. Thus, EGFR TKIs
evoke innate drug resistance by preventing 
</P>
<P STYLE="margin-bottom: 0cm">Akt activity and inactivating Ets-1
function in NSCLC cells.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26150526 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">12. BMC Cancer. 2015 Jul 4;15:497. doi:
10.1186/s12885-015-1515-3.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Variations of BRAF mutant allele
percentage in melanomas.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Hélias-Rodzewicz Z(1,)(2),
Funck-Brentano E(3,)(4), Baudoux L(5), Jung CK(6),</P>
<P STYLE="margin-bottom: 0cm">Zimmermann U(7,)(8), Marin C(9,)(10),
Clerici T(11,)(12), Le Gall C(13,)(14),</P>
<P STYLE="margin-bottom: 0cm">Peschaud F(15,)(16), Taly V(17), Saiag
P(18,)(19), Emile JF(20,)(21).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)EA4340, Versailles University,
Boulogne-Billancourt, France.</P>
<P STYLE="margin-bottom: 0cm">zofia.helias@aphp.fr. (2)Department of
Pathology, Ambroise Paré Hospital, APHP,</P>
<P STYLE="margin-bottom: 0cm">Boulogne-Billancourt, France.
zofia.helias@aphp.fr. (3)EA4340, Versailles</P>
<P STYLE="margin-bottom: 0cm">University, Boulogne-Billancourt,
France. elisa.funck-brentano@aphp.fr.</P>
<P STYLE="margin-bottom: 0cm">(4)Department of Dermatology, Ambroise
Paré Hospital, APHP, Boulogne-Billancourt,</P>
<P STYLE="margin-bottom: 0cm">France. elisa.funck-brentano@aphp.fr.
(5)EA4340, Versailles University,</P>
<P STYLE="margin-bottom: 0cm">Boulogne-Billancourt, France.
laure.baudoux@yahoo.fr. (6)Department of Hospital</P>
<P STYLE="margin-bottom: 0cm">Pathology, College of Medicine, The
Catholic University of Korea, Seoul, Korea.</P>
<P STYLE="margin-bottom: 0cm">ckjung@catholic.ac.kr. (7)EA4340,
Versailles University, Boulogne-Billancourt,</P>
<P STYLE="margin-bottom: 0cm">France. us.zimmermann@gmail.fr.
(8)Department of Pathology, Ambroise Paré</P>
<P STYLE="margin-bottom: 0cm">Hospital, APHP, Boulogne-Billancourt,
France. us.zimmermann@gmail.fr. (9)EA4340, 
</P>
<P STYLE="margin-bottom: 0cm">Versailles University,
Boulogne-Billancourt, France. cristi.marin@aphp.fr.</P>
<P STYLE="margin-bottom: 0cm">(10)Department of Pathology, Ambroise
Paré Hospital, APHP, Boulogne-Billancourt, 
</P>
<P STYLE="margin-bottom: 0cm">France. cristi.marin@aphp.fr.
(11)EA4340, Versailles University,</P>
<P STYLE="margin-bottom: 0cm">Boulogne-Billancourt, France.
thierryclerici@noos.fr. (12)Department of</P>
<P STYLE="margin-bottom: 0cm">Pathology, Ambroise Paré Hospital,
APHP, Boulogne-Billancourt, France.</P>
<P STYLE="margin-bottom: 0cm">thierryclerici@noos.fr. (13)EA4340,
Versailles University, Boulogne-Billancourt, 
</P>
<P STYLE="margin-bottom: 0cm">France. legall.catherine@voila.fr.
(14)Department of Pathology, Ambroise Paré</P>
<P STYLE="margin-bottom: 0cm">Hospital, APHP, Boulogne-Billancourt,
France. legall.catherine@voila.fr.</P>
<P STYLE="margin-bottom: 0cm">(15)EA4340, Versailles University,
Boulogne-Billancourt, France.</P>
<P STYLE="margin-bottom: 0cm">frederique.peschaud@aphp.fr.
(16)Department of Surgery, Ambroise Paré Hospital,</P>
<P STYLE="margin-bottom: 0cm">APHP, Boulogne-Billancourt, France.
frederique.peschaud@aphp.fr. (17)INSERM</P>
<P STYLE="margin-bottom: 0cm">UMR-S1147, University Paris Sorbonne
Cite, Paris, France.</P>
<P STYLE="margin-bottom: 0cm">valerie.taly@parisdescartes.fr.
(18)EA4340, Versailles University,</P>
<P STYLE="margin-bottom: 0cm">Boulogne-Billancourt, France.
philippe.saiag@uvsq.fr. (19)Department of</P>
<P STYLE="margin-bottom: 0cm">Dermatology, Ambroise Paré Hospital,
APHP, Boulogne-Billancourt, France.</P>
<P STYLE="margin-bottom: 0cm">philippe.saiag@uvsq.fr. (20)EA4340,
Versailles University, Boulogne-Billancourt, 
</P>
<P STYLE="margin-bottom: 0cm">France. jean-francois.emile@uvsq.fr.
(21)Department of Pathology, Ambroise Paré</P>
<P STYLE="margin-bottom: 0cm">Hospital, APHP, Boulogne-Billancourt,
France. jean-francois.emile@uvsq.fr.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND: BRAF mutations are present
in 40 % of human skin melanomas. Mutated</P>
<P STYLE="margin-bottom: 0cm">tumors with an increased percentage of
BRAF mutant alleles (BRAF-M%) may have a</P>
<P STYLE="margin-bottom: 0cm">better response to RAF/MEK inhibitors.
We evaluated the BRAF-M% in melanomas, and</P>
<P STYLE="margin-bottom: 0cm">the genetic causes of its variation.</P>
<P STYLE="margin-bottom: 0cm">METHODS: BRAF-M% was quantified by
pyrosequencing, real-time PCR (rtPCR) and/or</P>
<P STYLE="margin-bottom: 0cm">picoliter-droplet PCR (dPCR). BRAF
mutant expression was detected by</P>
<P STYLE="margin-bottom: 0cm">immunohistochemistry. Chromosomal
alterations were analyzed with fluorescence in 
</P>
<P STYLE="margin-bottom: 0cm">situ hybridization (FISH), and single
nucleotide polymorphism (SNP) arrays.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: BRAF-M% quantification
obtained with pyrosequencing was highly</P>
<P STYLE="margin-bottom: 0cm">correlated (R = 0.94) with rtPCR,
and with dPCR. BRAF-M% quantified from DNA and 
</P>
<P STYLE="margin-bottom: 0cm">RNA were also highly correlated
(R = 0.98). Among 368 samples with &gt;80 % tumor</P>
<P STYLE="margin-bottom: 0cm">cells, 38.6 % had a BRAF (V600E)
mutation. Only 66.2 % cases were heterozygous</P>
<P STYLE="margin-bottom: 0cm">(BRAF-M% 30 to 60 %). Increased BRAF-M%
(&gt;60 %) was observed in 19 % of cases.</P>
<P STYLE="margin-bottom: 0cm">FISH showed a polysomy of chromosome 7
in 13.6 %, 35.3 % and 54.5 % of BRAF</P>
<P STYLE="margin-bottom: 0cm">wild-type, heterozygous and
non-heterozygous BRAF-mutated samples, respectively</P>
<P STYLE="margin-bottom: 0cm">(P &lt; 0.005). Amplification (5.6
%) and loss (3.2 %) of BRAF locus were rare. By</P>
<P STYLE="margin-bottom: 0cm">contrast, chromosome 7 was disomic in
27/27 BRAF-mutated nevi.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: BRAF-M% is heterogeneous
and frequently increased in BRAF-mutant</P>
<P STYLE="margin-bottom: 0cm">melanomas. Aneuploidy of chromosome 7
is more frequent in BRAF mutant melanomas, 
</P>
<P STYLE="margin-bottom: 0cm">specifically in those with high
BRAF-M%.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4491198</P>
<P STYLE="margin-bottom: 0cm">PMID: 26141748 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">13. Cell Physiol Biochem.
2015;36(3):1223-36. doi: 10.1159/000430292. Epub 2015 Jun</P>
<P STYLE="margin-bottom: 0cm">30.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Caveolin-1 Confers Resistance of
Hepatoma Cells to Anoikis by Activating IGF-1</P>
<P STYLE="margin-bottom: 0cm">Pathway.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Tang W(1), Feng X, Zhang S, Ren Z, Liu
Y, Yang B, Lv B, Cai Y, Xia J, Ge N.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Liver Cancer Institute, Zhongshan
Hospital, Fudan University, Shanghai, China;</P>
<P STYLE="margin-bottom: 0cm">Key Laboratory of Carcinogenesis and
Cancer Invasion, Ministry of Education,</P>
<P STYLE="margin-bottom: 0cm">Shanghai Medical College, Fudan
University, Shanghai, China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">BACKGROUND/AIMS: Anoikis resistance is
a prerequisite for hepatocellular</P>
<P STYLE="margin-bottom: 0cm">carcinoma (HCC) metastasis. The role of
Caveolin-1 (CAV1) in anoikis resistance</P>
<P STYLE="margin-bottom: 0cm">of HCC remains unclear.</P>
<P STYLE="margin-bottom: 0cm">METHODS: The oncogenic effect of CAV1
on anchor-independent growth and anoikis</P>
<P STYLE="margin-bottom: 0cm">resistance was investigated by
overexpression and knockdown of CAV1 in hepatoma</P>
<P STYLE="margin-bottom: 0cm">cells. IGF-1 pathway and its downstream
signals were detected by immunoblot</P>
<P STYLE="margin-bottom: 0cm">analysis. Caveolae invagination and
IGF-1R internalization was studied by</P>
<P STYLE="margin-bottom: 0cm">electron microscopy and (125)I-IGF1
internalization assay, respectively. The role</P>
<P STYLE="margin-bottom: 0cm">of IGF-1R and tyrosine-14 residue
(Y-14) of CAV1 was explored by deletion</P>
<P STYLE="margin-bottom: 0cm">experiment and mutation experiment,
respectively. The correlation of CAV1 and</P>
<P STYLE="margin-bottom: 0cm">IGF-1R was further examined by
immunochemical analysis in 120 HCC specimens.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: CAV1 could promote
anchor-independent growth and anoikis resistance in</P>
<P STYLE="margin-bottom: 0cm">hepatoma cells. CAV1-overexpression
increased the expression of IGF-1R and</P>
<P STYLE="margin-bottom: 0cm">subsequently activated PI3K/Akt and
RAF/MEK/ERK pathway, while CAV1 knockdown</P>
<P STYLE="margin-bottom: 0cm">showed the opposite effect. The
mechanism study revealed that CAV1 facilitated</P>
<P STYLE="margin-bottom: 0cm">caveolae invagination and (125)I-IGF1
internalization. IGF-1R deletion or Y-14</P>
<P STYLE="margin-bottom: 0cm">mutation reversed CAV1 mediated
anchor-independent growth and anoikis resistance.</P>
<P STYLE="margin-bottom: 0cm">In addition, CAV1 expression was
positively related to IGF-1R expression in human</P>
<P STYLE="margin-bottom: 0cm">HCC tissues.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSION: CAV1 confers resistance of
hepatoma cells to anoikis by activating</P>
<P STYLE="margin-bottom: 0cm">IGF-1 pathway, providing a potential
therapeutic target for HCC metastasis. ©</P>
<P STYLE="margin-bottom: 0cm">2015 S. Karger AG, Basel.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26138883 [PubMed - in process]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">14. Int J Oncol. 2015 Jul 2. doi:
10.3892/ijo.2015.3071. [Epub ahead of print]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Bcl-xl and Mcl-1 are the major
determinants of the apoptotic response to dual</P>
<P STYLE="margin-bottom: 0cm">PI3K and MEK blockage.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Jokinen E(1), Koivunen JP(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Medical Oncology and
Radiotherapy and Medical Research Center</P>
<P STYLE="margin-bottom: 0cm">Oulu, Oulu University Hospital and
University of Oulu, Oulu, PB22 90029 OYS,</P>
<P STYLE="margin-bottom: 0cm">Finland.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The dual targeting of PI3K-AKT-mTOR and
Ras-Raf-MEK-ERK pathways is a potential</P>
<P STYLE="margin-bottom: 0cm">anticancer therapy, but unfortunately,
the response rate has been low in early</P>
<P STYLE="margin-bottom: 0cm">phase clinical trials. Pre-clinical
models have suggested that an apoptotic</P>
<P STYLE="margin-bottom: 0cm">response to dual PI3K and MEK targeting
is relatively rare and understanding</P>
<P STYLE="margin-bottom: 0cm">apoptotic avoidance could lead to
increased clinical efficiency. This study</P>
<P STYLE="margin-bottom: 0cm">investigated solid cancer cell lines,
which are known to be sensitive to dual</P>
<P STYLE="margin-bottom: 0cm">PI3K and MEK inhibition but to have a
limited apoptotic response. The cells were 
</P>
<P STYLE="margin-bottom: 0cm">exposed to dual PI3K and MEK blockage
in combination with a panel of additional</P>
<P STYLE="margin-bottom: 0cm">pharmacological agents and cytotoxicity
and apoptosis were analyzed. Our results 
</P>
<P STYLE="margin-bottom: 0cm">indicated that the BH3 mimetic ABT-263,
the HDAC inhibitor entinostat and the</P>
<P STYLE="margin-bottom: 0cm">multikinase inhibitor dasatinib
increased the cytotoxicity and apoptotic response</P>
<P STYLE="margin-bottom: 0cm">of dual PI3K and MEK targeting.
Furthermore, ABT-263 and entinostat was able to</P>
<P STYLE="margin-bottom: 0cm">induce apoptosis in combination with
single agent PI3K and MEK inhibitors.</P>
<P STYLE="margin-bottom: 0cm">Protein expression, immunoprecipitation
and siRNA knockdown models suggested that</P>
<P STYLE="margin-bottom: 0cm">Bcl-xl and Mcl-1 were the most
important factors circumventing PI3K and/or MEK</P>
<P STYLE="margin-bottom: 0cm">inhibition-mediated apoptosis. The
results suggest that the cytotoxicity of PI3K 
</P>
<P STYLE="margin-bottom: 0cm">and/or MEK inhibitor treatments can be
augmented by combinatory approaches</P>
<P STYLE="margin-bottom: 0cm">targeting anti-apoptotic mediators
Bcl-xl and Mcl-1.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMID: 26135106 [PubMed - as supplied by
publisher]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">15. Int J Clin Exp Med. 2015 Apr
15;8(4):5553-8. eCollection 2015.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">The role of leptin in the ventricular
remodeling process and its mechanism.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Zuo G(1), Du X(1), Zheng L(1), Wang
C(1), Wang K(1), Li Y(1).</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Department of Cardiology, Tianjin
Fifth Central Hospital No. 41 Zhejiang Road,</P>
<P STYLE="margin-bottom: 0cm">Tianjin 300450, P. R. China.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">OBJECTIVE: This study aims to explore
the role of leptin in the ventricular</P>
<P STYLE="margin-bottom: 0cm">remodeling process and its mechanism in
the diabetic rats' model.</P>
<P STYLE="margin-bottom: 0cm">METHODS: The diabetic SD rats model
induced by streptozotocin was established.</P>
<P STYLE="margin-bottom: 0cm">The SD rats were randomly divided into
4 groups: control group (20 rats treated</P>
<P STYLE="margin-bottom: 0cm">with citric acid/sodium citrate
buffer); M0 group (10 rats treated with</P>
<P STYLE="margin-bottom: 0cm">physiological saline); M1 group (10
rats treated with 50 μg/kg LP); M2 group (10 
</P>
<P STYLE="margin-bottom: 0cm">rats treated with 100 μg/kg LP).
Ang-II was detected by ELISA. The expression</P>
<P STYLE="margin-bottom: 0cm">levels of LP and Ob-Rb were detected by
RT-PCR. MAPK phosphorylation changes were</P>
<P STYLE="margin-bottom: 0cm">detected by western blotting.
Myocardial morphology was observed.</P>
<P STYLE="margin-bottom: 0cm">RESULTS: Compared with control group,
the blood glucose concentration and Ang-II 
</P>
<P STYLE="margin-bottom: 0cm">significantly increased in diabetic
model groups (P &lt; 0.01) and body weight</P>
<P STYLE="margin-bottom: 0cm">decreased (P &lt; 0.05). The expression
levels of LP and Ob-Rb increased and heart</P>
<P STYLE="margin-bottom: 0cm">function decreased in diabetic model
groups.</P>
<P STYLE="margin-bottom: 0cm">CONCLUSIONS: LP may be involved in the
myocardial cell hypertrophy through the</P>
<P STYLE="margin-bottom: 0cm">neuroendocrine system and associated
with the JAK-STAT, Ras-Raf-MEK-MAPK and</P>
<P STYLE="margin-bottom: 0cm">PI-3K signaling pathway, which provides
a new concept for the pathogenesis of</P>
<P STYLE="margin-bottom: 0cm">cardiac hypertrophy.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">PMCID: PMC4483875</P>
<P STYLE="margin-bottom: 0cm">PMID: 26131137 [PubMed]</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">16. EJNMMI Res. 2014 Dec;4(1):34. doi:
10.1186/s13550-014-0034-6. Epub 2014 Sep 9.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Evaluation of efficacy of a new MEK
inhibitor, RO4987655, in human tumor</P>
<P STYLE="margin-bottom: 0cm">xenografts by [(18)F] FDG-PET imaging
combined with proteomic approaches.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Tegnebratt T(1), Ruge E, Bader S, Ishii
N, Aida S, Yoshimura Y, Ooi CH, Lu L,</P>
<P STYLE="margin-bottom: 0cm">Mitsios N, Meresse V, Mulder J, Pawlak
M, Venturi M, Tessier J, Stone-Elander S.</P>
<P STYLE="margin-bottom: 0cm"><BR>
</P>
<P STYLE="margin-bottom: 0cm">Author information: 
</P>
<P STYLE="margin-bottom: 0cm">(1)Karolinska Institutet and Department
of Neuroradiology, R3:00, MicroPET and</P>
<P STYLE="margin-bottom: 0cm">Clinical Neurosciences, Karolinska
University Hospital, Stockholm, 17176, Sweden,</P>
<P STYLE="margin-bottom: 0cm">tetyana.tegnebratt@ki.se.</P>
</BODY>
</HTML>